{
  "meta": {
    "id": "test3",
    "title": "Medicine E&D - Mission 2.0 (Batch 3) - 14-02-2025 - 2025-02-14",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "Rajesh, a 55-year-old businessman from Delhi, visits your clinic with complaints of chest discomfort and tightness that occurs during brisk walking and resolves within 5 minutes of rest. He mentions that these symptoms have been consistent over the past three months and are reproducible with similar levels of exertion. There are no associated symptoms like sweating or nausea at rest. Laboratory investigations are ordered. Which of the following findings are typically seen in such a case?",
      "options": [
        {
          "label": "A",
          "text": "\u2191Trop I, \u2191Myoglobin",
          "correct": false
        },
        {
          "label": "B",
          "text": "\u2191CK-MB, Normal Trop I",
          "correct": false
        },
        {
          "label": "C",
          "text": "\u2191Myoglobin, Normal CK-MB",
          "correct": false
        },
        {
          "label": "D",
          "text": "Normal cardiac enzymes",
          "correct": true
        }
      ],
      "correct_answer": "D. Normal cardiac enzymes",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Normal cardiac enzymes</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Stable angina is characterized by predictable chest discomfort triggered by exertion or stress, which resolves with rest or nitroglycerin. It occurs due to a fixed atherosclerotic plaque limiting coronary blood flow without causing myocardial injury. Since there is no myocardial necrosis or significant injury, cardiac biomarkers such as Troponin I (Trop I), CK-MB, and Myoglobin remain within normal ranges.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. \u2191Trop I, \u2191Myoglobin: Elevated cardiac enzymes indicate myocardial injury, which is seen in acute coronary syndromes, not stable angina.</li><li>\u2022 Option A. \u2191Trop I, \u2191Myoglobin:</li><li>\u2022 Option B. \u2191CK-MB, Normal Trop I: This pattern is also indicative of myocardial injury or ischemia, potentially from unstable angina or early myocardial infarction.</li><li>\u2022 Option B. \u2191CK-MB, Normal Trop I:</li><li>\u2022 Option C. \u2191Myoglobin, Normal CK-MB: Myoglobin elevation is non-specific and typically an early marker of myocardial injury, which does not occur in stable angina.</li><li>\u2022 Option C. \u2191Myoglobin, Normal CK-MB:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In stable angina, cardiac enzymes remain normal, as the condition reflects ischemia without myocardial injury or necrosis. Any rise in cardiac biomarkers should prompt evaluation for acute coronary syndromes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "562f10e7",
      "audio": ""
    },
    {
      "text": "Vikram, a 45-year-old school teacher, is undergoing an exercise tolerance test as part of his cardiac evaluation for chest discomfort during exertion. He is asked to achieve his maximum predicted heart rate during the test for accurate assessment. What is his maximum predicted heart rate?",
      "options": [
        {
          "label": "A",
          "text": "165/min",
          "correct": false
        },
        {
          "label": "B",
          "text": "175/min",
          "correct": true
        },
        {
          "label": "C",
          "text": "185/min",
          "correct": false
        },
        {
          "label": "D",
          "text": "195/min",
          "correct": false
        }
      ],
      "correct_answer": "B. 175/min",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.\u00a0B) 175/min</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The maximum predicted heart rate (MPHR) during an exercise tolerance test is calculated using the formula:</li><li>\u2022 MPHR = 220 - Age</li><li>\u2022 MPHR = 220 - Age</li><li>\u2022 For a 45-year-old individual:</li><li>\u2022 MPHR = 220 - 45 = 175/min.</li><li>\u2022 Reaching this level indicates the maximum physiological heart rate under exertion. For a satisfactory test, the person should reach at least 85% of their MPHR (approximately 149/min in this case).</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. 165/min: This is lower than the calculated MPHR for a 45-year-old and does not match the formula.</li><li>\u2022 Option A. 165/min:</li><li>\u2022 Option C. 185/min: This is higher than the calculated MPHR and represents an overestimation.</li><li>\u2022 Option C. 185/min:</li><li>\u2022 Option D. 195/min: This is an even greater overestimation, unlikely for a 45-year-old based on the standard formula.</li><li>\u2022 Option D. 195/min:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The maximum predicted heart rate is derived from the formula 220 - Age and is a crucial parameter in assessing exercise tolerance during a treadmill test.</li><li>\u27a4 220 - Age</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "74b33b5c",
      "audio": ""
    },
    {
      "text": "A 60-year-old man from Kolkata is admitted with chest pain and diagnosed with a non-ST-elevation myocardial infarction (NSTEMI). Following a brief period of ischemia, his echocardiogram reveals prolonged myocardial dysfunction without infarction. Which of the following statements regarding myocardial stunning is not true?",
      "options": [
        {
          "label": "A",
          "text": "Stunning is a state of depressed myocardial function due to chronic hypoperfusion",
          "correct": true
        },
        {
          "label": "B",
          "text": "Stunning can be global or regional",
          "correct": false
        },
        {
          "label": "C",
          "text": "Oxygen free radicals and excess intracellular calcium likely contribute to stunning",
          "correct": false
        },
        {
          "label": "D",
          "text": "Stunning affects both systolic and diastolic function",
          "correct": false
        }
      ],
      "correct_answer": "A. Stunning is a state of depressed myocardial function due to chronic hypoperfusion",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Stunning is a state of depressed myocardial function due to chronic hypoperfusion</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Myocardial stunning refers to reversible, prolonged myocardial dysfunction that occurs after a brief period of severe ischemia, even after reperfusion restores normal coronary blood flow. It is not caused by chronic hypoperfusion; this is a feature of myocardial hibernation. Oxygen free radicals, excess intracellular calcium, and inflammatory mediators play a role in the pathogenesis of stunning. Both systolic and diastolic functions are affected in stunning, and it may occur globally or regionally in ischemic myocardium.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Stunning can be global or regional: This is true, as stunning may affect the entire myocardium or specific ischemic regions.</li><li>\u2022 Option B. Stunning can be global or regional:</li><li>\u2022 Option C. Oxygen free radicals and excess intracellular calcium likely contribute to stunning: These are important mediators in the pathophysiology of myocardial stunning.</li><li>\u2022 Option C. Oxygen free radicals and excess intracellular calcium likely contribute to stunning:</li><li>\u2022 Option D. Stunning affects both systolic and diastolic function: Stunning impacts the contractility (systolic function) and relaxation (diastolic function) of the myocardium.</li><li>\u2022 Option D. Stunning affects both systolic and diastolic function:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Myocardial stunning is a reversible condition resulting from transient ischemia and reperfusion injury, distinct from chronic hypoperfusion (myocardial hibernation). Understanding its mechanisms helps guide appropriate management.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d1786c4f",
      "audio": ""
    },
    {
      "text": "A 54-year-old man presents to the emergency department with sudden onset chest pain radiating to his left arm. An ECG is performed immediately. Which of the following is the earliest finding in a patient with suspected acute myocardial infarction (AMI)?",
      "options": [
        {
          "label": "A",
          "text": "Prolonged QT interval",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tall T wave",
          "correct": true
        },
        {
          "label": "C",
          "text": "Terminal QRS distortion",
          "correct": false
        },
        {
          "label": "D",
          "text": "ST depression",
          "correct": false
        }
      ],
      "correct_answer": "B. Tall T wave",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Tall T wave</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In the early stages of acute myocardial infarction, tall, broad-based, and symmetrical T waves appear due to local hyperkalemia in ischemic myocardial cells. These T waves are often referred to as \"hyperacute T waves\" and are one of the earliest ECG changes seen in AMI, occurring even before ST-segment changes.</li><li>\u2022 tall, broad-based, and symmetrical T waves</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Prolonged QT interval: While QT prolongation can occur, it is not an immediate finding and typically follows T-wave changes in the ischemic cascade.</li><li>\u2022 Option A. Prolonged QT interval:</li><li>\u2022 Option C. Terminal QRS distortion: This finding lacks a defined timeframe and may not be present in all patients with AMI.</li><li>\u2022 Option C. Terminal QRS distortion:</li><li>\u2022 Option D. ST depression: This is typically seen in reciprocal leads in the context of ST-elevation myocardial infarction (STEMI) and is not the earliest change.</li><li>\u2022 Option D. ST depression:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hyperacute T waves are the earliest ECG changes in acute myocardial infarction and should prompt immediate attention and further evaluation for timely intervention.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e29cfc3d",
      "audio": ""
    },
    {
      "text": "A 45-year-old man is brought to the emergency room with complaints of sudden onset chest pain, diaphoresis, and giddiness. On arrival, his blood pressure is 86/60 mmHg. An immediate ECG reveals signs of inferoposterior wall myocardial infarction (MI). Which of the following is most useful in the management of this condition?",
      "options": [
        {
          "label": "A",
          "text": "Sublingual nitrate",
          "correct": false
        },
        {
          "label": "B",
          "text": "IV nitrates",
          "correct": false
        },
        {
          "label": "C",
          "text": "Morphine",
          "correct": false
        },
        {
          "label": "D",
          "text": "IV fluids",
          "correct": true
        }
      ],
      "correct_answer": "D. IV fluids",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20133439.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) IV fluids</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The patient\u2019s clinical presentation and ECG findings suggest an inferoposterior wall MI, which is commonly associated with right ventricular myocardial infarction (RVMI). Low blood pressure in RVMI is often due to reduced preload caused by impaired right ventricular function. Administration of IV fluids is essential to optimize preload and maintain adequate cardiac output.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Sublingual nitrate: Nitrates reduce preload and may worsen hypotension in RVMI; they are contraindicated.</li><li>\u2022 Option A. Sublingual nitrate:</li><li>\u2022 Option B. IV nitrates: Similar to sublingual nitrates, IV nitrates decrease preload and can exacerbate hemodynamic instability.</li><li>\u2022 Option B. IV nitrates:</li><li>\u2022 Option C. Morphine: While morphine can help alleviate pain, it also causes vasodilation and further reduces preload, which is detrimental in RVMI.</li><li>\u2022 Option C. Morphine:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with RVMI, maintaining adequate preload with IV fluids is crucial for stabilizing hemodynamics. Nitrates and preload-reducing medications should be avoided as they can exacerbate hypotension.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "acd077fa",
      "audio": ""
    },
    {
      "text": "A 50-year-old man with a history of obesity and hypertension presents with symptoms of dyspnea and orthopnea. Brain natriuretic peptide (BNP) levels are assessed to evaluate heart failure. In which of the following conditions might falsely low BNP values be observed?",
      "options": [
        {
          "label": "A",
          "text": "Advanced age",
          "correct": false
        },
        {
          "label": "B",
          "text": "Obesity",
          "correct": true
        },
        {
          "label": "C",
          "text": "Female gender",
          "correct": false
        },
        {
          "label": "D",
          "text": "Smoking",
          "correct": false
        }
      ],
      "correct_answer": "B. Obesity",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Obesity</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Obesity is associated with increased clearance and metabolism of BNP, resulting in lower-than-expected levels. Despite the presence of heart failure, obese individuals may show reduced BNP levels due to altered natriuretic peptide physiology. Other conditions such as constrictive pericarditis, cardiac tamponade, and flash pulmonary edema can also lead to lower BNP values.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Advanced age: BNP levels tend to increase with age due to reduced renal clearance and ventricular stiffness.</li><li>\u2022 Option A. Advanced age:</li><li>\u2022 Option C. Female gender: BNP levels are higher in females due to hormonal differences, particularly estrogen effects.</li><li>\u2022 Option C. Female gender:</li><li>\u2022 Option D. Smoking: Smoking is associated with elevated BNP levels due to endothelial dysfunction and subclinical cardiac stress.</li><li>\u2022 Option D. Smoking:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Obesity can result in falsely low BNP levels due to increased clearance and metabolism, and clinicians should interpret BNP values cautiously in this population when evaluating for heart failure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ffce3fc4",
      "audio": ""
    },
    {
      "text": "A 58-year-old man with heart failure is being evaluated for the risk of sudden cardiac death (SCD). Based on NYHA classification, in which of the following classes is the risk of sudden cardiac death proportionally highest?",
      "options": [
        {
          "label": "A",
          "text": "Class I",
          "correct": false
        },
        {
          "label": "B",
          "text": "Class II",
          "correct": true
        },
        {
          "label": "C",
          "text": "Class III",
          "correct": false
        },
        {
          "label": "D",
          "text": "Class IV",
          "correct": false
        }
      ],
      "correct_answer": "B. Class II",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Class II</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Patients with NYHA Class II heart failure have a high risk of sudden cardiac death (SCD) relative to their total mortality. Although absolute mortality increases with the severity of heart failure, the proportion of deaths due to SCD decreases in advanced heart failure. The MERIT-HF trial demonstrated that while patients with NYHA Class II, III, and IV had increasing absolute rates of SCD (6.3%, 10.5%, and 18.6%, respectively), the percentage of total deaths attributed to SCD decreased (64%, 59%, and 33%, respectively).</li><li>\u2022 NYHA Class II heart failure</li><li>\u2022 MERIT-HF trial</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Class I: Incorrect. NYHA Class I patients have a low risk of death.</li><li>\u2022 Option A. Class I:</li><li>\u2022 Option C. Class III: SCD risk is high but represents a smaller proportion of total mortality compared to Class II.</li><li>\u2022 Option C. Class III:</li><li>\u2022 Option D. Class IV: Although the absolute risk of death is highest, most deaths are due to progressive pump failure rather than SCD.</li><li>\u2022 Option D. Class IV:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The risk of sudden cardiac death is proportionally highest in patients with NYHA Class II heart failure, making this group a key target for preventive strategies like implantable cardioverter-defibrillators (ICDs).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5fd0e1f6",
      "audio": ""
    },
    {
      "text": "A 40-year-old man presents with exertional dyspnea and left ventricular hypertrophy on echocardiography. Myocardial biopsy reveals myocyte disarray and interstitial fibrosis. Which of the following disorders is most likely?",
      "options": [
        {
          "label": "A",
          "text": "Fabry disease",
          "correct": true
        },
        {
          "label": "B",
          "text": "Pheochromocytoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Keshan's disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypereosinophilic syndrome",
          "correct": false
        }
      ],
      "correct_answer": "A. Fabry disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Fabry disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Fabry disease, an X-linked lysosomal storage disorder, is caused by a deficiency of \u03b1-galactosidase A leading to the accumulation of globotriaosylceramide. This results in hypertrophic cardiomyopathy (HCM), characterized by myocyte disarray and interstitial fibrosis on myocardial biopsy. These histological changes correlate with an increased risk of sudden cardiac death in affected individuals.</li><li>\u2022 \u03b1-galactosidase A</li><li>\u2022 myocyte disarray and interstitial fibrosis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Pheochromocytoma: Causes dilated cardiomyopathy (DCM) due to catecholamine-induced myocardial injury, not hypertrophy or myocyte disarray.</li><li>\u2022 Option B. Pheochromocytoma:</li><li>\u2022 Option C. Keshan's disease: A selenium deficiency-related cardiomyopathy, presenting as DCM with no myocyte disarray.</li><li>\u2022 Option C. Keshan's disease:</li><li>\u2022 Option D. Hypereosinophilic syndrome: Characterized by eosinophilic infiltration causing endomyocardial fibrosis, not myocyte disarray.</li><li>\u2022 Option D. Hypereosinophilic syndrome:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Myocyte disarray and interstitial fibrosis on myocardial biopsy are hallmark features of hypertrophic cardiomyopathy (HCM), which can be seen in genetic conditions like Fabry disease. Early recognition and management are crucial to reduce the risk of sudden cardiac death.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c4f46a38",
      "audio": ""
    },
    {
      "text": "The Brockenbrough-Braunwald-Morrow sign, characterized by a decrease in systolic blood pressure and an increase in left ventricular systolic pressure following a premature ventricular contraction (PVC), is seen in which of the following conditions?",
      "options": [
        {
          "label": "A",
          "text": "Hypertrophic cardiomyopathy (HCM)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Dilated cardiomyopathy (DCM)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Restrictive cardiomyopathy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Takotsubo cardiomyopathy",
          "correct": false
        }
      ],
      "correct_answer": "A. Hypertrophic cardiomyopathy (HCM)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Hypertrophic cardiomyopathy (HCM)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The Brockenbrough-Braunwald-Morrow sign is a hallmark of hypertrophic cardiomyopathy (HCM) with left ventricular outflow tract (LVOT) obstruction. In HCM, a post-PVC beat leads to an increase in contractility, worsening the obstruction and resulting in a paradoxical decrease in systolic blood pressure despite an increase in left ventricular systolic pressure .</li><li>\u2022 Brockenbrough-Braunwald-Morrow sign</li><li>\u2022 decrease in systolic blood pressure</li><li>\u2022 left ventricular systolic pressure</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Dilated cardiomyopathy (DCM): Characterized by systolic dysfunction and chamber dilation, DCM does not cause LVOT obstruction or this sign.</li><li>\u2022 Option B. Dilated cardiomyopathy (DCM):</li><li>\u2022 Option C. Restrictive cardiomyopathy: Marked by impaired diastolic filling with normal ventricular dimensions, it is not associated with dynamic LVOT obstruction or this sign.</li><li>\u2022 Option C. Restrictive cardiomyopathy:</li><li>\u2022 Option D. Takotsubo cardiomyopathy: A stress-induced cardiomyopathy causing transient systolic dysfunction, unrelated to LVOT obstruction or this phenomenon.</li><li>\u2022 Option D. Takotsubo cardiomyopathy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The Brockenbrough-Braunwald-Morrow sign is a specific finding in HCM with dynamic LVOT obstruction and helps differentiate it from other cardiomyopathies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2b470bc4",
      "audio": ""
    },
    {
      "text": "A 25-year-old man with Marfan syndrome presents with worsening chest pain and dyspnea. On examination, asymmetrical pulses are noted, and a chest X-ray reveals a widened mediastinum. A CT angiogram confirms thoracic aortic aneurysm. Which of the following is true regarding the management of this patient?",
      "options": [
        {
          "label": "A",
          "text": "Operative repair indicated if diameter >5.5 cm",
          "correct": false
        },
        {
          "label": "B",
          "text": "Operative repair if diameter >4-5 cm",
          "correct": true
        },
        {
          "label": "C",
          "text": "Operative repair if diameter >6 cm",
          "correct": false
        },
        {
          "label": "D",
          "text": "Operative repair if diameter >4.5 cm",
          "correct": false
        }
      ],
      "correct_answer": "B. Operative repair if diameter >4-5 cm",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20133521.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Operative repair if diameter >4-5 cm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In Marfan syndrome, the risk of aortic dissection increases at smaller aortic diameters compared to the general population. Current guidelines recommend operative repair for thoracic aortic aneurysms in Marfan syndrome patients:</li><li>\u2022 operative repair for thoracic aortic aneurysms</li><li>\u2022 >5.0 cm in asymptomatic patients or those with a family history of aortic dissection. >4.0 cm in women planning pregnancy. >4.5 cm when undergoing other cardiothoracic surgeries.</li><li>\u2022 >5.0 cm in asymptomatic patients or those with a family history of aortic dissection.</li><li>\u2022 >5.0 cm</li><li>\u2022 >4.0 cm in women planning pregnancy.</li><li>\u2022 >4.0 cm</li><li>\u2022 >4.5 cm when undergoing other cardiothoracic surgeries.</li><li>\u2022 >4.5 cm</li><li>\u2022 The vignette describes a Marfan syndrome patient with features suggestive of aortic dissection or aneurysm, where a diameter of 4\u20135 cm warrants repair to prevent catastrophic rupture or dissection.</li><li>\u2022 4\u20135 cm warrants repair</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. >5.5 cm: This is the threshold for repair in patients without Marfan syndrome or bicuspid aortic valve (BAV).</li><li>\u2022 Option A. >5.5 cm:</li><li>\u2022 Option C. >6 cm: This is the threshold for descending thoracic aortic aneurysms, not applicable here.</li><li>\u2022 Option C. >6 cm:</li><li>\u2022 Option D. >4.5 cm: While significant, this threshold applies in patients undergoing concurrent cardiothoracic surgery.</li><li>\u2022 Option D. >4.5 cm:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Patients with Marfan syndrome require earlier surgical intervention for thoracic aortic aneurysms due to their increased risk of dissection. Aneurysms >4\u20135 cm should prompt consideration for operative repair.</li><li>\u27a4 Aneurysms >4\u20135 cm should prompt consideration for operative repair.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f1d69b31",
      "audio": ""
    },
    {
      "text": "A 45-year-old man presents to the clinic with complaints of progressive exertional dyspnea and fatigue. An ECG is performed and is shown below. What is the likely cardiac axis in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Right axis deviation",
          "correct": true
        },
        {
          "label": "B",
          "text": "Left axis deviation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Extreme axis deviation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Physiological left axis deviation",
          "correct": false
        }
      ],
      "correct_answer": "A. Right axis deviation",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20170945.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Right axis deviation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The ECG findings of a negative QRS complex in Lead I and a positive QRS complex in Lead aVF indicate right axis deviation (RAD) . This axis shift is commonly associated with conditions like COPD, pulmonary hypertension, or right ventricular hypertrophy.</li><li>\u2022 negative QRS complex in Lead I</li><li>\u2022 positive QRS complex in Lead aVF</li><li>\u2022 right axis deviation (RAD)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Left axis deviation: Requires a positive Lead I and a negative Lead aVF , not seen in this case.</li><li>\u2022 Option B. Left axis deviation:</li><li>\u2022 positive Lead I</li><li>\u2022 negative Lead aVF</li><li>\u2022 Option C. Extreme axis deviation: Requires both Lead I (-) and Lead aVF (-) .</li><li>\u2022 Option C. Extreme axis deviation:</li><li>\u2022 Lead I (-)</li><li>\u2022 Lead aVF (-)</li><li>\u2022 Option D. Physiological left axis deviation: This is a mild leftward axis shift seen with Lead I (+) and Lead II (+) , which is not consistent with the given findings.</li><li>\u2022 Option D. Physiological left axis deviation:</li><li>\u2022 Lead I (+)</li><li>\u2022 Lead II (+)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Right axis deviation is often associated with pulmonary diseases and conditions causing right ventricular overload. It is characterized by a negative Lead I and a positive Lead aVF on ECG.</li><li>\u27a4 negative Lead I</li><li>\u27a4 positive Lead aVF</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c1b7b701",
      "audio": ""
    },
    {
      "text": "A 40-year-old man with a history of depression, presents to the emergency room with giddiness and fatigue. On arrival, his blood pressure is 80/60 mmHg. ECG is done and it is shown. Which of the following drugs is appropriate for the management of this patient?",
      "options": [
        {
          "label": "A",
          "text": "Antiarrhythmics",
          "correct": false
        },
        {
          "label": "B",
          "text": "Intravenous sodium bicarbonate",
          "correct": true
        },
        {
          "label": "C",
          "text": "Propranolol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Phenytoin",
          "correct": false
        }
      ],
      "correct_answer": "B. Intravenous sodium bicarbonate",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20133622.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Intravenous sodium bicarbonate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This patient\u2019s presentation suggests tricyclic antidepressant (TCA) toxicity , characterized by sodium channel blockade leading to wide QRS complexes, sinus tachycardia, hypotension, and specific ECG findings (e.g., an \"S\" wave in lead I and a terminal R wave in lead aVR). Intravenous sodium bicarbonate is the first-line treatment as it:</li><li>\u2022 tricyclic antidepressant (TCA) toxicity</li><li>\u2022 Intravenous sodium bicarbonate</li><li>\u2022 Alkalinizes the serum, reducing drug binding to sodium channels. Increases extracellular sodium concentration, overcoming sodium channel blockade.</li><li>\u2022 Alkalinizes the serum, reducing drug binding to sodium channels.</li><li>\u2022 Increases extracellular sodium concentration, overcoming sodium channel blockade.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Antiarrhythmics: Drugs like class IA, IC, or amiodarone may worsen sodium channel blockade and are contraindicated.</li><li>\u2022 Option A. Antiarrhythmics:</li><li>\u2022 Option C. Propranolol: A beta-blocker that can exacerbate hypotension and bradycardia in TCA toxicity.</li><li>\u2022 Option C. Propranolol:</li><li>\u2022 Option D. Phenytoin: Not effective in managing sodium channel blockade caused by TCA overdose.</li><li>\u2022 Option D. Phenytoin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 TCA toxicity causes life-threatening arrhythmias and hypotension due to sodium channel blockade. IV sodium bicarbonate is the antidote, and early administration is critical to prevent complications like seizures and arrhythmias.</li><li>\u27a4 TCA toxicity</li><li>\u27a4 IV sodium bicarbonate</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2d8a49f6",
      "audio": ""
    },
    {
      "text": "A 40-year-old male with a recent history of CABG presents with chest pain. On arrival, his BP is 60/30 mmHg, and his HR is 30/min. The ECG shows a narrow-complex bradyarrhythmia. He receives three boluses of IV atropine without improvement. While awaiting transcutaneous pacing, what is the next appropriate step in the management of this patient?",
      "options": [
        {
          "label": "A",
          "text": "Another bolus of atropine",
          "correct": false
        },
        {
          "label": "B",
          "text": "IV norepinephrine",
          "correct": false
        },
        {
          "label": "C",
          "text": "IV dopamine",
          "correct": true
        },
        {
          "label": "D",
          "text": "IV dobutamine",
          "correct": false
        }
      ],
      "correct_answer": "C. IV dopamine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20133643.jpg"
      ],
      "explanation": "<p><strong>Ans. C) IV dopamine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 IV dopamine is the next step in managing symptomatic bradycardia when atropine is ineffective. Dopamine stimulates D1 , B1 , and A1 receptors , increasing both heart rate and blood pressure. This dual effect is particularly beneficial in patients with bradycardia and hypotension. Dopamine is a recommended vasopressor and inotrope in the ACLS algorithm for symptomatic bradycardia.</li><li>\u2022 D1</li><li>\u2022 B1</li><li>\u2022 A1 receptors</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Another bolus of atropine: ACLS guidelines limit atropine to a maximum of three boluses for symptomatic bradycardia. Additional doses are unlikely to be beneficial.</li><li>\u2022 Option A. Another bolus of atropine:</li><li>\u2022 Option B. IV norepinephrine: Although norepinephrine raises BP through A1 agonism , it may cause reflex bradycardia and is not first-line for bradyarrhythmia.</li><li>\u2022 Option B. IV norepinephrine:</li><li>\u2022 A1 agonism</li><li>\u2022 Option D. IV dobutamine: Dobutamine predominantly acts on B1 and B2 receptors , enhancing inotropy but causing peripheral vasodilation due to B2 stimulation, which could exacerbate hypotension.</li><li>\u2022 Option D. IV dobutamine:</li><li>\u2022 B1 and B2 receptors</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In symptomatic bradycardia unresponsive to atropine, IV dopamine is a logical next step while preparing for transcutaneous pacing, as it effectively increases both heart rate and blood pressure.</li><li>\u27a4 IV dopamine</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4134df69",
      "audio": ""
    },
    {
      "text": "A 30-year-old IT employee developed sudden loss of consciousness after hearing an ambulance alarm. On arrival to the emergency room, she was hemodynamically stable. She reports a history of similar episodes in the past. An ECG is performed and it is shown. What is the likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Congenital Long QT syndrome Type 1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Congenital Long QT syndrome Type 2",
          "correct": true
        },
        {
          "label": "C",
          "text": "Catecholaminergic polymorphic ventricular tachycardia (VT)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Short QT syndrome",
          "correct": false
        }
      ],
      "correct_answer": "B. Congenital Long QT syndrome Type 2",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20133700.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Congenital Long QT syndrome Type 2</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation of syncope triggered by a startling noise (e.g., an ambulance alarm) with a prolonged QT interval and bifid T waves on ECG strongly suggests Congenital Long QT syndrome Type 2 (LQT2) .</li><li>\u2022 startling noise</li><li>\u2022 bifid T waves</li><li>\u2022 Congenital Long QT syndrome Type 2 (LQT2)</li><li>\u2022 LQT2 is caused by mutations in the KCNH2 gene, which affects the delayed rectifier potassium current (IKr). The condition is typically triggered by sudden loud noises, alarms, or emotional stress. Beta-blockers \u00b1 ICD (implantable cardioverter-defibrillator) are the standard treatment.</li><li>\u2022 LQT2 is caused by mutations in the KCNH2 gene, which affects the delayed rectifier potassium current (IKr).</li><li>\u2022 LQT2</li><li>\u2022 KCNH2</li><li>\u2022 The condition is typically triggered by sudden loud noises, alarms, or emotional stress.</li><li>\u2022 Beta-blockers \u00b1 ICD (implantable cardioverter-defibrillator) are the standard treatment.</li><li>\u2022 Beta-blockers \u00b1 ICD (implantable cardioverter-defibrillator)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Congenital Long QT syndrome Type 1: Associated with exercise or swimming as triggers and wide-based T waves on ECG, not bifid T waves.</li><li>\u2022 Option A. Congenital Long QT syndrome Type 1:</li><li>\u2022 exercise or swimming</li><li>\u2022 Option C. Catecholaminergic polymorphic VT: Triggers include exercise or emotional stress , but the ECG is typically normal at rest, showing polymorphic VT during stress.</li><li>\u2022 Option C. Catecholaminergic polymorphic VT:</li><li>\u2022 exercise or emotional stress</li><li>\u2022 Option D. Short QT syndrome: Characterized by a shortened QT interval and high risk of arrhythmias but not associated with noise-triggered syncope.</li><li>\u2022 Option D. Short QT syndrome:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Congenital Long QT syndrome Type 2 (LQT2) presents with syncope triggered by auditory or emotional stimuli and bifid T waves on ECG. Early diagnosis and treatment are critical to prevent sudden cardiac death.</li><li>\u27a4 Congenital Long QT syndrome Type 2 (LQT2)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c2d38ffb",
      "audio": ""
    },
    {
      "text": "A 30-year-old male presents with recurrent episodes of palpitations. On arrival, he is stable, and an ECG is performed and shown. What is the likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "RBBB",
          "correct": false
        },
        {
          "label": "B",
          "text": "LBBB",
          "correct": false
        },
        {
          "label": "C",
          "text": "Brugada syndrome",
          "correct": true
        },
        {
          "label": "D",
          "text": "WPW syndrome",
          "correct": false
        }
      ],
      "correct_answer": "C. Brugada syndrome",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20133720.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Brugada syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The ECG findings of RBBB-like morphology , ST-segment elevation with a \"coved\" pattern in leads V1\u2013V3 , and T-wave inversion in V1\u2013V4 are characteristic of Brugada syndrome . This condition is associated with mutations in sodium channel genes (e.g., SCN5A) and carries a high risk of sudden cardiac death due to ventricular arrhythmias.</li><li>\u2022 RBBB-like morphology</li><li>\u2022 ST-segment elevation with a \"coved\" pattern in leads V1\u2013V3</li><li>\u2022 T-wave inversion in V1\u2013V4</li><li>\u2022 Brugada syndrome</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. RBBB: RBBB does not cause ST-segment elevation or T-wave inversions in the anterior leads. It follows an \"appropriate discordance\" rule where ST changes are opposite to the terminal deflection of the QRS.</li><li>\u2022 Option A. RBBB:</li><li>\u2022 Option B. LBBB: LBBB shows wide QRS complexes with characteristic patterns, but it does not produce ST-segment elevation in V1\u2013V3.</li><li>\u2022 Option B. LBBB:</li><li>\u2022 Option D. WPW syndrome: Characterized by delta waves , a short PR interval , and wide QRS complexes , none of which are present in this ECG.</li><li>\u2022 Option D. WPW syndrome:</li><li>\u2022 delta waves</li><li>\u2022 short PR interval</li><li>\u2022 wide QRS complexes</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Brugada syndrome is identified by its unique ECG pattern in V1\u2013V3 and is a significant cause of sudden cardiac death in young individuals. Early diagnosis is critical, with ICD placement often recommended for high-risk patients.</li><li>\u27a4 Brugada syndrome</li><li>\u27a4 ICD placement</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fd2db4a0",
      "audio": ""
    },
    {
      "text": "A 28-year-old pregnant woman, G2P1L1, at 37 weeks of gestation presents with worsening headache, blurred vision, and reduced perception of fetal movements. On arrival, her BP is 200/100 mmHg. ECG is taken and shown. What is the best management for this patient?",
      "options": [
        {
          "label": "A",
          "text": "IV MgSO4",
          "correct": true
        },
        {
          "label": "B",
          "text": "IV Lignocaine",
          "correct": false
        },
        {
          "label": "C",
          "text": "IV Amiodarone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Defibrillation",
          "correct": false
        }
      ],
      "correct_answer": "A. IV MgSO4",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20133741.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) IV MgSO4</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The patient has torsades de pointes , characterized by polymorphic ventricular tachycardia associated with a prolonged QT interval. The definitive treatment is intravenous magnesium sulfate (IV MgSO4) , which stabilizes the myocardial membrane and prevents recurrent episodes by shortening the QT interval. IV MgSO4 is also safe during pregnancy, making it the treatment of choice.</li><li>\u2022 torsades de pointes</li><li>\u2022 intravenous magnesium sulfate (IV MgSO4)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. IV Lignocaine: Used for monomorphic ventricular tachycardia, particularly in ischemic heart disease, but it is not effective for torsades de pointes.</li><li>\u2022 Option B. IV Lignocaine:</li><li>\u2022 Option C. IV Amiodarone: Appropriate for wide-complex tachycardias, but it can prolong the QT interval, worsening torsades de pointes.</li><li>\u2022 Option C. IV Amiodarone:</li><li>\u2022 Option D. Defibrillation: Indicated for pulseless ventricular tachycardia or ventricular fibrillation, but not for hemodynamically stable torsades de pointes.</li><li>\u2022 Option D. Defibrillation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In torsades de pointes , particularly in the setting of prolonged QT interval, IV magnesium sulfate is the first-line treatment, even during pregnancy, due to its safety and efficacy.</li><li>\u27a4 torsades de pointes</li><li>\u27a4 IV magnesium sulfate</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "07c88843",
      "audio": ""
    },
    {
      "text": "A 62-year-old man presents to the emergency department with sudden onset right-sided weakness and slurred speech that began 3 hours ago. His blood pressure on arrival is 190/110 mmHg. He has a history of myocardial infarction 2 months ago and a history of gastrointestinal bleeding 15 days ago. A non-contrast CT head shows no hemorrhage. Which of the following is a contraindication for thrombolysis in this patient?",
      "options": [
        {
          "label": "A",
          "text": "BP >185/110 mmHg despite treatment",
          "correct": true
        },
        {
          "label": "B",
          "text": "Myocardial infarction 2 months ago",
          "correct": false
        },
        {
          "label": "C",
          "text": "Gastrointestinal bleeding in the preceding 21 days",
          "correct": false
        },
        {
          "label": "D",
          "text": "Age >60 years",
          "correct": false
        }
      ],
      "correct_answer": "A. BP >185/110 mmHg despite treatment",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) BP >185/110 mmHg despite treatment</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Thrombolysis in acute ischemic stroke requires strict adherence to contraindication criteria. Sustained increased BP >185/110 mmHg despite treatment is an absolute contraindication because of the high risk of intracranial hemorrhage. Blood pressure must be lowered to below this threshold before considering thrombolysis. Other absolute contraindications include recent gastrointestinal bleeding (within 21 days), major surgery (within 14 days), or recent myocardial infarction (if high hemorrhagic risk).</li><li>\u2022 Sustained increased BP >185/110 mmHg despite treatment</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Myocardial infarction 2 months ago: This is not an absolute contraindication unless the patient has ongoing hemorrhagic risk.</li><li>\u2022 Option B. Myocardial infarction 2 months ago:</li><li>\u2022 Option C. Gastrointestinal bleeding in the preceding 21 days: While a contraindication, it is not the most relevant answer in this vignette, where uncontrolled BP is the immediate concern.</li><li>\u2022 Option C. Gastrointestinal bleeding in the preceding 21 days:</li><li>\u2022 Option D. Age >60 years: Age alone is not a contraindication for thrombolysis.</li><li>\u2022 Option D. Age >60 years:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Thrombolysis in ischemic stroke requires careful evaluation of contraindications, with uncontrolled hypertension being a critical factor to address before administration. Treat BP aggressively to below 185/110 mmHg before initiating rtPA.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7258bce5",
      "audio": ""
    },
    {
      "text": "A 45-year-old man presents with recurrent episodes of migraine headaches, progressive memory loss, and multiple transient ischemic attacks over the past few years. His family history reveals similar symptoms in his father and grandfather, both of whom developed dementia in their 50s. MRI of the brain shows diffuse white matter hyperintensities, particularly in the anterior temporal lobes. Genetic testing is performed. Which gene is most likely mutated in this condition?",
      "options": [
        {
          "label": "A",
          "text": "Notch-1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Notch-2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Notch-3",
          "correct": true
        },
        {
          "label": "D",
          "text": "Notch-4",
          "correct": false
        }
      ],
      "correct_answer": "C. Notch-3",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Notch-3</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 CADASIL is an inherited disorder of the small cerebral arteries leading to recurrent subcortical strokes , progressive dementia, and white matter changes on MRI, especially in the anterior temporal lobes . It is caused by mutations in the Notch-3 gene located on chromosome 19, which encodes a transmembrane receptor involved in vascular smooth muscle function. These mutations result in abnormal accumulation of granular osmiophilic material (GOM) in vascular smooth muscle cells, leading to progressive vascular damage.</li><li>\u2022 recurrent subcortical strokes</li><li>\u2022 anterior temporal lobes</li><li>\u2022 Notch-3 gene</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Notch-1: Associated with other developmental and oncological disorders, not CADASIL.</li><li>\u2022 Option A. Notch-1:</li><li>\u2022 Option B. Notch-2: Implicated in Alagille syndrome, a genetic disorder affecting the liver, heart, and skeletal system.</li><li>\u2022 Option B. Notch-2:</li><li>\u2022 Option D. Notch-4: Has limited known associations with human vascular diseases.</li><li>\u2022 Option D. Notch-4:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Notch-3 mutations are pathognomonic for CADASIL , an autosomal dominant disorder characterized by recurrent strokes, dementia, and anterior temporal lobe involvement on MRI. Early recognition is critical for genetic counseling and management.</li><li>\u27a4 Notch-3 mutations</li><li>\u27a4 CADASIL</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "83cb4529",
      "audio": ""
    },
    {
      "text": "A 72-year-old woman with a history of atrial fibrillation presents for routine follow-up. She has a history of hypertension and diabetes but denies any recent symptoms. Her medications include antihypertensives and oral hypoglycemics. On examination, she is in normal sinus rhythm. Her physician decides to assess her stroke risk. Which of the following is not a component of the score used?",
      "options": [
        {
          "label": "A",
          "text": "Congestive heart failure",
          "correct": false
        },
        {
          "label": "B",
          "text": "Age",
          "correct": false
        },
        {
          "label": "C",
          "text": "Smoking",
          "correct": true
        },
        {
          "label": "D",
          "text": "Previous stroke",
          "correct": false
        }
      ],
      "correct_answer": "C. Smoking",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Smoking</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The CHA\u2082DS\u2082-VASc score is used to estimate stroke risk in patients with atrial fibrillation. It includes:</li><li>\u2022 CHA\u2082DS\u2082-VASc score</li><li>\u2022 C : Congestive heart failure (+1) H : Hypertension (+1) A\u2082 : Age \u226575 years (+2) D : Diabetes mellitus (+1) S\u2082 : Prior stroke, TIA, or thromboembolism (+2) V : Vascular disease (e.g., prior MI, PAD) (+1) A : Age 65\u201374 years (+1) Sc : Sex category (female) (+1)</li><li>\u2022 C : Congestive heart failure (+1)</li><li>\u2022 C</li><li>\u2022 H : Hypertension (+1)</li><li>\u2022 H</li><li>\u2022 A\u2082 : Age \u226575 years (+2)</li><li>\u2022 A\u2082</li><li>\u2022 D : Diabetes mellitus (+1)</li><li>\u2022 D</li><li>\u2022 S\u2082 : Prior stroke, TIA, or thromboembolism (+2)</li><li>\u2022 S\u2082</li><li>\u2022 V : Vascular disease (e.g., prior MI, PAD) (+1)</li><li>\u2022 V</li><li>\u2022 A : Age 65\u201374 years (+1)</li><li>\u2022 A</li><li>\u2022 Sc : Sex category (female) (+1)</li><li>\u2022 Sc</li><li>\u2022 Smoking is not a component of this score but is an independent cardiovascular risk factor.</li><li>\u2022 not a component</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Congestive heart failure: A key component of the score, contributing 1 point.</li><li>\u2022 Option A. Congestive heart failure:</li><li>\u2022 Option B. Age: Age \u226575 years scores 2 points, and 65\u201374 years scores 1 point.</li><li>\u2022 Option B. Age:</li><li>\u2022 Option D. Previous stroke: A prior stroke, TIA, or thromboembolism adds 2 points, reflecting a high risk of recurrence.</li><li>\u2022 Option D. Previous stroke:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The CHA\u2082DS\u2082-VASc score is a validated tool for assessing stroke risk in atrial fibrillation, excluding factors like smoking, which are not part of its criteria.</li><li>\u27a4 CHA\u2082DS\u2082-VASc score</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "30546d7c",
      "audio": ""
    },
    {
      "text": "A 72-year-old man presents to the emergency department with sudden onset weakness on the left side of his body and altered consciousness. On arrival, his Glasgow Coma Scale (GCS) score is 10. A CT scan reveals a supratentorial intracerebral hemorrhage measuring 40 mL with intraventricular extension. His vitals are stable, and his family denies any significant past medical history. Which of the following is not a component of the score used to predict his prognosis?",
      "options": [
        {
          "label": "A",
          "text": "GCS score",
          "correct": false
        },
        {
          "label": "B",
          "text": "Volume of blood",
          "correct": false
        },
        {
          "label": "C",
          "text": "Age",
          "correct": false
        },
        {
          "label": "D",
          "text": "Gender",
          "correct": true
        }
      ],
      "correct_answer": "D. Gender",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.\u00a0D) Gender</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The ICH score is a validated tool used to predict mortality in patients with intracerebral hemorrhage. It includes the following components:</li><li>\u2022 ICH score</li><li>\u2022 Glasgow Coma Scale (GCS): Lower scores indicate worse prognosis (3\u20134 = 2 points, 5\u201312 = 1 point, 13\u201315 = 0 points). ICH Volume: Hemorrhages >30 mL score 1 point; \u226430 mL score 0 points. Intraventricular Hemorrhage (IVH): Presence of IVH scores 1 point; absence scores 0 points. Location: Infratentorial hemorrhages score 1 point; supratentorial score 0 points. Age: Age >80 years scores 1 point; \u226480 years scores 0 points.</li><li>\u2022 Glasgow Coma Scale (GCS): Lower scores indicate worse prognosis (3\u20134 = 2 points, 5\u201312 = 1 point, 13\u201315 = 0 points).</li><li>\u2022 Glasgow Coma Scale (GCS):</li><li>\u2022 ICH Volume: Hemorrhages >30 mL score 1 point; \u226430 mL score 0 points.</li><li>\u2022 ICH Volume:</li><li>\u2022 Intraventricular Hemorrhage (IVH): Presence of IVH scores 1 point; absence scores 0 points.</li><li>\u2022 Intraventricular Hemorrhage (IVH):</li><li>\u2022 Location: Infratentorial hemorrhages score 1 point; supratentorial score 0 points.</li><li>\u2022 Location:</li><li>\u2022 Age: Age >80 years scores 1 point; \u226480 years scores 0 points.</li><li>\u2022 Age:</li><li>\u2022 Gender is not a component of the ICH score.</li><li>\u2022 Gender</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. GCS score: A critical determinant of prognosis in ICH patients.</li><li>\u2022 Option A. GCS score:</li><li>\u2022 Option B. Volume of blood: Larger hematomas (> 30mL) are associated with higher mortality.</li><li>\u2022 Option B. Volume of blood:</li><li>\u2022 Option C. Age: Older age (>80 years) worsens prognosis.</li><li>\u2022 Option C. Age:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The ICH score assesses prognosis in intracerebral hemorrhage based on GCS , ICH volume , IVH presence , location , and age , but it does not include gender as a factor.</li><li>\u27a4 ICH score</li><li>\u27a4 GCS</li><li>\u27a4 ICH volume</li><li>\u27a4 IVH presence</li><li>\u27a4 location</li><li>\u27a4 age</li><li>\u27a4 gender</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "231a491d",
      "audio": ""
    },
    {
      "text": "A 65-year-old woman with a history of hypertension presents with sudden onset right-sided weakness and numbness. Which of the following is incorrect regarding MCA infarcts?",
      "options": [
        {
          "label": "A",
          "text": "Contralateral hemiplegia, hemianesthesia, and homonymous hemianopia are seen if the entire MCA is occluded at its origin.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dysarthria is rare in MCA lesions.",
          "correct": true
        },
        {
          "label": "C",
          "text": "When the dominant hemisphere is involved, global aphasia is present.",
          "correct": false
        },
        {
          "label": "D",
          "text": "When the nondominant hemisphere is affected, anosognosia, constructional apraxia, and neglect are found.",
          "correct": false
        }
      ],
      "correct_answer": "B. Dysarthria is rare in MCA lesions.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Dysarthria is rare in MCA lesions.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Dysarthria is common in MCA lesions due to facial weakness caused by involvement of the motor cortex areas supplying the face and mouth. The MCA supplies both cortical and penetrating branches that affect motor and sensory functions on the contralateral side.</li><li>\u2022 Dysarthria is common</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Contralateral hemiplegia, hemianesthesia, and homonymous hemianopia: These findings are characteristic of MCA occlusion at its origin due to disruption of both penetrating and cortical branches.</li><li>\u2022 Option A. Contralateral hemiplegia, hemianesthesia, and homonymous hemianopia:</li><li>\u2022 Option C. When the dominant hemisphere is involved, global aphasia is present: This is true as the dominant hemisphere (usually the left) includes Broca\u2019s and Wernicke\u2019s areas.</li><li>\u2022 Option C. When the dominant hemisphere is involved, global aphasia is present:</li><li>\u2022 Option D. When the nondominant hemisphere is affected, anosognosia, constructional apraxia, and neglect are found: These symptoms occur due to spatial and attentional deficits linked to nondominant hemisphere involvement.</li><li>\u2022 Option D. When the nondominant hemisphere is affected, anosognosia, constructional apraxia, and neglect are found:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 MCA infarctions produce significant neurological deficits, including contralateral motor and sensory loss, aphasia (dominant hemisphere), or neglect (nondominant hemisphere) . Dysarthria is a common symptom due to facial muscle involvement.</li><li>\u27a4 contralateral motor and sensory loss, aphasia (dominant hemisphere), or neglect (nondominant hemisphere)</li><li>\u27a4 common symptom</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e6e6b1ea",
      "audio": ""
    },
    {
      "text": "An elderly patient presents with difficulty in visual scanning and spatial perception. On examination, simultagnosia is identified. Lesions in which region of the brain are most likely to cause this condition?",
      "options": [
        {
          "label": "A",
          "text": "Watershed area between anterior and middle cerebral artery",
          "correct": false
        },
        {
          "label": "B",
          "text": "Watershed area between posterior and middle cerebral artery",
          "correct": true
        },
        {
          "label": "C",
          "text": "Bilateral infarction in the distal PCAs",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bilateral infarction in the distal ACAs",
          "correct": false
        }
      ],
      "correct_answer": "B. Watershed area between posterior and middle cerebral artery",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Watershed area between posterior and middle cerebral artery</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Balint\u2019s syndrome is caused by bilateral damage to the visual association areas in the brain. This typically occurs in the \"watershed\" zone between the posterior cerebral artery (PCA) and the middle cerebral artery (MCA), where the blood supply is most vulnerable to ischemia during low-flow states such as cardiac arrest or systemic hypotension. The syndrome is characterized by three primary features: simultanagnosia (inability to perceive multiple objects simultaneously), optic ataxia (difficulty in reaching for objects under visual guidance), and ocular apraxia (difficulty in initiating voluntary eye movements).</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A . Watershed area between anterior and middle cerebral artery : Lesions here predominantly affect motor or executive functions rather than visual-spatial integration.</li><li>\u2022 Option</li><li>\u2022 A</li><li>\u2022 Watershed area between anterior and middle cerebral artery</li><li>\u2022 Option C. Bilateral infarction in the distal PCAs : While bilateral PCA infarctions can cause visual deficits like cortical blindness, but Balint syndrome is more specific to watershed infarctions between the posterior and middle cerebral arteries.</li><li>\u2022 Option C.</li><li>\u2022 Bilateral infarction in the distal PCAs</li><li>\u2022 Option D . Bilateral infarction in the distal ACAs : These infarctions are associated with frontal lobe dysfunctions, such as behavioral changes or lower limb weakness, not visual-spatial deficits.</li><li>\u2022 Option D</li><li>\u2022 Bilateral infarction in the distal ACAs</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Balint\u2019s syndrome results from bilateral ischemic damage in the watershed zone between the PCA and MCA territories, emphasizing the vulnerability of this region during low-flow states like cardiac arrest.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b6646a8f",
      "audio": ""
    },
    {
      "text": "A 58-year-old man, Rajesh, presents to the emergency department with complaints of sudden-onset dizziness, difficulty swallowing, hoarseness of voice, and numbness on the left side of his face and the right side of his body. He also reports blurred vision and unsteadiness while walking. On examination, he has left-sided ptosis, miosis, and decreased pain and temperature sensation on the left side of the face. There is also loss of pain and temperature sensation on the right side of his body. Which artery is most likely occluded in this condition?",
      "options": [
        {
          "label": "A",
          "text": "ACA occlusion",
          "correct": false
        },
        {
          "label": "B",
          "text": "M1 segment of MCA",
          "correct": false
        },
        {
          "label": "C",
          "text": "V4 segment of vertebral artery",
          "correct": true
        },
        {
          "label": "D",
          "text": "M2 segment of MCA",
          "correct": false
        }
      ],
      "correct_answer": "C. V4 segment of vertebral artery",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) V4 segment of vertebral artery</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Wallenberg\u2019s syndrome occurs due to ischemia in the lateral medulla, which is primarily supplied by branches of the vertebral artery, especially the V4 segment. Occlusion of this segment leads to characteristic symptoms such as vertigo, ipsilateral facial numbness, contralateral limb numbness, hoarseness, dysphagia, diplopia, dysarthria, and ipsilateral Horner\u2019s syndrome. The constellation of these findings is diagnostic of lateral medullary syndrome.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. ACA occlusion: ACA occlusion typically affects the medial frontal and parietal lobes, causing contralateral leg weakness and sensory deficits but not lateral medullary symptoms.</li><li>\u2022 Option A. ACA occlusion:</li><li>\u2022 Option B. M1 segment of MCA: M1 segment occlusion affects cortical areas supplied by the MCA, leading to hemiplegia, aphasia, or neglect depending on the hemisphere involved.</li><li>\u2022 Option B. M1 segment of MCA:</li><li>\u2022 Option D. M2 segment of MCA: M2 segment occlusion results in cortical strokes with symptoms such as aphasia or visual field deficits, not medullary findings.</li><li>\u2022 Option D. M2 segment of MCA:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Wallenberg\u2019s syndrome is caused by ischemia in the lateral medulla, most commonly due to occlusion of the V4 segment of the vertebral artery, resulting in a characteristic cluster of neurological deficits.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e322760d",
      "audio": ""
    },
    {
      "text": "A 62-year-old man, Ravi, presents with symptoms of slowness of movement, stiffness, and autonomic disturbances, including orthostatic hypotension. On examination, he has features resembling Parkinson\u2019s disease but does not respond well to levodopa therapy. MRI of the brain reveals high signal changes along the external surface of the putamen on T2-weighted imaging. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Corticobasal syndrome",
          "correct": false
        },
        {
          "label": "B",
          "text": "Multiple system atrophy - P",
          "correct": true
        },
        {
          "label": "C",
          "text": "Multiple system atrophy - C",
          "correct": false
        },
        {
          "label": "D",
          "text": "Progressive supranuclear palsy",
          "correct": false
        }
      ],
      "correct_answer": "B. Multiple system atrophy - P",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Multiple system atrophy - P</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The putaminal rim sign is a characteristic MRI finding in Multiple System Atrophy - Parkinsonian type (MSA-P) . It represents a hyperintense signal on T2-weighted imaging along the external surface of the putamen due to pathological iron deposition and gliosis. MSA is a neurodegenerative disorder presenting with atypical parkinsonian features (poor levodopa response) along with autonomic dysfunction and, in some cases, cerebellar symptoms.</li><li>\u2022 putaminal rim sign</li><li>\u2022 Multiple System Atrophy - Parkinsonian type (MSA-P)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Corticobasal syndrome: Primarily involves asymmetric cortical dysfunction with dystonia, myoclonus, and alien limb phenomenon. MRI findings do not include the putaminal rim sign.</li><li>\u2022 Option A. Corticobasal syndrome:</li><li>\u2022 Option C. Multiple system atrophy - C: The cerebellar form of MSA (MSA-C) is characterized by ataxia and cerebellar symptoms with MRI findings such as brainstem and cerebellar atrophy and the classic \"hot cross bun\" sign in the pons.</li><li>\u2022 Option C. Multiple system atrophy - C:</li><li>\u2022 Option D. Progressive supranuclear palsy: Presents with vertical gaze palsy, early falls, and axial rigidity. MRI findings include midbrain atrophy with the \"hummingbird\" or \"penguin\" sign but not the putaminal rim sign.</li><li>\u2022 Option D. Progressive supranuclear palsy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The putaminal rim sign on MRI is specific to MSA-P , helping distinguish it from other atypical parkinsonian syndromes. Proper recognition of these imaging findings aids in diagnosis.</li><li>\u27a4 putaminal rim sign</li><li>\u27a4 MSA-P</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7fc5dffd",
      "audio": ""
    },
    {
      "text": "Which of the following is not a feature of atypical parkinsonism?",
      "options": [
        {
          "label": "A",
          "text": "Early involvement of speech and gait",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lack of motor asymmetry",
          "correct": false
        },
        {
          "label": "C",
          "text": "Presence of Rest tremor",
          "correct": true
        },
        {
          "label": "D",
          "text": "Poor response to levodopa",
          "correct": false
        }
      ],
      "correct_answer": "C. Presence of Rest tremor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Presence of Rest tremor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Rest tremor is a hallmark feature of Parkinson\u2019s disease (PD) but is typically absent in atypical parkinsonism . Atypical parkinsonism includes disorders such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS). These conditions exhibit parkinsonian features (rigidity and bradykinesia) but differ from PD with their early involvement of speech and gait, symmetrical motor symptoms, poor levodopa response, and more aggressive progression.</li><li>\u2022 Parkinson\u2019s disease (PD)</li><li>\u2022 absent</li><li>\u2022 atypical parkinsonism</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Early involvement of speech and gait: This is a common feature in atypical parkinsonism, unlike PD, where speech and gait involvement occur later.</li><li>\u2022 Option A. Early involvement of speech and gait:</li><li>\u2022 Option B. Lack of motor asymmetry: Motor symptoms are typically symmetrical in atypical parkinsonism, unlike PD, where asymmetry is a key feature.</li><li>\u2022 Option B. Lack of motor asymmetry:</li><li>\u2022 Option D. Poor response to levodopa: Atypical parkinsonism usually responds poorly to levodopa, differentiating it from PD, where levodopa is highly effective.</li><li>\u2022 Option D. Poor response to levodopa:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Atypical parkinsonism is characterized by early speech and gait issues, symmetrical symptoms, poor response to levodopa, and absence of rest tremor , distinguishing it from Parkinson\u2019s disease.</li><li>\u27a4 absence of rest tremor</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2c4bfc24",
      "audio": ""
    },
    {
      "text": "A 65-year-old man, Arjun, with advanced Parkinson\u2019s disease, is being evaluated for deep brain stimulation (DBS) to manage his motor symptoms. He has a history of depression that has settled over time. Which of the following DBS is preferred in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Globus pallidus externa",
          "correct": false
        },
        {
          "label": "B",
          "text": "Globus pallidus interna",
          "correct": true
        },
        {
          "label": "C",
          "text": "Subthalamic nucleus",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ventral intermediate (VIM) nucleus of the thalamus",
          "correct": false
        }
      ],
      "correct_answer": "B. Globus pallidus interna",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Globus pallidus interna</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 DBS targeting the globus pallidus interna (GPi) has been shown to have comparable motor benefits to subthalamic nucleus (STN) stimulation, but studies suggest that GPi stimulation may be associated with a lower frequency of depression. GPi stimulation may provide better emotional and cognitive outcomes in patients with Parkinson\u2019s disease who have pre-existing mood disturbances.</li><li>\u2022 globus pallidus interna (GPi)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Globus pallidus externa: This structure is not a standard DBS target for Parkinson\u2019s disease.</li><li>\u2022 Option A. Globus pallidus externa:</li><li>\u2022 Option C. Subthalamic nucleus: While effective for motor symptoms, STN stimulation has been associated with an increased risk of mood disturbances, including depression.</li><li>\u2022 Option C. Subthalamic nucleus:</li><li>\u2022 Option D. Ventral intermediate (VIM) nucleus of the thalamus: VIM DBS is primarily used for tremor control in essential tremor and is not a preferred target for Parkinson\u2019s disease (unless the patient has refractory tremors).</li><li>\u2022 Option D. Ventral intermediate (VIM) nucleus of the thalamus:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 DBS of the GPi is associated with a reduced frequency of depression in Parkinson\u2019s disease compared to STN stimulation, making it a preferable choice in patients with pre-existing mood disturbances.</li><li>\u27a4 DBS of the GPi</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4eecaa71",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman, Sneha, presents with recurrent migraine attacks that are not relieved by over-the-counter medications. She has a history of coronary artery disease, and her physician decides to prescribe a medication that selectively targets a different serotonin receptor to manage her migraine. Which of the following drugs is the most appropriate choice?",
      "options": [
        {
          "label": "A",
          "text": "Eletriptan",
          "correct": false
        },
        {
          "label": "B",
          "text": "Rimegepant",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lasmiditan",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ubrogepant",
          "correct": false
        }
      ],
      "correct_answer": "C. Lasmiditan",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Lasmiditan</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Lasmiditan is a selective 5-HT1F receptor agonist , categorized as a \"ditan,\" used for the acute management of migraines. Unlike triptans, lasmiditan does not cause vasoconstriction, making it suitable for patients with cardiovascular risk factors, such as Sneha. It acts by modulating neuronal activity associated with migraine pathophysiology, particularly in the trigeminal system.</li><li>\u2022 Lasmiditan</li><li>\u2022 5-HT1F receptor agonist</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Eletriptan: A 5-HT1B/1D receptor agonist (triptan) effective for migraines but contraindicated in patients with cardiovascular conditions due to its vasoconstrictive properties.</li><li>\u2022 Option A. Eletriptan:</li><li>\u2022 Option B. Rimegepant: A CGRP receptor antagonist (gepant) used for both acute and preventive migraine management but does not act on 5serotonin receptors.</li><li>\u2022 Option B. Rimegepant:</li><li>\u2022 Option D. Ubrogepant: Another CGRP receptor antagonist effective for migraines but unrelated to the serontonin receptor pathway.</li><li>\u2022 Option D. Ubrogepant:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Lasmiditan , a 5-HT1F receptor agonist, is a safe and effective option for migraine patients, especially those with contraindications to vasoconstrictive therapies like triptans.</li><li>\u27a4 Lasmiditan</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7dec45bd",
      "audio": ""
    },
    {
      "text": "A 72-year-old woman, Shanta, reports experiencing recurrent headaches that wake her from sleep every night around the same time. The pain is dull and generalized, lasting 30\u201360 minutes. She has no associated nausea, photophobia, or phonophobia. Her neurological examination is normal. Based on her diagnosis, which of the following is the treatment of choice?",
      "options": [
        {
          "label": "A",
          "text": "Fluoxetine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Diazepam",
          "correct": false
        },
        {
          "label": "C",
          "text": "Amitriptyline",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lithium",
          "correct": true
        }
      ],
      "correct_answer": "D. Lithium",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Lithium</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The patient is suffering from hypnic headache and Lithium carbonate (200\u2013600 mg at bedtime) is the treatment of choice. Hypnic headache, a rare primary headache disorder that predominantly affects older adults and wakes up people from sleep. Lithium is effective in preventing nocturnal attacks, likely by modulating the brain's circadian rhythms. For patients intolerant to lithium, verapamil may be used as an alternative.</li><li>\u2022 The patient is suffering from hypnic headache and Lithium carbonate</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Fluoxetine: This selective serotonin reuptake inhibitor (SSRI) is not effective in treating hypnic headache.</li><li>\u2022 Option A. Fluoxetine:</li><li>\u2022 Option B. Diazepam: This benzodiazepine is used for anxiety and sleep disorders but has no role in managing hypnic headache.</li><li>\u2022 Option B. Diazepam:</li><li>\u2022 Option C. Amitriptyline: While amitriptyline can be used for certain headache disorders, it is not the first-line treatment for hypnic headache.</li><li>\u2022 Option C. Amitriptyline:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The treatment of choice for hypnic headache is lithium carbonate , given at bedtime to prevent nocturnal headache attacks. Alternative treatments, such as verapamil, may be considered for patients unable to tolerate lithium.</li><li>\u27a4 treatment of choice for hypnic headache</li><li>\u27a4 lithium carbonate</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b287143f",
      "audio": ""
    },
    {
      "text": "A 45-year-old man, Ramesh, presents with acute onset diplopia, ataxia, and areflexia following a mild respiratory infection two weeks ago. Neurological examination reveals ophthalmoplegia, gait instability, and absent reflexes. Cerebrospinal fluid analysis shows albuminocytological dissociation. Which of the following antibodies is characteristic of this disorder?",
      "options": [
        {
          "label": "A",
          "text": "Anti-GM1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anti-GD1a",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anti-GQ1b",
          "correct": true
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "C. Anti-GQ1b",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Anti-GQ1b</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The case scenario is suggestive of Miller Fisher syndrome (MFS), a variant of Guillain-Barr\u00e9 syndrome (GBS). Anti-GQ1b IgG antibodies are found in over 90% of patients with MFS. These antibodies target gangliosides, particularly in the peripheral nerves and extraocular motor nerves, and are highest early in the disease course. Their presence is a diagnostic marker for MFS and distinguishes it from other GBS variants.</li><li>\u2022 The case scenario is suggestive of Miller Fisher syndrome (MFS),</li><li>\u2022 Anti-GQ1b IgG antibodies</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Anti-GM1: Found in other GBS variants, particularly those with motor axonal involvement, but not characteristic of MFS.</li><li>\u2022 Option A. Anti-GM1:</li><li>\u2022 Option B. Anti-GD1a: Associated with motor axonal GBS but not with MFS.</li><li>\u2022 Option B. Anti-GD1a:</li><li>\u2022 Option D. None of the above: This is incorrect as anti-GQ1b antibodies are specific for MFS.</li><li>\u2022 Option D. None of the above:</li><li>\u2022 anti-GQ1b antibodies</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anti-GQ1b antibodies are a hallmark of Miller Fisher syndrome , aiding in its diagnosis and distinguishing it from other forms of Guillain-Barr\u00e9 syndrome.</li><li>\u27a4 Anti-GQ1b antibodies</li><li>\u27a4 Miller Fisher syndrome</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "21bec921",
      "audio": ""
    },
    {
      "text": "A 65-year-old man, Ravi, presents with progressive weakness in his legs, difficulty climbing stairs, and dry mouth over the past few months. Neurological examination reveals reduced deep tendon reflexes that improve after exercise. Blood tests reveal the presence of anti-voltage-gated calcium channel antibodies. Imaging is ordered to rule out an associated malignancy. Which of the following cancers is most commonly associated with the disorder?",
      "options": [
        {
          "label": "A",
          "text": "Non-small-cell lung cancer",
          "correct": false
        },
        {
          "label": "B",
          "text": "Small-cell lung cancer",
          "correct": true
        },
        {
          "label": "C",
          "text": "Thymoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "Breast cancer",
          "correct": false
        }
      ],
      "correct_answer": "B. Small-cell lung cancer",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Small-cell lung cancer</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder often associated with small-cell lung cancer (SCLC) in older adults. The malignancy expresses voltage-gated calcium channels (VGCCs), triggering an autoimmune response that impairs acetylcholine release at the neuromuscular junction. Around 50\u201360% of LEMS cases in older adults are associated with malignancy, with SCLC being the most common.</li><li>\u2022 Lambert-Eaton myasthenic syndrome (LEMS)</li><li>\u2022 small-cell lung cancer (SCLC)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Non-small-cell lung cancer: Rarely associated with LEMS compared to small-cell lung cancer.</li><li>\u2022 Option A. Non-small-cell lung cancer:</li><li>\u2022 Option C. Thymoma: Commonly associated with myasthenia gravis , not LEMS.</li><li>\u2022 Option C. Thymoma:</li><li>\u2022 myasthenia gravis</li><li>\u2022 Option D. Breast cancer: LEMS is not typically associated with breast cancer.</li><li>\u2022 Option D. Breast cancer:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Small-cell lung cancer (SCLC) is the malignancy most commonly associated with Lambert-Eaton myasthenic syndrome , highlighting the importance of cancer screening in older adults diagnosed with LEMS.</li><li>\u27a4 Small-cell lung cancer (SCLC)</li><li>\u27a4 Lambert-Eaton myasthenic syndrome</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b1eb5f91",
      "audio": ""
    },
    {
      "text": "Which of the following hormones uses Receptor Tyrosine Kinase (RTK) signaling?",
      "options": [
        {
          "label": "A",
          "text": "Growth hormone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Insulin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Activin",
          "correct": false
        },
        {
          "label": "D",
          "text": "TGF-\u03b2",
          "correct": false
        }
      ],
      "correct_answer": "B. Insulin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Insulin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Insulin exerts its effects via the Receptor Tyrosine Kinase (RTK) signaling pathway. RTKs are membrane-bound receptors that, upon ligand binding, activate intracellular kinase domains, leading to phosphorylation cascades. This mechanism is shared by insulin, insulin-like growth factor-1 (IGF-1) , epidermal growth factor (EGF), and nerve growth factor (NGF).</li><li>\u2022 Insulin</li><li>\u2022 Receptor Tyrosine Kinase (RTK)</li><li>\u2022 insulin-like growth factor-1 (IGF-1)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Growth hormone: Uses the cytokine receptor-linked kinase pathway, involving the JAK-STAT signaling cascade.</li><li>\u2022 Option A. Growth hormone:</li><li>\u2022 cytokine receptor-linked kinase</li><li>\u2022 Option C. Activin: Uses the serine/threonine kinase signaling pathway.</li><li>\u2022 Option C. Activin:</li><li>\u2022 serine/threonine kinase</li><li>\u2022 Option D. TGF-\u03b2: Activates the serine/threonine kinase receptors to regulate gene transcription.</li><li>\u2022 Option D. TGF-\u03b2:</li><li>\u2022 serine/threonine kinase</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Receptor Tyrosine Kinase (RTK) signaling is the primary pathway for hormones like insulin and IGF-1, which regulate critical metabolic and growth functions. Other hormones may use different receptor types and signaling mechanisms.</li><li>\u27a4 Receptor Tyrosine Kinase (RTK) signaling</li><li>\u27a4 insulin</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d3f947e4",
      "audio": ""
    },
    {
      "text": "A neonate presents with failure to thrive, and signs of skeletal demineralization. Genetic testing reveals an autosomal recessive inactivating mutation in the calcium-sensing receptor (CaSR) gene. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Familial hypocalciuric hypercalcemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Familial hypocalciuric hypocalcemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Neonatal severe hyperparathyroidism",
          "correct": true
        },
        {
          "label": "D",
          "text": "Familial hypocalcemic hypercalciuria",
          "correct": false
        }
      ],
      "correct_answer": "C. Neonatal severe hyperparathyroidism",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Neonatal severe hyperparathyroidism</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Neonatal severe hyperparathyroidism (NSHPT) is caused by autosomal recessive (AR) inactivating mutations in the calcium-sensing receptor (CaSR) gene. The loss of function in CaSR reduces the sensitivity of the parathyroid gland and kidneys to serum calcium levels, leading to severe hypercalcemia, profound hyperparathyroidism, and skeletal abnormalities in neonates. This condition is life-threatening and often requires prompt surgical intervention.</li><li>\u2022 Neonatal severe hyperparathyroidism (NSHPT)</li><li>\u2022 autosomal recessive (AR)</li><li>\u2022 calcium-sensing receptor (CaSR)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Familial hypocalciuric hypercalcemia (FHH): Caused by autosomal dominant (AD) inactivating mutations in CaSR, leading to mild hypercalcemia with hypocalciuria, not the severe symptoms seen in NSHPT.</li><li>\u2022 Option A. Familial hypocalciuric hypercalcemia (FHH):</li><li>\u2022 autosomal dominant (AD)</li><li>\u2022 Option B. Familial hypocalciuric hypocalcemia: Not a recognized clinical entity; likely a misinterpretation.</li><li>\u2022 Option B. Familial hypocalciuric hypocalcemia:</li><li>\u2022 Option D. Familial hypocalcemic hypercalciuria: Caused by AD activating mutations in CaSR, resulting in hypocalcemia and hypercalciuria, which contrasts with the hypercalcemia in NSHPT.</li><li>\u2022 Option D. Familial hypocalcemic hypercalciuria:</li><li>\u2022 AD activating mutations</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Neonatal severe hyperparathyroidism results from AR inactivating mutations in the CaSR gene , leading to life-threatening hypercalcemia and hyperparathyroidism in neonates, distinct from the milder phenotype of FHH.</li><li>\u27a4 Neonatal severe hyperparathyroidism</li><li>\u27a4 AR inactivating mutations</li><li>\u27a4 CaSR gene</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ac87db8e",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman, Anita, presents with irregular menstrual cycles and galactorrhea. Blood tests reveal elevated prolactin levels, and an MRI shows a small pituitary adenoma. The physician explains that dopamine normally inhibits prolactin synthesis via specific receptors. Which dopamine receptor mediates this effect?",
      "options": [
        {
          "label": "A",
          "text": "D1 receptor",
          "correct": false
        },
        {
          "label": "B",
          "text": "D2 receptor",
          "correct": true
        },
        {
          "label": "C",
          "text": "D3 receptor",
          "correct": false
        },
        {
          "label": "D",
          "text": "D4 receptor",
          "correct": false
        }
      ],
      "correct_answer": "B. D2 receptor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) D2 receptor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Dopamine inhibits prolactin (PRL) synthesis and secretion by acting on D2 receptors located on lactotrophs in the anterior pituitary gland. Activation of these receptors suppresses PRL release and reduces lactotroph proliferation. Disruption of D2 receptor signaling, such as in gene knockout studies, leads to hyperprolactinemia and lactotroph hyperplasia. Dopamine agonists like bromocriptine and cabergoline are used to manage hyperprolactinemic disorders by targeting D2 receptors.</li><li>\u2022 prolactin (PRL) synthesis and secretion</li><li>\u2022 D2 receptors</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. D1 receptor: Primarily involved in excitatory pathways in the central nervous system, not in prolactin inhibition.</li><li>\u2022 Option A. D1 receptor:</li><li>\u2022 Option C. D3 receptor: Has a minor role in dopamine signaling but is not the main receptor for prolactin regulation.</li><li>\u2022 Option C. D3 receptor:</li><li>\u2022 Option D. D4 receptor: Primarily implicated in neurological functions, not prolactin regulation.</li><li>\u2022 Option D. D4 receptor:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Dopamine inhibits prolactin synthesis and secretion through D2 receptors in the anterior pituitary, making these receptors a critical target for treating hyperprolactinemia.</li><li>\u27a4 prolactin synthesis and secretion</li><li>\u27a4 D2 receptors</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "10b97430",
      "audio": ""
    },
    {
      "text": "A 5-year-old boy presents with concerns about short stature. His father\u2019s height is 175 cm, and his mother\u2019s height is 165 cm. Based on this information, what is his mid-parental height (MPH)?",
      "options": [
        {
          "label": "A",
          "text": "170 cm",
          "correct": false
        },
        {
          "label": "B",
          "text": "176.5 cm",
          "correct": true
        },
        {
          "label": "C",
          "text": "163.5 cm",
          "correct": false
        },
        {
          "label": "D",
          "text": "168.5 cm",
          "correct": false
        }
      ],
      "correct_answer": "B. 176.5 cm",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 176.5 cm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The mid-parental height (MPH) for boys is calculated using the formula:</li><li>\u2022 mid-parental height (MPH)</li><li>\u2022 MPH= (Father\u2019s Height + Mother\u2019s Height/2) +6.5\u2009cm [-6.5cm for girls]</li><li>\u2022 Substitute the values:</li><li>\u2022 MPH=(175+165/2)+6.5 =170+6.5 = 176.5\u2009cm</li><li>\u2022 This value represents the estimated adult height based on parental heights.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. 170 cm: This value is the average of the parents' heights without adding the gender adjustment.</li><li>\u2022 Option A. 170 cm:</li><li>\u2022 Option C. 163.5 cm: This is incorrect and it is the MPH for a girl (170-6.5 = 163.5)</li><li>\u2022 Option C. 163.5 cm:</li><li>\u2022 Option D. 168.5 cm: This value does not match the formula for calculating the mid-parental height.</li><li>\u2022 Option D. 168.5 cm:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The mid-parental height (MPH) for boys is calculated by averaging the parents' heights and adding 6.5 cm , giving an estimate of the child\u2019s adult height potential.</li><li>\u27a4 mid-parental height (MPH)</li><li>\u27a4 6.5 cm</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4a80237c",
      "audio": ""
    },
    {
      "text": "A 32-year-old woman, Priya, presents with galactorrhea, amenorrhea, and fatigue. Her prolactin level is found to be 260 \u03bcg/L. She has a history of psychiatric illness and is on long-term medication. Which of the following drugs is most likely responsible for her elevated prolactin levels?",
      "options": [
        {
          "label": "A",
          "text": "Verapamil",
          "correct": false
        },
        {
          "label": "B",
          "text": "Methyldopa",
          "correct": false
        },
        {
          "label": "C",
          "text": "Risperidone",
          "correct": true
        },
        {
          "label": "D",
          "text": "Metoclopramide",
          "correct": false
        }
      ],
      "correct_answer": "C. Risperidone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Risperidone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Risperidone , an atypical antipsychotic, blocks dopamine D2 receptors in the tuberoinfundibular pathway, leading to decreased inhibition of prolactin release and resulting in hyperprolactinemia. Risperidone is well-known to cause significant increases in prolactin levels, sometimes exceeding 200 \u03bcg/L. This is a common side effect and may require management in symptomatic patients.</li><li>\u2022 Risperidone</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Verapamil: Verapamil can cause mild hyperprolactinemia by inhibiting dopamine release but rarely results in prolactin levels as high as 200 \u03bcg/L.</li><li>\u2022 Option A. Verapamil:</li><li>\u2022 Option B. Methyldopa: Methyldopa inhibits dopamine synthesis, leading to mild-to-moderate increases in prolactin but not to the extent caused by risperidone.</li><li>\u2022 Option B. Methyldopa:</li><li>\u2022 Option D. Metoclopramide: Metoclopramide, a dopamine antagonist used as an antiemetic, can elevate prolactin levels but typically does not exceed 200 \u03bcg/L unless used in high doses.</li><li>\u2022 Option D. Metoclopramide:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Risperidone is a frequent cause of significant hyperprolactinemia, with prolactin levels potentially exceeding 200 \u03bcg/L , due to its potent dopamine D2 receptor antagonism.</li><li>\u27a4 Risperidone</li><li>\u27a4 200 \u03bcg/L</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3e099957",
      "audio": ""
    },
    {
      "text": "A 50-year-old woman, Anita, diagnosed with acromegaly, is being treated with a medication that normalizes her serum IGF-1 levels but causes elevated GH levels. Which of the following drugs used for acromegaly is most likely responsible for this effect?",
      "options": [
        {
          "label": "A",
          "text": "Octreotide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Lanreotide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pegvisomant",
          "correct": true
        },
        {
          "label": "D",
          "text": "Pasireotide",
          "correct": false
        }
      ],
      "correct_answer": "C. Pegvisomant",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Pegvisomant</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Pegvisomant is a growth hormone receptor antagonist that blocks the peripheral action of endogenous GH by preventing its binding to receptors. While this reduces serum IGF-1 levels and alleviates the effects of GH excess, it causes resistance to GH action, causing elevated GH levels. Pegvisomant is effective in normalizing IGF-1 levels in ~70% of patients with acromegaly.</li><li>\u2022 Pegvisomant</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Octreotide: A somatostatin analog that suppresses GH secretion from the pituitary adenoma, leading to reduced GH and IGF-1 levels.</li><li>\u2022 Option A. Octreotide:</li><li>\u2022 Option B. Lanreotide: Another somatostatin analog similar to octreotide, which lowers both GH and IGF-1 levels.</li><li>\u2022 Option B. Lanreotide:</li><li>\u2022 Option D. Pasireotide: A broader-spectrum somatostatin analog that also suppresses GH secretion from the adenoma, reducing GH and IGF-1 levels.</li><li>\u2022 Option D. Pasireotide:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pegvisomant reduces IGF-1 levels by blocking GH receptors but does not target the pituitary adenoma, so GH levels remain elevated , making it unique among drugs used to treat acromegaly. Tumor size should be monitored during therapy.</li><li>\u27a4 Pegvisomant</li><li>\u27a4 GH levels remain elevated</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3abec4ff",
      "audio": ""
    },
    {
      "text": "A 30-year-old man presents for a routine health check-up. His lab reports show the following: Fasting Blood Glucose (FBS): 98 mg/dL 2-hour Postprandial Glucose (PG): 130 mg/dL HbA1c: 5.0% What is the most appropriate diagnosis based on these findings?",
      "options": [
        {
          "label": "A",
          "text": "Normal glucose tolerance",
          "correct": true
        },
        {
          "label": "B",
          "text": "Impaired glucose tolerance",
          "correct": false
        },
        {
          "label": "C",
          "text": "Diabetes Mellitus",
          "correct": false
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "A. Normal glucose tolerance",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20161825.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Normal glucose tolerance</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The patient\u2019s glucose values fall within the normal range for glucose tolerance based on the criteria:</li><li>\u2022 normal range</li><li>\u2022 Fasting Blood Glucose (FBS): <100 mg/dL (normal: <100 mg/dL) 2-hour Postprandial Glucose (PG): <140 mg/dL (normal: <140 mg/dL) HbA1c: <5.7% (normal: <5.7%)</li><li>\u2022 Fasting Blood Glucose (FBS): <100 mg/dL (normal: <100 mg/dL)</li><li>\u2022 Fasting Blood Glucose (FBS):</li><li>\u2022 2-hour Postprandial Glucose (PG): <140 mg/dL (normal: <140 mg/dL)</li><li>\u2022 2-hour Postprandial Glucose (PG):</li><li>\u2022 HbA1c: <5.7% (normal: <5.7%)</li><li>\u2022 HbA1c:</li><li>\u2022 These values indicate normal glucose tolerance , with no evidence of prediabetes or diabetes.</li><li>\u2022 normal glucose tolerance</li><li>\u2022 Diagnostic Criteria for Glucose Tolerance:</li><li>\u2022 Diagnostic Criteria for Glucose Tolerance:</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Impaired glucose tolerance: Requires 2-hour postprandial glucose of 140\u2013199 mg/dL or FBS of 100\u2013125 mg/dL , which this patient does not have.</li><li>\u2022 Option B. Impaired glucose tolerance:</li><li>\u2022 140\u2013199 mg/dL</li><li>\u2022 100\u2013125 mg/dL</li><li>\u2022 Option C. Diabetes Mellitus: Requires FBS \u2265126 mg/dL, 2-hour PG \u2265200 mg/dL, or HbA1c \u22656.5%.</li><li>\u2022 Option C. Diabetes Mellitus:</li><li>\u2022 Option D. None of the above: Incorrect as the patient meets the criteria for normal glucose tolerance .</li><li>\u2022 Option D. None of the above:</li><li>\u2022 normal glucose tolerance</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 This patient\u2019s lab values indicate normal glucose tolerance based on fasting glucose, 2-hour postprandial glucose, and HbA1c, confirming no evidence of diabetes or prediabetes.</li><li>\u27a4 normal glucose tolerance</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "79352005",
      "audio": ""
    },
    {
      "text": "A 14-year-old boy presents with weight loss, polyuria, and polydipsia. Lab tests reveal hyperglycemia, and he is diagnosed with type 1 diabetes mellitus. Autoantibody testing is ordered to confirm the autoimmune etiology. Which of the following autoantibodies are associated with it?",
      "options": [
        {
          "label": "A",
          "text": "GAD",
          "correct": false
        },
        {
          "label": "B",
          "text": "ZnT-8",
          "correct": false
        },
        {
          "label": "C",
          "text": "IA-2",
          "correct": false
        },
        {
          "label": "D",
          "text": "All of the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All of the above",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) All of the above</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Islet cell autoantibodies (ICAs) are markers of the autoimmune process in type 1 diabetes mellitus (T1DM). These antibodies are directed against various pancreatic islet cell antigens, including:</li><li>\u2022 Islet cell autoantibodies (ICAs)</li><li>\u2022 GAD (Glutamic Acid Decarboxylase): Commonly detected in T1DM and associated with \u03b2-cell destruction. ZnT-8 (Zinc Transporter 8): Highly specific to T1DM and contributes to \u03b2-cell dysfunction. IA-2 (Islet Antigen-2): A tyrosine phosphatase protein targeted by autoantibodies in T1DM.</li><li>\u2022 GAD (Glutamic Acid Decarboxylase): Commonly detected in T1DM and associated with \u03b2-cell destruction.</li><li>\u2022 GAD (Glutamic Acid Decarboxylase):</li><li>\u2022 ZnT-8 (Zinc Transporter 8): Highly specific to T1DM and contributes to \u03b2-cell dysfunction.</li><li>\u2022 ZnT-8 (Zinc Transporter 8):</li><li>\u2022 IA-2 (Islet Antigen-2): A tyrosine phosphatase protein targeted by autoantibodies in T1DM.</li><li>\u2022 IA-2 (Islet Antigen-2):</li><li>\u2022 The presence of one or more of these autoantibodies is diagnostic of autoimmune T1DM and helps differentiate it from other forms of diabetes.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Each autoantibody (A, B, C) is individually correct, making the most appropriate answer D. All of the above .</li><li>\u2022 D. All of the above</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Type 1 diabetes mellitus is characterized by the presence of islet cell autoantibodies , including GAD , ZnT-8 , and IA-2 , which serve as markers of the autoimmune destruction of pancreatic \u03b2-cells.</li><li>\u27a4 islet cell autoantibodies</li><li>\u27a4 GAD</li><li>\u27a4 ZnT-8</li><li>\u27a4 IA-2</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "63db821f",
      "audio": ""
    },
    {
      "text": "A 45-year-old man with central obesity and a BMI of 32 kg/m\u00b2 is being evaluated for insulin resistance. Lab studies reveal elevated levels of inflammatory markers and metabolic byproducts. Which of the following is unlikely to be elevated?",
      "options": [
        {
          "label": "A",
          "text": "Free fatty acids",
          "correct": false
        },
        {
          "label": "B",
          "text": "TNF-\u03b1",
          "correct": false
        },
        {
          "label": "C",
          "text": "Adiponectin",
          "correct": true
        },
        {
          "label": "D",
          "text": "IL-6",
          "correct": false
        }
      ],
      "correct_answer": "C. Adiponectin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Adiponectin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Adiponectin is an insulin-sensitizing peptide secreted by adipocytes. Unlike other adipocyte-derived factors, its levels are reduced in obesity and insulin resistance. Lower adiponectin levels contribute to hepatic and systemic insulin resistance, highlighting its protective role in glucose metabolism and inflammation.</li><li>\u2022 Adiponectin</li><li>\u2022 insulin-sensitizing peptide</li><li>\u2022 reduced</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Free fatty acids: Elevated in insulin resistance due to increased lipolysis in adipocytes, contributing to impaired insulin signaling.</li><li>\u2022 Option A. Free fatty acids:</li><li>\u2022 Option B. TNF-\u03b1: Increased levels are secreted by adipocytes and macrophages in obese individuals, promoting systemic inflammation and insulin resistance.</li><li>\u2022 Option B. TNF-\u03b1:</li><li>\u2022 Option D. IL-6: Elevated in obesity, IL-6 promotes inflammation and is linked to insulin resistance.</li><li>\u2022 Option D. IL-6:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In insulin resistance , most adipocyte-derived factors like free fatty acids , TNF-\u03b1 , and IL-6 are elevated, while adiponectin levels are reduced , contributing to impaired insulin sensitivity and metabolic dysfunction.</li><li>\u27a4 insulin resistance</li><li>\u27a4 free fatty acids</li><li>\u27a4 TNF-\u03b1</li><li>\u27a4 IL-6</li><li>\u27a4 adiponectin levels are reduced</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1a8a4e99",
      "audio": ""
    },
    {
      "text": "A 50-year-old man with type 2 diabetes mellitus is started on an antidiabetic medication that works by reducing insulin resistance and is weight neutral. What is the exact mechanism of action?",
      "options": [
        {
          "label": "A",
          "text": "Stimulating AMP kinase",
          "correct": true
        },
        {
          "label": "B",
          "text": "Stimulating GLP1R",
          "correct": false
        },
        {
          "label": "C",
          "text": "Inhibiting ATP-sensitive potassium channels",
          "correct": false
        },
        {
          "label": "D",
          "text": "Activating PPAR-\u03b3",
          "correct": false
        }
      ],
      "correct_answer": "A. Stimulating AMP kinase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Stimulating AMP kinase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The medication described is most likely metformin. Metformin works by stimulating AMP-activated protein kinase (AMPK), an enzyme that plays a crucial role in cellular energy homeostasis. Activation of AMPK reduces hepatic gluconeogenesis, increases insulin sensitivity, and promotes glucose uptake in peripheral tissues. Metformin is weight neutral and does not directly increase insulin secretion.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Stimulating GLP1R : Refers to GLP-1 receptor agonists, which enhance insulin secretion, slow gastric emptying, and promote weight loss, not weight neutrality.</li><li>\u2022 Option B. Stimulating GLP1R</li><li>\u2022 Option C. Inhibiting ATP-sensitive potassium channels: Is the mechanism of sulfonylureas, which stimulate insulin release and are associated with weight gain.</li><li>\u2022 Option C. Inhibiting ATP-sensitive potassium channels:</li><li>\u2022 Option D. Activating PPAR-\u03b3: Is the mechanism of thiazolidinediones (TZDs), which improve insulin sensitivity but are often associated with weight gain.</li><li>\u2022 Option D. Activating PPAR-\u03b3:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Metformin stimulates AMP kinase, reduces hepatic gluconeogenesis, and improves insulin sensitivity while being weight neutral, making it a first-line treatment for type 2 diabetes mellitus.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "df19f69c",
      "audio": ""
    },
    {
      "text": "A 60-year-old woman with type 2 diabetes mellitus is started on an antidiabetic medication. Over the next few months, she reports worsening vision. On examination, she has evidence of diabetic macular edema. Which of the following medications is most likely responsible?",
      "options": [
        {
          "label": "A",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Liraglutide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Canagliflozin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pioglitazone",
          "correct": true
        }
      ],
      "correct_answer": "D. Pioglitazone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Pioglitazone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Pioglitazone , a thiazolidinedione (TZD) , is associated with fluid retention and peripheral edema, which can exacerbate diabetic macular edema in rare cases. The FDA has issued a warning regarding this potential adverse effect. TZDs increase plasma volume and vascular permeability, which may worsen retinal edema, leading to a decline in vision in some patients.</li><li>\u2022 Pioglitazone</li><li>\u2022 thiazolidinedione (TZD)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Metformin: Does not affect fluid retention or vascular permeability and is not associated with macular edema.</li><li>\u2022 Option A. Metformin:</li><li>\u2022 Option B. Liraglutide: A GLP-1 receptor agonist not linked to worsening macular edema.</li><li>\u2022 Option B. Liraglutide:</li><li>\u2022 Option C. Canagliflozin: An SGLT2 inhibitor that promotes glycosuria; it has no reported effects on macular edema.</li><li>\u2022 Option C. Canagliflozin:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pioglitazone , a TZD, may rarely worsen diabetic macular edema due to fluid retention and vascular permeability changes, necessitating caution in patients with preexisting macular edema.</li><li>\u27a4 Pioglitazone</li><li>\u27a4 diabetic macular edema</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "519cab8a",
      "audio": ""
    },
    {
      "text": "A 45-year-old man, Rajesh, presents with recurrent kidney stones, visual disturbances, and recurrent admissions for hypoglycemic episodes. Which of the following tumors is not characteristic of this disorder?",
      "options": [
        {
          "label": "A",
          "text": "Parathyroid tumor",
          "correct": false
        },
        {
          "label": "B",
          "text": "Pancreatic tumor",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pituitary tumor",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thyroid tumor",
          "correct": true
        }
      ],
      "correct_answer": "D. Thyroid tumor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Thyroid tumor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation is suggestive of Multiple Endocrine Neoplasia type 1 (MEN1). This syndrome is characterized by the \"3 P's\": parathyroid tumors (leading to primary hyperparathyroidism), pancreatic neuroendocrine tumors (such as insulinomas causing hypoglycemia), and pituitary tumors (e.g., prolactinomas causing visual disturbances). Thyroid tumors are not characteristic of MEN1 and are more commonly associated with MEN2.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Parathyroid tumor: Is a defining feature of MEN1 and typically presents as primary hyperparathyroidism with symptoms like recurrent kidney stones.</li><li>\u2022 Option A. Parathyroid tumor:</li><li>\u2022 Option B. Pancreatic tumor: Such as insulinoma or gastrinoma, is a common manifestation of MEN1 and explains the hypoglycemic episodes.</li><li>\u2022 Option B. Pancreatic tumor:</li><li>\u2022 Option C. Pituitary tumor : Is another hallmark of MEN1, often presenting with hormone-related symptoms and visual disturbances due to compression of the optic chiasm.</li><li>\u2022 Option C. Pituitary tumor</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 MEN1 is characterized by tumors of the parathyroid, pancreas, and pituitary. Thyroid tumors are not associated with MEN1 but are a feature of MEN2 syndromes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bb31c013",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman presents with features of weight gain, central obesity, and purple abdominal striae. She also has multiple pigmented skin lesions and a family history of similar findings. She recently underwent surgery for atrial myxoma. Which of the following is the most common endocrine manifestation of this disorder?",
      "options": [
        {
          "label": "A",
          "text": "Cushing\u2019s syndrome",
          "correct": true
        },
        {
          "label": "B",
          "text": "Addison\u2019s disease",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hyperparathyroidism",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypothyroidism",
          "correct": false
        }
      ],
      "correct_answer": "A. Cushing\u2019s syndrome",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Cushing\u2019s syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This presentation is consistent with Carney complex, a genetic condition characterized by a combination of endocrine and non-endocrine tumors, pigmented skin lesions, and atrial myxomas. The most common endocrine manifestation is Cushing\u2019s syndrome, which occurs due to primary pigmented nodular adrenal disease (PPNAD).</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Addison\u2019s disease: Is not associated with Carney complex; it is related to autoimmune adrenalitis or APS-1.</li><li>\u2022 Option B. Addison\u2019s disease:</li><li>\u2022 Option C. Hyperparathyroidism: Is more characteristic of multiple endocrine neoplasia (MEN) syndromes, not Carney complex.</li><li>\u2022 Option C. Hyperparathyroidism:</li><li>\u2022 Option D. Hypothyroidism: Is not commonly seen in Carney complex and is unrelated to the described presentation.</li><li>\u2022 Option D. Hypothyroidism:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Cushing\u2019s syndrome, due to primary pigmented nodular adrenal disease, is the most common endocrine manifestation of Carney complex, a rare genetic syndrome often associated with atrial myxomas and pigmented skin lesions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "82e86cff",
      "audio": ""
    },
    {
      "text": "A 4-month-old boy presents with severe diarrhea, eczema, and hyperglycemia. His family history is significant for autoimmune diseases in male relatives. Which of the following genes is likely to be mutated?",
      "options": [
        {
          "label": "A",
          "text": "AIRE gene",
          "correct": false
        },
        {
          "label": "B",
          "text": "CDKN1B",
          "correct": false
        },
        {
          "label": "C",
          "text": "FOXP3 gene",
          "correct": true
        },
        {
          "label": "D",
          "text": "RET",
          "correct": false
        }
      ],
      "correct_answer": "C. FOXP3 gene",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) FOXP3 gene</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 IPEX syndrome (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked) is caused by mutations in the FOXP3 gene , which encodes a transcription factor critical for the development and function of regulatory T cells (Tregs). Loss of FOXP3 function leads to impaired immune regulation and widespread autoimmunity. Key clinical features include:</li><li>\u2022 IPEX syndrome</li><li>\u2022 FOXP3 gene</li><li>\u2022 Severe enteropathy (diarrhea). Type 1 diabetes mellitus (T1DM). Dermatitis (eczema). Other autoimmune manifestations.</li><li>\u2022 Severe enteropathy (diarrhea).</li><li>\u2022 Type 1 diabetes mellitus (T1DM).</li><li>\u2022 Dermatitis (eczema).</li><li>\u2022 Other autoimmune manifestations.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. AIRE gene: Mutations in AIRE cause autoimmune polyendocrine syndrome type 1 (APS 1), not IPEX.</li><li>\u2022 Option A. AIRE gene:</li><li>\u2022 Option B. CDKN1B: Mutations in CDKN1B are associated with MEN 4, not IPEX.</li><li>\u2022 Option B. CDKN1B:</li><li>\u2022 Option D. RET: Mutations in RET are associated with MEN 2, not IPEX.</li><li>\u2022 Option D. RET:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 IPEX syndrome is caused by mutations in the FOXP3 gene , leading to severe autoimmunity due to defective regulatory T cell function. It presents in infancy with enteropathy, T1DM, and skin manifestations.</li><li>\u27a4 IPEX syndrome</li><li>\u27a4 FOXP3 gene</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "70d46c91",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman presents with progressive shortness of breath and wheezing. Pulmonary function testing includes the measurement of diffusing capacity of the lungs for carbon monoxide (DLCO). Which of the following conditions is not typically associated with a decreased DLCO?",
      "options": [
        {
          "label": "A",
          "text": "Asthma",
          "correct": true
        },
        {
          "label": "B",
          "text": "COPD",
          "correct": false
        },
        {
          "label": "C",
          "text": "ILD",
          "correct": false
        },
        {
          "label": "D",
          "text": "ARDS",
          "correct": false
        }
      ],
      "correct_answer": "A. Asthma",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Asthma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In asthma , DLCO is typically normal or increased due to factors such as increased pulmonary blood flow and capillary recruitment during bronchospasm. Asthma does not cause structural damage to the alveolar-capillary interface, which is necessary to decrease DLCO.</li><li>\u2022 asthma</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. COPD: In emphysema, destruction of alveolar walls leads to reduced alveolar surface area and impaired gas exchange, resulting in decreased DLCO.</li><li>\u2022 Option B. COPD:</li><li>\u2022 Option C. ILD: Interstitial lung disease causes thickening of the alveolar-capillary membrane, reducing the transfer of gas and decreasing DLCO.</li><li>\u2022 Option C. ILD:</li><li>\u2022 Option D. ARDS: Acute damage to the alveolar-capillary barrier in ARDS impairs gas exchange, leading to a decreased DLCO.</li><li>\u2022 Option D. ARDS:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Decreased DLCO is seen in conditions that disrupt the alveolar-capillary membrane, such as COPD (emphysema), ILD, ARDS , and others. In contrast, asthma does not typically decrease DLCO and may even increase it due to enhanced pulmonary blood flow.</li><li>\u27a4 Decreased DLCO</li><li>\u27a4 COPD (emphysema), ILD, ARDS</li><li>\u27a4 asthma</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e9fc263b",
      "audio": ""
    },
    {
      "text": "A 55-year-old man presents for follow-up after being treated for deep vein thrombosis (DVT) 6 months ago. He is concerned about the risk of recurrence of venous thromboembolism. Which of the following risk factors has the highest risk of recurrent venous thromboembolism?",
      "options": [
        {
          "label": "A",
          "text": "Prior DVT",
          "correct": true
        },
        {
          "label": "B",
          "text": "Genetic thrombophilia",
          "correct": false
        },
        {
          "label": "C",
          "text": "OCP use",
          "correct": false
        },
        {
          "label": "D",
          "text": "Malignancy",
          "correct": false
        }
      ],
      "correct_answer": "A. Prior DVT",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Prior DVT</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The prior history of DVT is the most significant risk factor for recurrent venous thromboembolism (VTE) . Individuals who have experienced a previous VTE event, such as DVT or pulmonary embolism, have a higher likelihood of recurrence, even if other risk factors are managed or absent. The recurrence risk is highest in the first 6\u201312 months following the initial event.</li><li>\u2022 prior history of DVT</li><li>\u2022 recurrent venous thromboembolism (VTE)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Genetic thrombophilia: While genetic thrombophilia (e.g., Factor V Leiden mutation, prothrombin gene mutation) increases the risk of VTE, it is still not as high as the risk posed by a prior DVT, which indicates the individual has already experienced a thrombotic event.</li><li>\u2022 Option B. Genetic thrombophilia:</li><li>\u2022 Option C. OCP use: Oral contraceptive use increases the risk of VTE, but the risk is lower compared to the recurrence risk seen in patients with a prior DVT, particularly once the OCP is discontinued.</li><li>\u2022 Option C. OCP use:</li><li>\u2022 Option D. Malignancy: Malignancy is a significant risk factor for VTE, particularly in the context of certain cancers, but prior DVT still poses a higher recurrence risk.</li><li>\u2022 Option D. Malignancy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Prior DVT is the most significant risk factor for the recurrence of venous thromboembolism, and patients with a history of DVT require careful management and monitoring for recurrence.</li><li>\u27a4 Prior DVT</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5bfa6ed6",
      "audio": ""
    },
    {
      "text": "A 34-year-old patient with a history of allergic bronchopulmonary aspergillosis (ABPA) on chronic steroids presents to the emergency room with swelling and pain in the left lower limb and sudden onset breathlessness. On arrival, the patient is hemodynamically stable, but the shock index is >1. A compression ultrasound confirms a left lower limb deep vein thrombosis (DVT). Which of the following tests will best confirm the underlying diagnosis of a pulmonary embolism?",
      "options": [
        {
          "label": "A",
          "text": "CT Pulmonary angiogram",
          "correct": true
        },
        {
          "label": "B",
          "text": "ECG",
          "correct": false
        },
        {
          "label": "C",
          "text": "Echocardiogram",
          "correct": false
        },
        {
          "label": "D",
          "text": "MRI Thorax",
          "correct": false
        }
      ],
      "correct_answer": "A. CT Pulmonary angiogram",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) CT Pulmonary angiogram</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 A CT pulmonary angiogram (CTPA) is the gold standard for diagnosing pulmonary embolism (PE) . In a patient with DVT and sudden-onset breathlessness, a CTPA will allow direct visualization of the pulmonary arteries and detect filling defects , which are characteristic of a pulmonary embolism. It provides detailed imaging of the pulmonary vasculature, which is crucial in confirming the diagnosis.</li><li>\u2022 CT pulmonary angiogram (CTPA)</li><li>\u2022 pulmonary embolism (PE)</li><li>\u2022 DVT</li><li>\u2022 filling defects</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. ECG: An ECG may show sinus tachycardia or signs of right ventricular strain (e.g., S1Q3T3 pattern), but it cannot confirm the diagnosis of pulmonary embolism, as these findings are nonspecific.</li><li>\u2022 Option B. ECG:</li><li>\u2022 right ventricular strain</li><li>\u2022 confirm the diagnosis</li><li>\u2022 Option C. Echocardiogram: While an echocardiogram can assess right ventricular (RV) dysfunction , it is not diagnostic for pulmonary embolism . RV dilation or hypokinesis may be seen in PE, but these findings are also present in other conditions.</li><li>\u2022 Option C. Echocardiogram:</li><li>\u2022 right ventricular (RV) dysfunction</li><li>\u2022 pulmonary embolism</li><li>\u2022 Option D. MRI Thorax: While MRI is useful in some cases, it is not the first-line imaging modality for diagnosing PE. It is more time-consuming and not preferred for acute cases of pulmonary embolism.</li><li>\u2022 Option D. MRI Thorax:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In a patient with suspected pulmonary embolism , especially when DVT is present, a CT pulmonary angiogram (CTPA) is the preferred and most accurate diagnostic test to confirm the diagnosis by detecting filling defects in the pulmonary arteries.</li><li>\u27a4 pulmonary embolism</li><li>\u27a4 DVT</li><li>\u27a4 CT pulmonary angiogram (CTPA)</li><li>\u27a4 filling defects</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a640e4a0",
      "audio": ""
    },
    {
      "text": "A 45-year-old banker presents with shortness of breath (SOB) after climbing 2 flights of stairs. He develops chest tightness after 1 flight of stairs and has had multiple syncopal episodes in the past. His past medical history is significant for deep vein thrombosis (DVT) following limb immobilization 5 years ago. Pulmonary function tests (PFT) are normal, but his diffusing capacity for carbon monoxide (DLCO) is reduced. Echocardiogram shows right ventricular systolic pressure (RVSP) of 50 mmHg with normal left ventricular function. What is the most appropriate management strategy for this patient?",
      "options": [
        {
          "label": "A",
          "text": "MRI angiography of the thorax",
          "correct": false
        },
        {
          "label": "B",
          "text": "CTPA (CT pulmonary angiography)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Coronary angiography",
          "correct": false
        },
        {
          "label": "D",
          "text": "Start oral prostacyclin therapy",
          "correct": false
        }
      ],
      "correct_answer": "B. CTPA (CT pulmonary angiography)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) CTPA (CT pulmonary angiography)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This patient likely has chronic thromboembolic pulmonary hypertension (CTEPH) , a condition that develops after unresolved pulmonary embolism (PE), where thromboembolic material causes pulmonary vessel obstruction and increased right heart pressures. CTEPH can occur after a history of DVT , which has been shown to lead to small emboli that are not completely resolved, resulting in chronic obstruction and increasing right ventricular systolic pressure (RVSP) . CTPA is the diagnostic test of choice to visualize the pulmonary vasculature and assess the feasibility of surgical intervention , such as pulmonary thromboendarterectomy , which is the most effective treatment for CTEPH. This test helps identify residual emboli or chronic thromboembolic material in the pulmonary arteries.</li><li>\u2022 chronic thromboembolic pulmonary hypertension (CTEPH)</li><li>\u2022 pulmonary vessel obstruction</li><li>\u2022 history of DVT</li><li>\u2022 right ventricular systolic pressure (RVSP)</li><li>\u2022 CTPA</li><li>\u2022 feasibility of surgical intervention</li><li>\u2022 pulmonary thromboendarterectomy</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. MRI angiography of the thorax: MRI angiography is not the preferred imaging modality for diagnosing CTEPH. CTPA is more effective in visualizing pulmonary artery thromboembolic material and assessing the lung parenchyma.</li><li>\u2022 Option A. MRI angiography of the thorax:</li><li>\u2022 MRI angiography</li><li>\u2022 CTPA</li><li>\u2022 pulmonary artery thromboembolic material</li><li>\u2022 Option C. Coronary angiography: This test evaluates epicardial coronary vessels for obstructive coronary artery disease, which is unrelated to the pulmonary vascular pathology seen in CTEPH .</li><li>\u2022 Option C. Coronary angiography:</li><li>\u2022 epicardial coronary vessels</li><li>\u2022 CTEPH</li><li>\u2022 Option D. Start oral prostacyclin therapy: Oral prostacyclin (or PDE-5 inhibitors) are typically used in advanced pulmonary hypertension , particularly when endarterectomy is not feasible. However, surgical intervention should be prioritized if the patient is a candidate for pulmonary thromboendarterectomy .</li><li>\u2022 Option D. Start oral prostacyclin therapy:</li><li>\u2022 Oral prostacyclin (or PDE-5 inhibitors)</li><li>\u2022 advanced pulmonary hypertension</li><li>\u2022 endarterectomy</li><li>\u2022 pulmonary thromboendarterectomy</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 CTPA is the gold standard for diagnosing CTEPH and should be performed in patients with a history of DVT and symptoms of pulmonary hypertension , such as dyspnea and syncope. If CTEPH is confirmed, further evaluation with right heart catheterization and surgical options such as pulmonary thromboendarterectomy may be pursued. If surgery is not feasible, oral prostacyclin therapy is considered for managing pulmonary hypertension.</li><li>\u27a4 CTPA</li><li>\u27a4 gold standard</li><li>\u27a4 CTEPH</li><li>\u27a4 DVT</li><li>\u27a4 pulmonary hypertension</li><li>\u27a4 CTEPH</li><li>\u27a4 right heart catheterization</li><li>\u27a4 pulmonary thromboendarterectomy</li><li>\u27a4 oral prostacyclin therapy</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "59922964",
      "audio": ""
    },
    {
      "text": "A 60-year-old smoker presents with progressive breathlessness over the past year. Chest X-ray (CXR) reveals hyperinflated lungs, pulmonary function testing (PFT) shows moderate obstruction, and echocardiography (ECHO) indicates a right ventricular systolic pressure (RVSP) of 60 mmHg. Which category of pulmonary hypertension does this patient most likely belong to?",
      "options": [
        {
          "label": "A",
          "text": "WHO Class I",
          "correct": false
        },
        {
          "label": "B",
          "text": "WHO Class II",
          "correct": false
        },
        {
          "label": "C",
          "text": "WHO Class III",
          "correct": true
        },
        {
          "label": "D",
          "text": "WHO Class IV",
          "correct": false
        }
      ],
      "correct_answer": "C. WHO Class III",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) WHO Class III</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This patient has pulmonary hypertension secondary to underlying lung disease (likely chronic obstructive pulmonary disease, or COPD), as indicated by the hyperinflated lungs, moderate obstruction on PFT, and elevated RVSP. According to the World Health Organization (WHO) Classification of Pulmonary Hypertension , this patient falls into Class III , which is defined as pulmonary hypertension due to chronic lung disease , including obstructive and restrictive lung conditions. Group 3 includes conditions like COPD, interstitial lung disease, and other pulmonary diseases that cause pulmonary hypertension.</li><li>\u2022 pulmonary hypertension secondary to underlying lung disease</li><li>\u2022 World Health Organization (WHO) Classification of Pulmonary Hypertension</li><li>\u2022 Class III</li><li>\u2022 pulmonary hypertension due to chronic lung disease</li><li>\u2022 COPD, interstitial lung disease, and other pulmonary diseases</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. WHO Class I: This class refers to pulmonary arterial hypertension (PAH) , which can be idiopathic, familial, or associated with other conditions like connective tissue disease, left-to-right shunt, HIV, or portopulmonary hypertension. It does not apply to pulmonary hypertension caused by lung disease.</li><li>\u2022 Option A. WHO Class I:</li><li>\u2022 pulmonary arterial hypertension (PAH)</li><li>\u2022 Option B. WHO Class II: This class refers to pulmonary hypertension secondary to heart disease , including left ventricular or atrial causes, and does not apply in this case, as the patient\u2019s primary problem is lung disease.</li><li>\u2022 Option B. WHO Class II:</li><li>\u2022 pulmonary hypertension secondary to heart disease</li><li>\u2022 Option D. WHO Class IV: This class refers to chronic thromboembolic pulmonary hypertension (CTEPH) , where pulmonary hypertension is caused by unresolved pulmonary embolism leading to obstruction in the pulmonary vasculature. This is not suggested by the patient\u2019s history or diagnostic findings.</li><li>\u2022 Option D. WHO Class IV:</li><li>\u2022 chronic thromboembolic pulmonary hypertension (CTEPH)</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 WHO Class III pulmonary hypertension occurs due to underlying lung diseases , including COPD, interstitial lung disease , and other pulmonary conditions. The patient\u2019s history of smoking and lung disease, combined with elevated RVSP, points to this classification.</li><li>\u27a4 WHO Class III</li><li>\u27a4 underlying lung diseases</li><li>\u27a4 COPD, interstitial lung disease</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3d16c021",
      "audio": ""
    },
    {
      "text": "A 60-year-old man presents with swelling and redness in his left leg. Compression ultrasound confirms a deep vein thrombosis (DVT) in one of the veins of the leg. Which of the following venous thromboses is least likely to cause a pulmonary embolism?",
      "options": [
        {
          "label": "A",
          "text": "Superficial femoral vein",
          "correct": false
        },
        {
          "label": "B",
          "text": "Great saphenous vein",
          "correct": true
        },
        {
          "label": "C",
          "text": "Common femoral vein",
          "correct": false
        },
        {
          "label": "D",
          "text": "Popliteal vein",
          "correct": false
        }
      ],
      "correct_answer": "B. Great saphenous vein",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Great saphenous vein</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The great saphenous vein is part of the superficial venous system , which carries blood from the skin and subcutaneous tissues but does not directly connect to the deep venous system of the leg. Because of this, thrombosis in the great saphenous vein is very unlikely to cause a pulmonary embolism, as the thrombus would not typically propagate to the deep venous system, where it could then travel to the lungs.</li><li>\u2022 great saphenous vein</li><li>\u2022 superficial venous system</li><li>\u2022 thrombosis in the great saphenous vein</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Superficial femoral vein: Although termed \"superficial,\" the superficial femoral vein (SFV) is actually part of the deep venous system and is capable of propagating a clot that could travel to the lungs, causing a pulmonary embolism.</li><li>\u2022 Option A. Superficial femoral vein:</li><li>\u2022 superficial femoral vein (SFV)</li><li>\u2022 deep venous system</li><li>\u2022 Option C. Common femoral vein: This vein is part of the deep venous system and is directly connected to the iliac veins , where a thrombus can propagate and reach the pulmonary arteries, leading to pulmonary embolism.</li><li>\u2022 Option C. Common femoral vein:</li><li>\u2022 deep venous system</li><li>\u2022 iliac veins</li><li>\u2022 Option D. Popliteal vein: The popliteal vein is part of the deep venous system and can also lead to pulmonary embolism if a thrombus propagates from it to the larger venous channels.</li><li>\u2022 Option D. Popliteal vein:</li><li>\u2022 popliteal vein</li><li>\u2022 deep venous system</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Thrombosis in the great saphenous vein , being part of the superficial venous system, is least likely to cause pulmonary embolism , while thrombosis in the deep venous system (e.g., SFV, common femoral vein, and popliteal vein) is much more likely to propagate and cause a pulmonary embolism.</li><li>\u27a4 great saphenous vein</li><li>\u27a4 least likely to cause pulmonary embolism</li><li>\u27a4 deep venous system</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4c14a111",
      "audio": ""
    },
    {
      "text": "A 45-year-old male with a history of hypertension and diabetes mellitus presents to the emergency department with acute shortness of breath, hypoxia, and X ray is shown. His oxygen saturation is 85% on room air. The patient is intubated and placed on mechanical ventilation. Which of the following strategies does not have a mortality benefit?",
      "options": [
        {
          "label": "A",
          "text": "Corticosteroids",
          "correct": true
        },
        {
          "label": "B",
          "text": "Low tidal volume ventilation",
          "correct": false
        },
        {
          "label": "C",
          "text": "High PEEP",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prone ventilation",
          "correct": false
        }
      ],
      "correct_answer": "A. Corticosteroids",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20161904.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Corticosteroids</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Corticosteroids have no proven mortality benefit in the management of ARDS, except for COVID-19-related ARDS. Studies show that corticosteroids might help reduce inflammation but do not improve overall survival in non-COVID ARDS. The use of corticosteroids is limited to specific circumstances, such as refractory ARDS or COVID-19-associated ARDS, where they may help in reducing inflammation and improving oxygenation.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Low tidal volume ventilation: Low tidal volume ventilation (6 mL/kg of predicted body weight) is a cornerstone of ARDS management and has been shown to improve survival by preventing ventilator-induced lung injury. It is a lung-protective strategy that minimizes barotrauma and volutrauma.</li><li>\u2022 Option B. Low tidal volume ventilation:</li><li>\u2022 Option C. High PEEP: Higher levels of PEEP (positive end-expiratory pressure) can help prevent alveolar collapse and improve oxygenation in ARDS patients. It has been demonstrated to reduce mortality in ARDS by optimizing oxygenation and lung recruitment.</li><li>\u2022 Option C. High PEEP:</li><li>\u2022 Option D. Prone ventilation: Prone positioning, especially when maintained for 16 hours per day, has been shown to improve oxygenation and reduce mortality in ARDS patients. It helps recruit posterior lung zones, improving gas exchange and reducing ventilator-induced injury.</li><li>\u2022 Option D. Prone ventilation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Corticosteroids should not be routinely used in ARDS management except in COVID-19-related ARDS, while low tidal volume ventilation, high PEEP, and prone positioning are proven strategies for improving survival in ARDS.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "af042682",
      "audio": ""
    },
    {
      "text": "A 60-year-old male, a reformed smoker with COPD (GOLD Stage E), presents with worsening dyspnea and cough. He is started on salbutamol nebulizations, IV antibiotics, and corticosteroids. A repeat ABG shows pH 7.25, pCO2 60 mmHg, pO2 49.5 mmHg, RR 26/min. Which of the following is the next step in the management of this patient?",
      "options": [
        {
          "label": "A",
          "text": "Oxygen with NIV",
          "correct": true
        },
        {
          "label": "B",
          "text": "CPAP and Oxygen",
          "correct": false
        },
        {
          "label": "C",
          "text": "Invasive Mechanical Ventilation",
          "correct": false
        },
        {
          "label": "D",
          "text": "IV salbutamol, morphine",
          "correct": false
        }
      ],
      "correct_answer": "A. Oxygen with NIV",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Oxygen with NIV</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In patients with COPD exacerbations who have acid-base disturbances (pH < 7.35, pCO2 > 45 mmHg), non-invasive ventilation (NIV) is the preferred next step in management. NIV helps improve both oxygenation and ventilation (CO2 removal), making it particularly useful in preventing respiratory failure. The patient's ABG showing respiratory acidosis (pCO2 60 mmHg and pH 7.25) suggests CO2 retention, which can be alleviated with NIV. NIV also reduces the work of breathing, improves gas exchange, and avoids the complications of invasive mechanical ventilation.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. CPAP and Oxygen: CPAP (Continuous Positive Airway Pressure) primarily helps improve oxygenation but does not assist in CO2 removal. Since the patient's pCO2 is elevated, NIV is preferred over CPAP for improving ventilation as well as oxygenation.</li><li>\u2022 Option B. CPAP and Oxygen:</li><li>\u2022 Option C. Invasive Mechanical Ventilation: Invasive mechanical ventilation should be avoided initially in patients with COPD exacerbations, as most patients will respond to NIV. Intubation and mechanical ventilation are considered only if NIV fails or if there is hemodynamic instability, persistent respiratory acidosis, or other complications.</li><li>\u2022 Option C. Invasive Mechanical Ventilation:</li><li>\u2022 Option D. IV salbutamol, morphine: While IV salbutamol may help in managing bronchoconstriction, morphine should be avoided in this scenario. Morphine can worsen respiratory acidosis by causing central hypoventilation, and it is not indicated for the management of respiratory failure in this context.</li><li>\u2022 Option D. IV salbutamol, morphine:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with COPD exacerbations and respiratory acidosis, non-invasive ventilation (NIV) is the preferred treatment to improve both oxygenation and ventilation, and it should be initiated early to avoid the need for invasive mechanical ventilation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bbf6e456",
      "audio": ""
    },
    {
      "text": "A 70-year-old woman presents with a 4-week history of dry cough and dyspnea on exertion. She has been receiving treatment for swollen joints and morning stiffness for several years. Inspiratory fine crackles were audible on auscultation. HRCT is shown. Which of the following patterns is the patient\u2019s pulmonary function test (PFT) most likely to display?",
      "options": [
        {
          "label": "A",
          "text": "FEV1/FVC ratio < 0.7 and DLCO increases",
          "correct": false
        },
        {
          "label": "B",
          "text": "FEV1/FVC ratio < 0.7 and DLCO decreases",
          "correct": false
        },
        {
          "label": "C",
          "text": "FEV1/FVC ratio > 0.7 and DLCO decreases",
          "correct": true
        },
        {
          "label": "D",
          "text": "FEV1/FVC ratio > 0.7 and DLCO increases",
          "correct": false
        }
      ],
      "correct_answer": "C. FEV1/FVC ratio > 0.7 and DLCO decreases",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20161941.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) FEV1/FVC ratio > 0.7 and DLCO decreases</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This patient likely has interstitial lung disease (ILD) due to a connective tissue disease (CTD), such as rheumatoid arthritis (RA), as indicated by her chronic joint pain, dry cough, and HRCT findings of honeycombing, which is characteristic of Usual Interstitial Pneumonia (UIP) pattern. ILD, especially UIP, typically presents as restrictive lung disease, meaning there is a normal FEV1/FVC ratio (greater than 0.7), but a reduced diffusing capacity for carbon monoxide (DLCO). The reduced DLCO is due to impaired gas exchange in the damaged alveolar-capillary membrane seen in UIP.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. FEV1/FVC ratio < 0.7 and DLCO increases: An FEV1/FVC ratio less than 0.7 indicates obstructive lung disease, which is not typically seen in ILD or the UIP pattern. Additionally, DLCO increases in conditions such as pulmonary hemorrhage or high-output states, but it is unlikely in interstitial lung disease.</li><li>\u2022 Option A. FEV1/FVC ratio < 0.7 and DLCO increases:</li><li>\u2022 Option B. FEV1/FVC ratio < 0.7 and DLCO decreases: This combination is more characteristic of obstructive lung diseases like chronic obstructive pulmonary disease (COPD) or asthma. It is not consistent with restrictive lung disease (as seen in ILD) where FEV1/FVC remains normal.</li><li>\u2022 Option B. FEV1/FVC ratio < 0.7 and DLCO decreases:</li><li>\u2022 Option D. FEV1/FVC ratio > 0.7 and DLCO increases: An increased DLCO would not be expected in UIP or other forms of ILD. In restrictive lung disease, DLCO is typically decreased due to the thickening of the alveolar walls and impaired gas exchange.</li><li>\u2022 Option D. FEV1/FVC ratio > 0.7 and DLCO increases:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In interstitial lung diseases like UIP (seen in rheumatoid arthritis), patients typically present with restrictive lung patterns on PFTs, characterized by a normal FEV1/FVC ratio (greater than 0.7) and a decreased DLCO, reflecting impaired gas exchange.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1456d0f9",
      "audio": ""
    },
    {
      "text": "Hamman-Rich syndrome is a synonym of which of the following diseases?",
      "options": [
        {
          "label": "A",
          "text": "Usual interstitial pneumonia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cryptogenic organizing pneumonia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Respiratory bronchiolitis-associated ILD",
          "correct": false
        },
        {
          "label": "D",
          "text": "Acute interstitial pneumonia",
          "correct": true
        }
      ],
      "correct_answer": "D. Acute interstitial pneumonia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Acute interstitial pneumonia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Hamman-Rich syndrome is a term used synonymously with acute interstitial pneumonia (AIP), a rare and rapidly progressive form of idiopathic interstitial pneumonia. It has a fulminant course, presenting similarly to acute respiratory distress syndrome (ARDS) with rapid onset of hypoxemia and diffuse bilateral infiltrates. The condition has a poor prognosis with a mortality rate exceeding 60%. The exact pathophysiology is unclear, and treatment is generally supportive, primarily focusing on lung-protective ventilation.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Usual interstitial pneumonia (UIP): UIP is a pattern of lung injury often associated with idiopathic pulmonary fibrosis (IPF). It presents with a more chronic course compared to AIP and is not associated with the acute and rapidly progressive nature seen in Hamman-Rich syndrome.</li><li>\u2022 Option A. Usual interstitial pneumonia (UIP):</li><li>\u2022 Option B. Cryptogenic organizing pneumonia (COP): COP is characterized by the presence of polypoid plugs of organizing connective tissue in small airways and alveolar ducts. It generally presents with subacute symptoms and can improve with corticosteroid therapy, unlike the fulminant course of AIP.</li><li>\u2022 Option B. Cryptogenic organizing pneumonia (COP):</li><li>\u2022 Option C. Respiratory bronchiolitis-associated ILD: This form of interstitial lung disease is commonly associated with smoking and presents with a more chronic or insidious onset. It typically involves the respiratory bronchioles, unlike the diffuse alveolar involvement seen in AIP.</li><li>\u2022 Option C. Respiratory bronchiolitis-associated ILD:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hamman-Rich syndrome refers to acute interstitial pneumonia, a rare and severe form of idiopathic interstitial lung disease characterized by a rapid and progressive course, often resembling ARDS. It is associated with a high mortality rate and requires supportive care.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f3b77126",
      "audio": ""
    },
    {
      "text": "A 50-year-old lady presents with significant weight loss, fatigue, myalgia, and difficulty getting up from bed, particularly in a squatting position. Physical examination reveals papular lesions over the knuckles and fine crackles on auscultation, with a restrictive pulmonary function test (PFT) pattern. High-resolution CT (HRCT) reveals findings consistent with an interstitial lung disease pattern. What is the expected lung biopsy finding in this patient, and what is the likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Anti-Synthetase syndrome",
          "correct": true
        },
        {
          "label": "B",
          "text": "CREST Syndrome",
          "correct": false
        },
        {
          "label": "C",
          "text": "NERDS Syndrome",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hermansky-Pudlak syndrome",
          "correct": false
        }
      ],
      "correct_answer": "A. Anti-Synthetase syndrome",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20162007.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Anti-Synthetase syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This patient's presentation with weight loss, fatigue, myalgia, difficulty with movements (suggesting muscle weakness), skin changes (papular lesions on the knuckles), and fine crackles on auscultation is characteristic of a condition related to chronic inflammation and muscle weakness, which are typical features of dermatomyositis. The HRCT showing a pattern suggestive of non-specific interstitial pneumonia (NSIP) further points towards interstitial lung disease, often seen in autoimmune conditions. Anti-Synthetase syndrome, associated with amino-acyl tRNA antibodies (Jo-1), includes both muscle weakness and interstitial lung disease, fitting this patient's clinical picture.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. CREST Syndrome: CREST syndrome is a limited form of systemic sclerosis, characterized by Calcinosis, Raynaud\u2019s phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia. It does not typically present with muscle weakness or the skin lesions described in this patient, nor would it be associated with an NSIP pattern on HRCT.</li><li>\u2022 Option B. CREST Syndrome:</li><li>\u2022 Option C. NERDS Syndrome: NERDS is an eosinophilic disorder recently described in literature and is characterized by an association of nodules, eosinophilia, rheumatism, dermatitis and swelling.</li><li>\u2022 Option C. NERDS Syndrome:</li><li>\u2022 Option D. Hermansky-Pudlak Syndrome: Hermansky-Pudlak syndrome is a rare genetic condition characterized by albinism, bleeding tendencies, and lung disease, particularly in the form of pulmonary fibrosis. However, it does not typically present with muscle weakness or the skin lesions described in this case, nor would it be expected to cause a restrictive PFT pattern in the same way as Anti-Synthetase syndrome.</li><li>\u2022 Option D. Hermansky-Pudlak Syndrome:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anti-Synthetase syndrome is a condition characterized by the presence of antibodies to amino-acyl tRNA synthetase (Jo-1) and often involves a combination of muscle weakness (myositis), skin changes (like papular lesions on the knuckles), and interstitial lung disease with an NSIP pattern on HRCT. It is a key consideration in patients presenting with these features.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0641b87f",
      "audio": ""
    },
    {
      "text": "A 25-year-old male presents to the clinic with a 3-month history of recurrent episodes of wheezing, shortness of breath, and chest tightness, particularly at night. He reports that his symptoms worsen with exercise and exposure to cold air. He has a family history of asthma, and he is a non-smoker. On physical examination, his lung auscultation reveals widespread wheezing. Spirometry shows a reduced FEV1/FVC ratio. After administration of a bronchodilator, his FEV1 improves by 15% and 250 mL. What is the most appropriate method for confirming the diagnosis of his condition?",
      "options": [
        {
          "label": "A",
          "text": "Chest X-ray",
          "correct": false
        },
        {
          "label": "B",
          "text": "Skin prick test",
          "correct": false
        },
        {
          "label": "C",
          "text": "FEV1 measurement",
          "correct": false
        },
        {
          "label": "D",
          "text": "Reversible obstruction on PFT",
          "correct": true
        }
      ],
      "correct_answer": "D. Reversible obstruction on PFT",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Reversible obstruction on PFT</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The best method to diagnose bronchial asthma is to demonstrate reversible airway obstruction on pulmonary function tests (PFTs). Reversibility is confirmed when there is a greater than 12% and 200 mL increase in the forced expiratory volume in 1 second (FEV1) after administering a bronchodilator (such as a beta-2 agonist). This reversibility is a hallmark of asthma and helps confirm the diagnosis.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Chest X-ray: A chest X-ray is typically normal in bronchial asthma, as asthma is primarily a functional disorder of the airways rather than a structural problem. Chest X-rays may only show changes during an asthma exacerbation or if there are complications like pneumonia.</li><li>\u2022 Option A. Chest X-ray:</li><li>\u2022 Option B. Skin prick test: While the skin prick test can be helpful in identifying allergic triggers for asthma exacerbations, it does not diagnose asthma itself. It is used to evaluate the presence of atopy or identify specific allergens, but it does not directly confirm bronchial asthma.</li><li>\u2022 Option B. Skin prick test:</li><li>\u2022 Option C. FEV1 measurement: FEV1 measurement alone does not confirm the diagnosis of asthma. The FEV1/FVC ratio can help assess the degree of obstruction, but the diagnosis of asthma requires demonstrating reversible airflow obstruction, which is not determined by FEV1 measurement alone.</li><li>\u2022 Option C. FEV1 measurement:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The definitive method to diagnose bronchial asthma is by demonstrating reversible airway obstruction on pulmonary function tests, typically showing a significant improvement in FEV1 after bronchodilator administration.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "eaee8dd1",
      "audio": ""
    },
    {
      "text": "The Gold's criteria for very severe COPD is:",
      "options": [
        {
          "label": "A",
          "text": "FEV1/FVC < 0.7 and FEV1 < 30%",
          "correct": true
        },
        {
          "label": "B",
          "text": "FEV1/FVC < 0.7 and FEV1 < 70%",
          "correct": false
        },
        {
          "label": "C",
          "text": "FEV1/FVC < 0.7 and FEV1 < 50%",
          "correct": false
        },
        {
          "label": "D",
          "text": "Both A and C",
          "correct": false
        }
      ],
      "correct_answer": "A. FEV1/FVC < 0.7 and FEV1 < 30%",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) FEV1/FVC < 0.7 and FEV1 < 30%</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 According to the GOLD 2023 guidelines, very severe COPD (Stage IV) is defined by FEV1/FVC < 0.7 (common across all stages) and an FEV1 less than 30% of the predicted value. This stage indicates a significant reduction in airflow and severe impairment in lung function, often associated with respiratory failure and the need for long-term oxygen therapy.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. FEV1/FVC < 0.7 and FEV1 < 70%: This criteria describes moderate COPD (Stage II), where FEV1 is between 50% and 80% of the predicted value. It is not indicative of very severe COPD.</li><li>\u2022 Option B. FEV1/FVC < 0.7 and FEV1 < 70%:</li><li>\u2022 Option C. FEV1/FVC < 0.7 and FEV1 < 50%: This criteria refers to severe COPD (Stage III), where FEV1 is between 30% and 50% of the predicted value, but it does not qualify as very severe COPD, which requires an FEV1 of less than 30%.</li><li>\u2022 Option C. FEV1/FVC < 0.7 and FEV1 < 50%:</li><li>\u2022 Option D. Both A and C: This option is incorrect because Stage III (FEV1 < 50%) is not considered \"very severe\" COPD, which is defined by FEV1 < 30%.</li><li>\u2022 Option D. Both A and C:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Very severe COPD (Stage IV) is classified by FEV1/FVC < 0.7 and FEV1 < 30% of the predicted value, indicating significant impairment in lung function and often requiring intensive management, including oxygen therapy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9fbdd104",
      "audio": ""
    },
    {
      "text": "In which of the following situations would non-invasive ventilation (NIV) be considered contraindicated?",
      "options": [
        {
          "label": "A",
          "text": "Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Acute hypoxemic respiratory failure",
          "correct": false
        },
        {
          "label": "C",
          "text": "Acute myocardial infarction",
          "correct": true
        },
        {
          "label": "D",
          "text": "Acute decompensated heart failure",
          "correct": false
        }
      ],
      "correct_answer": "C. Acute myocardial infarction",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Acute myocardial infarction</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Non-invasive ventilation (NIV) is contraindicated in patients with acute myocardial infarction (MI) due to the risk of exacerbating cardiovascular instability. NIV can increase intrathoracic pressure, reducing venous return to the heart and potentially worsening hemodynamics in the acute MI setting. Additionally, NIV can cause barotrauma or lead to discomfort, potentially worsening the patient's condition in such a critical phase. Unstable angina and acute MI are both contraindications for NIV.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Acute exacerbation of chronic obstructive pulmonary disease (AECOPD): NIV is commonly used in the management of acute exacerbations of COPD, especially when the patient shows respiratory acidosis (pH between 7.25-7.35). It is effective in improving ventilation and reducing the need for intubation, making it a valuable treatment for patients with COPD exacerbations.</li><li>\u2022 Option A. Acute exacerbation of chronic obstructive pulmonary disease (AECOPD):</li><li>\u2022 Option B. Acute hypoxemic respiratory failure: NIV can be used in patients with acute hypoxemic respiratory failure, particularly when they are able to tolerate the interface and the condition is not too severe. It helps improve oxygenation and avoid intubation in appropriate cases.</li><li>\u2022 Option B. Acute hypoxemic respiratory failure:</li><li>\u2022 Option D. Acute decompensated heart failure: In decompensated systolic heart failure, NIV can be beneficial by providing positive end-expiratory pressure (PEEP), which helps reduce preload and afterload, improving symptoms. It is particularly helpful in patients with pulmonary edema and can stabilize the patient by improving gas exchange and decreasing the work of breathing.</li><li>\u2022 Option D. Acute decompensated heart failure:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 NIV is contraindicated in acute myocardial infarction due to potential hemodynamic instability. It is, however, beneficial in conditions like COPD exacerbations, mild ARDS, and decompensated heart failure without acute ischemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f23c502e",
      "audio": ""
    },
    {
      "text": "A 60-year-old female is referred for chronic cough and dyspnea with exertion. Over the past year, her cough and dyspnea have steadily worsened. According to pulmonary function testing, the FVC is 72%, FEV1 is 80%, and DLCO is 38%. HRCT is shown. A lung biopsy reveals foci of scarring dispersed and surrounded by healthy lung parenchyma with fibroblasts. Serology for autoimmune disease is negative. Which of the following is the appropriate therapy for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Pirfenidone",
          "correct": true
        },
        {
          "label": "B",
          "text": "Bosentan",
          "correct": false
        },
        {
          "label": "C",
          "text": "Acetylcysteine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prednisolone/azathioprine",
          "correct": false
        }
      ],
      "correct_answer": "A. Pirfenidone",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20162035.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Pirfenidone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The patient's presentation, including chronic cough, dyspnea on exertion, and pulmonary function test findings (low DLCO), negative serology, along with the CT showing a usual interstitial pneumonia (UIP) pattern and biopsy findings of scarring, is consistent with idiopathic pulmonary fibrosis (IPF). IPF is a progressive, fibrotic lung disease typically seen in individuals over 50 years old. The appropriate treatment for IPF includes antifibrotic agents like pirfenidone, which has been shown to slow disease progression and improve outcomes.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Bosentan: Bosentan is an endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH), not in the management of idiopathic pulmonary fibrosis. While it is effective for PAH, it is not appropriate for IPF.</li><li>\u2022 Option B. Bosentan:</li><li>\u2022 Option C. Acetylcysteine: Acetylcysteine is used as a mucolytic agent in conditions like chronic obstructive pulmonary disease (COPD) and cystic fibrosis, but it has not been shown to have a role in the treatment of idiopathic pulmonary fibrosis.</li><li>\u2022 Option C. Acetylcysteine:</li><li>\u2022 Option D. Prednisolone/azathioprine: Prednisolone and azathioprine are often used in the treatment of inflammatory interstitial lung diseases, but they are not recommended for IPF, which is a fibrotic disease rather than primarily inflammatory. In fact, immunosuppressive therapy can worsen the prognosis in IPF.</li><li>\u2022 Option D. Prednisolone/azathioprine:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pirfenidone and Nintedanib are appropriate options for idiopathic pulmonary fibrosis, as it slows the progression of fibrosis in IPF. It is important to recognize the UIP pattern on CT and confirm the diagnosis with biopsy, as management strategies for IPF differ from those of other ILDs.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3fc16985",
      "audio": ""
    },
    {
      "text": "A 58-year-old male with a history of cirrhosis and chronic alcoholic liver disease presents with worsening ascites, confusion, and oliguria over the past week. He has been on diuretics for ascites management but has had poor urine output despite increasing doses. On examination, he is hypotensive with a heart rate of 100 bpm and has asterixis. Laboratory tests show elevated serum creatinine, low urine sodium, and normal ascitic fluid analysis. The patient\u2019s condition has not improved with conventional treatments. What is the definitive treatment for his condition?",
      "options": [
        {
          "label": "A",
          "text": "Terlipressin + Albumin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Terlipressin + Octreotide + Albumin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Orthotopic liver transplantation",
          "correct": true
        },
        {
          "label": "D",
          "text": "Simultaneous liver-kidney transplantation",
          "correct": false
        }
      ],
      "correct_answer": "C. Orthotopic liver transplantation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Orthotopic liver transplantation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 This patient\u2019s presentation, including ascites, elevated serum creatinine, low urine sodium, and normal ascitic fluid analysis, suggests hepatorenal syndrome (HRS), a type of renal failure that occurs in cirrhosis. The definitive treatment for HRS is orthotopic liver transplantation (OLT), as it resolves both the liver dysfunction and the associated renal failure. HRS is a progressive condition, and without liver transplantation, kidney function typically does not improve.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Terlipressin + Albumin: Terlipressin (a vasopressin analog) combined with albumin can be used as a bridging therapy for HRS, improving renal perfusion and reducing renal failure. However, it does not cure the underlying liver disease, making it a short-term solution while waiting for liver transplantation.</li><li>\u2022 Option A. Terlipressin + Albumin:</li><li>\u2022 Option B. Terlipressin + Octreotide + Albumin: This combination therapy has been used as a bridge for patients with HRS, but it is not curative. While it may improve renal function temporarily, liver transplantation remains the definitive treatment for HRS.</li><li>\u2022 Option B. Terlipressin + Octreotide + Albumin:</li><li>\u2022 Option D. Simultaneous liver-kidney transplantation: Simultaneous liver-kidney transplantation is typically reserved for patients whose kidney function does not improve after liver transplantation or for those who have significant renal impairment prior to liver transplantation. In most cases of HRS, liver transplantation alone is sufficient to resolve renal failure.</li><li>\u2022 Option D. Simultaneous liver-kidney transplantation:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The definitive treatment for hepatorenal syndrome, a complication of cirrhosis and portal hypertension, is orthotopic liver transplantation. Bridge therapies like terlipressin and albumin can help stabilize patients, but liver transplantation is required for long-term resolution.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6417a5ed",
      "audio": ""
    },
    {
      "text": "A 55-year-old male with end-stage kidney disease (ESKD) has been undergoing peritoneal dialysis for the past 6 months. Which of the following is not a common complication of peritoneal dialysis therapy in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Hypoproteinemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hypoglycemia",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hypertriglyceridemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hyperphosphatemia",
          "correct": false
        }
      ],
      "correct_answer": "B. Hypoglycemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Hypoglycemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Hypoglycemia is not a common complication of peritoneal dialysis therapy. In fact, peritoneal dialysis typically leads to hyperglycemia due to the absorption of glucose from the dialysate, especially in patients with diabetes. The use of glucose-based dialysates often leads to weight gain and increased caloric intake, which can exacerbate insulin resistance and contribute to hyperglycemia rather than hypoglycemia.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Hypoproteinemia: Hypoproteinemia can occur in peritoneal dialysis patients due to the loss of proteins through the peritoneal membrane, which can lead to decreased serum albumin levels. It is a known complication, especially in patients with high-volume dialysate exchanges or those with infections.</li><li>\u2022 Option A. Hypoproteinemia:</li><li>\u2022 Option C. Hypertriglyceridemia: Hypertriglyceridemia is a common complication of peritoneal dialysis, particularly in patients with diabetes. The absorption of glucose from the dialysate leads to an increase in insulin resistance, which can promote hypertriglyceridemia. The increased caloric intake from glucose also contributes to this issue.</li><li>\u2022 Option C. Hypertriglyceridemia:</li><li>\u2022 Option D. Hyperphosphatemia: Hyperphosphatemia is a common complication in patients with kidney disease, including those on peritoneal dialysis, due to impaired renal clearance of phosphate. It is typically managed with phosphate binders, but it remains a common issue.</li><li>\u2022 Option D. Hyperphosphatemia:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hypoglycemia is not a common complication of peritoneal dialysis. Instead, hyperglycemia and associated issues like hypertriglyceridemia and weight gain due to glucose absorption are more frequently encountered, especially in diabetic patients.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6ad9fcf7",
      "audio": ""
    },
    {
      "text": "A 65-year-old male with a history of chronic kidney disease (CKD) requiring hemodialysis has recently had a central venous catheter placed for dialysis. After several weeks, he presents with signs of poor blood flow during dialysis. Imaging reveals narrowing in the vein used for the catheter insertion. Which of the following sites is most likely to have caused this complication due to stenosis?",
      "options": [
        {
          "label": "A",
          "text": "Femoral",
          "correct": false
        },
        {
          "label": "B",
          "text": "Subclavian",
          "correct": true
        },
        {
          "label": "C",
          "text": "Left Internal jugular",
          "correct": false
        },
        {
          "label": "D",
          "text": "Right Internal jugular",
          "correct": false
        }
      ],
      "correct_answer": "B. Subclavian",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Subclavian</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The subclavian vein is associated with a high risk of stenosis following catheter placement for hemodialysis. While it typically provides good flow rates initially, subclavian stenosis can develop over time, leading to compromised dialysis access. This stenosis can complicate future access and may prevent the use of that extremity for permanent vascular access (such as a fistula or graft).</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Femoral: While femoral vein access carries a higher risk of infection and is not typically preferred for long-term dialysis, it is not associated with the same risk of stenosis as the subclavian vein. The femoral vein is often used in emergency situations or for short-term access.</li><li>\u2022 Option A. Femoral:</li><li>\u2022 Option C. Left Internal jugular: The left internal jugular vein is a commonly used site for hemodialysis catheters and is less prone to stenosis compared to the subclavian vein. It provides reliable access for dialysis with fewer long-term complications related to stenosis.</li><li>\u2022 Option C. Left Internal jugular:</li><li>\u2022 Option D. Right Internal jugular: The right internal jugular vein is frequently used for hemodialysis catheter placement due to its accessibility and low risk of stenosis. It does not carry the same complication risk as the subclavian vein for stenosis.</li><li>\u2022 Option D. Right Internal jugular:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Subclavian veins, although providing good flow for dialysis, are prone to stenosis, which can hinder long-term dialysis access and complicate future vascular access procedures.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a465fc84",
      "audio": ""
    },
    {
      "text": "A 60-year-old female with a 10-year history of rheumatoid arthritis presents to the clinic with deformities in her fingers. On examination, you see a swan-neck deformity. Which of the following is the most likely description of this deformity?",
      "options": [
        {
          "label": "A",
          "text": "Flexion of the PIP joint with hyperextension of the DIP joint",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hyperextension of the PIP joint with flexion of the DIP joint",
          "correct": true
        },
        {
          "label": "C",
          "text": "Subluxation of the first MCP joint with hyperextension of the first interphalangeal (IP) joint",
          "correct": false
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "B. Hyperextension of the PIP joint with flexion of the DIP joint",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Hyperextension of the PIP joint with flexion of the DIP joint</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The deformity described in this patient, with hyperextension of the proximal interphalangeal (PIP) joint and flexion of the distal interphalangeal (DIP) joint, is known as \"swan-neck deformity.\" This deformity is commonly seen in rheumatoid arthritis and results from damage to the tendons, joint capsule, and soft tissues around the finger joints. The deformity can arise due to imbalances between the flexor and extensor tendons, leading to this characteristic presentation.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Flexion of the PIP joint with hyperextension of the DIP joint: This description is incorrect for swan-neck deformity. It actually describes \"boutonni\u00e8re deformity,\" which is characterized by the flexion of the PIP joint with hyperextension of the DIP joint, a different type of deformity commonly seen in rheumatoid arthritis.</li><li>\u2022 Option A. Flexion of the PIP joint with hyperextension of the DIP joint:</li><li>\u2022 Option C. Subluxation of the first MCP joint with hyperextension of the first interphalangeal (IP) joint: This describes a different deformity known as \"Z-line deformity,\" which involves the first metacarpophalangeal (MCP) joint and the first interphalangeal (IP) joint. It is not associated with the swan-neck deformity.</li><li>\u2022 Option C. Subluxation of the first MCP joint with hyperextension of the first interphalangeal (IP) joint:</li><li>\u2022 Option D. None of the above: This option is incorrect because the correct description is provided in option B for swan-neck deformity.</li><li>\u2022 Option D. None of the above:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Swan-neck deformity in rheumatoid arthritis is characterized by hyperextension of the PIP joint with flexion of the DIP joint. It is caused by imbalances in tendon and joint capsule function, commonly seen in the progression of rheumatoid arthritis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c7498a7a",
      "audio": ""
    },
    {
      "text": "A 55-year-old female with a long history of rheumatoid arthritis (RA) presents with increasing difficulty in fighting off infections. On examination, she has splenomegaly, and her lab results show neutropenia. Her RA is complicated by nodular disease. Which of the following is not characteristic of Felty\u2019s syndrome in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Neutropenia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Neutrophilia",
          "correct": true
        },
        {
          "label": "C",
          "text": "Splenomegaly",
          "correct": false
        },
        {
          "label": "D",
          "text": "Nodular RA",
          "correct": false
        }
      ],
      "correct_answer": "B. Neutrophilia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Neutrophilia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Felty\u2019s syndrome is characterized by the clinical triad of neutropenia , splenomegaly , and nodular rheumatoid arthritis (RA) . Neutropenia refers to an abnormally low neutrophil count, which makes patients more prone to infections. This syndrome is seen in a small percentage of patients with RA, often in those with long-standing and severe disease. Neutrophilia (an elevated neutrophil count) is not a characteristic feature of Felty\u2019s syndrome, making option B the correct answer.</li><li>\u2022 neutropenia</li><li>\u2022 splenomegaly</li><li>\u2022 nodular rheumatoid arthritis (RA)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Neutropenia: Neutropenia is one of the hallmark features of Felty\u2019s syndrome. It occurs due to the increased destruction of neutrophils or impaired production by the bone marrow, leading to a reduced neutrophil count, which is a key aspect of the syndrome.</li><li>\u2022 Option A. Neutropenia:</li><li>\u2022 Option C. Splenomegaly: Splenomegaly is another characteristic feature of Felty\u2019s syndrome. The spleen enlarges due to the increased removal of neutrophils and other immune cells, contributing to the patient\u2019s susceptibility to infections.</li><li>\u2022 Option C. Splenomegaly:</li><li>\u2022 Option D. Nodular RA: Nodular rheumatoid arthritis (RA) refers to the development of rheumatoid nodules, which are firm, non-tender lumps that can occur under the skin, particularly in areas of pressure. These nodules are a common finding in Felty\u2019s syndrome.</li><li>\u2022 Option D. Nodular RA:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Felty\u2019s syndrome is characterized by neutropenia, splenomegaly, and nodular RA. Neutrophilia is not a feature of this syndrome, and its presence would point toward other underlying conditions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "effd00d7",
      "audio": ""
    },
    {
      "text": "A 60-year-old female with a long history of rheumatoid arthritis (RA) presents with shortness of breath. What is the most likely pulmonary manifestation of rheumatoid arthritis in this patient?",
      "options": [
        {
          "label": "A",
          "text": "ILD",
          "correct": false
        },
        {
          "label": "B",
          "text": "Pleuritis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Pulmonary nodules",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lung malignancy",
          "correct": false
        }
      ],
      "correct_answer": "B. Pleuritis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Pleuritis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Pleuritis is the most common pulmonary manifestation of rheumatoid arthritis (RA). It occurs due to inflammation of the pleura, and patients typically present with pleuritic chest pain, dyspnea, and a pleural friction rub. Pleural effusions associated with RA tend to be exudative, with an increased number of monocytes and neutrophils in the pleural fluid, as described in this patient.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. ILD (Interstitial Lung Disease): Interstitial lung disease (ILD) is another pulmonary manifestation of RA but is less common than pleuritis. ILD typically presents with progressive dyspnea, a restrictive pattern on pulmonary function tests, and characteristic findings on high-resolution CT scans. However, pleuritis remains the most common manifestation.</li><li>\u2022 Option A. ILD (Interstitial Lung Disease):</li><li>\u2022 Option C. Pulmonary nodules: Rheumatoid pulmonary nodules are common in patients with RA, particularly those with long-standing disease. These nodules are typically found on imaging but are less likely to be the cause of pleuritic chest pain, and the patient's effusion and pleural friction rub point more toward pleuritis.</li><li>\u2022 Option C. Pulmonary nodules:</li><li>\u2022 Option D. Lung malignancy: Lung malignancy can occur in patients with rheumatoid arthritis, but it is not the most common pulmonary manifestation. Furthermore, the presence of a pleural effusion with an inflammatory profile and pleuritic chest pain is more consistent with pleuritis than lung cancer.</li><li>\u2022 Option D. Lung malignancy:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pleuritis is the most common pulmonary manifestation of rheumatoid arthritis and is characterized by pleuritic chest pain, dyspnea, and exudative pleural effusion with a predominance of monocytes and neutrophils.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1d552036",
      "audio": ""
    },
    {
      "text": "A 45-year-old female presents with morning stiffness, joint pain, and swelling in her hands and wrists. Laboratory tests reveal positive rheumatoid factor and anti-citrullinated protein antibody (ACPA). Which of the following is most likely true regarding this patient's genetic risk?",
      "options": [
        {
          "label": "A",
          "text": "HLA-DRB1*1301",
          "correct": false
        },
        {
          "label": "B",
          "text": "HLA-DRB1*1302",
          "correct": false
        },
        {
          "label": "C",
          "text": "HLA-DRB1*0401",
          "correct": true
        },
        {
          "label": "D",
          "text": "None of the above",
          "correct": false
        }
      ],
      "correct_answer": "C. HLA-DRB1*0401",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) HLA-DRB1*0401</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 HLA-DRB1*0401 is a high-risk allele for rheumatoid arthritis (RA), significantly increasing the likelihood of developing the disease. The presence of this allele, particularly in individuals with a family history of RA, suggests a genetic predisposition to the disease. The allele is associated with an increased risk of ACPA-positive RA, a subtype of RA characterized by the presence of antibodies against citrullinated proteins.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. HLA-DRB1*1301: This allele is associated with a protective effect against ACPA-positive RA. It confers protection from developing the disease rather than increasing the risk, making it an unlikely genetic factor for this patient's RA.</li><li>\u2022 Option A. HLA-DRB1*1301:</li><li>\u2022 protective</li><li>\u2022 Option B. HLA-DRB1*1302: HLA-DRB1*1302, similar to *1301, also confers protection from ACPA-positive RA. It is not a risk allele and would not contribute to the development of RA in this patient.</li><li>\u2022 Option B. HLA-DRB1*1302:</li><li>\u2022 Option D. None of the above: This option is incorrect because HLA-DRB1*0401 is indeed a high-risk allele for RA, as explained.</li><li>\u2022 Option D. None of the above:</li><li>\u2022 HLA-DRB1*0401</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The HLA-DRB1*0401 allele is a high-risk genetic factor for rheumatoid arthritis, particularly in individuals with a family history of the disease. It is strongly associated with ACPA-positive RA. In contrast, alleles such as HLA-DRB1*1301 and HLA-DRB1*1302 are protective against RA.</li><li>\u27a4 HLA-DRB1*0401</li><li>\u27a4 HLA-DRB1*1301</li><li>\u27a4 HLA-DRB1*1302</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c024ef87",
      "audio": ""
    },
    {
      "text": "A 65-year-old male presents to the clinic with joint pain, especially in the knees and hips, that worsens with activity but improves with rest. Which of the following is not typical of a noninflammatory joint disorder?",
      "options": [
        {
          "label": "A",
          "text": "Pain without synovial swelling",
          "correct": false
        },
        {
          "label": "B",
          "text": "Absence of inflammatory or systemic features",
          "correct": false
        },
        {
          "label": "C",
          "text": "Prolonged morning stiffness",
          "correct": true
        },
        {
          "label": "D",
          "text": "Negative laboratory investigations",
          "correct": false
        }
      ],
      "correct_answer": "C. Prolonged morning stiffness",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Prolonged morning stiffness</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Prolonged morning stiffness lasting for more than 60 minutes is typical of inflammatory joint disorders, such as rheumatoid arthritis (RA) or polymyalgia rheumatica (PMR). In noninflammatory joint disorders, such as osteoarthritis (OA), the morning stiffness is usually brief (less than 60 minutes) and tends to improve with activity. The patient\u2019s clinical features, including brief morning stiffness, pain without synovial swelling, and normal inflammatory markers, are consistent with a noninflammatory joint disorder like osteoarthritis, which does not typically cause prolonged morning stiffness.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Pain without synovial swelling: Pain without synovial swelling is a hallmark feature of noninflammatory joint disorders, like osteoarthritis. Inflammatory joint disorders typically present with synovial swelling and warmth due to active inflammation in the joints.</li><li>\u2022 Option A. Pain without synovial swelling:</li><li>\u2022 Option B. Absence of inflammatory or systemic features: Noninflammatory joint disorders typically do not cause systemic symptoms, such as fever, weight loss, or fatigue, that are often seen in inflammatory conditions. The absence of systemic features is consistent with a noninflammatory condition.</li><li>\u2022 Option B. Absence of inflammatory or systemic features:</li><li>\u2022 Option D. Negative laboratory investigations: Negative laboratory investigations, including normal inflammatory markers (such as ESR and CRP), are typical of noninflammatory joint disorders. In contrast, inflammatory conditions usually present with elevated markers of inflammation.</li><li>\u2022 Option D. Negative laboratory investigations:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Prolonged morning stiffness (lasting longer than 60 minutes) is characteristic of inflammatory joint disorders, whereas noninflammatory joint disorders, like osteoarthritis, typically present with shorter morning stiffness and no synovial swelling or systemic features.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1782ee70",
      "audio": ""
    },
    {
      "text": "A 50-year-old female presents with skin thickening involving the limbs and trunk, Raynaud\u2019s phenomenon, and difficulty swallowing. Laboratory tests reveal a positive antinuclear antibody (ANA) test with a speckled pattern. Which of the following is most likely to be positive?",
      "options": [
        {
          "label": "A",
          "text": "Anti Jo-1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anti Centromeric Antibody",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anti Scl-70",
          "correct": true
        },
        {
          "label": "D",
          "text": "Anti Histone",
          "correct": false
        }
      ],
      "correct_answer": "C. Anti Scl-70",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Anti Scl-70</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation is consistent with systemic sclerosis (scleroderma), particularly the diffuse subtype. Anti-Scl-70 (anti-topoisomerase I antibody) is strongly associated with diffuse systemic sclerosis, which involves extensive skin thickening and internal organ involvement, such as esophageal dysmotility.</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Anti Jo-1 : Is associated with polymyositis and dermatomyositis, not systemic sclerosis.</li><li>\u2022 Option</li><li>\u2022 A. Anti Jo-1</li><li>\u2022 Option B. Anti Centromeric Antibody: Is commonly associated with the limited form of systemic sclerosis (CREST syndrome), which involves localized skin thickening, primarily of the distal extremities, and less severe internal organ involvement.</li><li>\u2022 Option B. Anti Centromeric Antibody:</li><li>\u2022 Option D. Anti Histone : Is typically associated with drug-induced lupus, not systemic sclerosis.</li><li>\u2022 Option D. Anti Histone</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Anti-Scl-70 is a key marker for diffuse systemic sclerosis, characterized by widespread skin involvement and significant internal organ complications, such as esophageal dysmotility.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4878ca91",
      "audio": ""
    },
    {
      "text": "A 50-year-old male presents with joint swelling, warmth, and pain in the knee. The physician performs a joint aspiration, and synovial fluid is sent for analysis. Which of the following is not characteristic of the synovial fluid analysis in this case?",
      "options": [
        {
          "label": "A",
          "text": "Inflammatory fluid is turbid and yellow",
          "correct": false
        },
        {
          "label": "B",
          "text": "Polymorphonuclear leukocyte predominance",
          "correct": false
        },
        {
          "label": "C",
          "text": "Presence of stringing effect",
          "correct": true
        },
        {
          "label": "D",
          "text": "Increased WBC count (2000\u201350,000/\u03bcL)",
          "correct": false
        }
      ],
      "correct_answer": "C. Presence of stringing effect",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Presence of stringing effect</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The presence of a stringing effect is not characteristic of inflammatory synovial fluid. Inflammatory synovial fluid has reduced viscosity , which results in the absence of stringing or a long tail behind the drop when the fluid is expressed. In contrast, non-inflammatory synovial fluid (such as in osteoarthritis or trauma) has normal viscosity, which produces a stringing effect.</li><li>\u2022 stringing effect</li><li>\u2022 not</li><li>\u2022 reduced viscosity</li><li>\u2022 non-inflammatory</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Inflammatory fluid is turbid and yellow: This is characteristic of inflammatory synovial fluid. Inflammatory effusions, such as those seen in rheumatoid arthritis, gout, or infection, often appear turbid and yellow due to the presence of inflammatory cells, such as neutrophils.</li><li>\u2022 Option A. Inflammatory fluid is turbid and yellow:</li><li>\u2022 Option B. Polymorphonuclear leukocyte predominance: This is a key feature of inflammatory synovial fluid. Polymorphonuclear leukocytes (PMNs or neutrophils) predominate in inflammatory conditions, often reflecting acute inflammation or infection in the joint.</li><li>\u2022 Option B. Polymorphonuclear leukocyte predominance:</li><li>\u2022 Option D. Increased WBC count (2000\u201350,000/\u03bcL): An elevated white blood cell (WBC) count in the synovial fluid, typically between 2000-50,000/\u03bcL , is characteristic of inflammatory conditions. Higher levels may indicate infection (septic arthritis), while lower counts may suggest conditions like gout or rheumatoid arthritis.</li><li>\u2022 Option D. Increased WBC count (2000\u201350,000/\u03bcL):</li><li>\u2022 2000-50,000/\u03bcL</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Inflammatory synovial fluid has reduced viscosity and no stringing effect , with polymorphonuclear leukocyte predominance , increased WBC count, and a turbid yellow appearance. A stringing effect is seen in non-inflammatory fluid, typically associated with conditions like osteoarthritis.</li><li>\u27a4 reduced viscosity</li><li>\u27a4 no stringing effect</li><li>\u27a4 polymorphonuclear leukocyte predominance</li><li>\u27a4 non-inflammatory</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9cdb5582",
      "audio": ""
    },
    {
      "text": "A 60-year-old male presents with neck and back pain. X-ray is taken and shown. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Diffuse idiopathic skeletal hyperostosis",
          "correct": true
        },
        {
          "label": "B",
          "text": "Ankylosing spondylitis",
          "correct": false
        },
        {
          "label": "C",
          "text": "TB spine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Spine metastases",
          "correct": false
        }
      ],
      "correct_answer": "A. Diffuse idiopathic skeletal hyperostosis",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20162155.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Diffuse idiopathic skeletal hyperostosis (DISH)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The X-ray findings of calcification and ossification of the paraspinous ligaments with a \"flowing wax\" appearance on the anterior vertebral bodies are characteristic of diffuse idiopathic skeletal hyperostosis (DISH) . DISH is a condition that typically affects middle-aged or older adults and is often asymptomatic, though it can present with neck and back pain. The hallmark of DISH is the calcification of the ligaments, leading to the characteristic appearance on X-ray. It usually involves the thoracic spine but can affect other regions as well.</li><li>\u2022 diffuse idiopathic skeletal hyperostosis (DISH)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. Ankylosing spondylitis: Ankylosing spondylitis typically involves the sacroiliac joints and causes bilateral sacroiliitis with spinal involvement. It is associated with bamboo spine appearance on X-ray, characterized by syndesmophytes and fused vertebrae. The calcification seen in DISH is different from the characteristic changes seen in ankylosing spondylitis.</li><li>\u2022 Option B. Ankylosing spondylitis:</li><li>\u2022 bamboo spine</li><li>\u2022 Option C. TB spine: Tuberculosis of the spine (Pott\u2019s disease) can present with back pain and deformity but is typically associated with vertebral destruction and collapse, which is not seen in the \"flowing wax\" appearance of DISH. The X-ray would typically show vertebral body collapse and paraspinal abscesses in Pott\u2019s disease.</li><li>\u2022 Option C. TB spine:</li><li>\u2022 Option D. Spine metastases: Spinal metastases usually present with a history of primary malignancy and would show irregular lesions in the vertebral bodies with possible collapse or destruction. The calcified ligaments seen in DISH would not be seen in spine metastases, which often involve lytic or blastic lesions rather than ossification of ligaments.</li><li>\u2022 Option D. Spine metastases:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Diffuse idiopathic skeletal hyperostosis (DISH) is characterized by the calcification and ossification of paraspinous ligaments, giving a \"flowing wax\" appearance on X-ray. It typically affects older adults and can lead to neck and back pain, though it is often asymptomatic.</li><li>\u27a4 Diffuse idiopathic skeletal hyperostosis (DISH)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2cb3147a",
      "audio": ""
    },
    {
      "text": "A 40-year-old male with a history of psoriasis presents with joint pain and swelling. The patient has involvement of the distal interphalangeal (DIP) joints, and his X-rays show changes in the sacroiliac joints. Family members have a similar history of psoriasis and arthritis. Based on this, which of the following characteristics does not favor the diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Distal interphalangeal (DIP) joint is involved",
          "correct": false
        },
        {
          "label": "B",
          "text": "Familial aggregation is seen",
          "correct": false
        },
        {
          "label": "C",
          "text": "Arthritis is usually seropositive",
          "correct": true
        },
        {
          "label": "D",
          "text": "Spine and sacroiliac joints are involved",
          "correct": false
        }
      ],
      "correct_answer": "C. Arthritis is usually seropositive",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Arthritis is usually seropositive</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Unlike rheumatoid arthritis (RA), psoriatic arthritis (PsA) is usually seronegative for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). In contrast, RA is typically seropositive , meaning that most patients with RA have positive RF or ACPA. Therefore, the statement that arthritis is usually seropositive does not favor PsA and is more typical of RA.</li><li>\u2022 psoriatic arthritis (PsA)</li><li>\u2022 seronegative</li><li>\u2022 seropositive</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Distal interphalangeal (DIP) joint is involved: In psoriatic arthritis, the distal interphalangeal (DIP) joints are often involved, which is a key distinguishing feature from RA. RA typically affects the proximal joints (such as the metacarpophalangeal (MCP) joints), whereas PsA commonly affects the DIP joints.</li><li>\u2022 Option A. Distal interphalangeal (DIP) joint is involved:</li><li>\u2022 distal interphalangeal (DIP)</li><li>\u2022 Option B. Familial aggregation is seen: Psoriatic arthritis has a strong familial aggregation . A family history of psoriasis or PsA is common in patients with PsA, which distinguishes it from RA, where familial aggregation is less pronounced.</li><li>\u2022 Option B. Familial aggregation is seen:</li><li>\u2022 familial aggregation</li><li>\u2022 Option D. Spine and sacroiliac joints are involved: Psoriatic arthritis often affects the spine and sacroiliac joints . This axial involvement is more common in PsA than in RA, which tends to spare these areas in favor of peripheral joints. Sacroiliitis and spondylitis are common features in PsA, especially in patients with the spondyloarthritis subtype.</li><li>\u2022 Option D. Spine and sacroiliac joints are involved:</li><li>\u2022 spine</li><li>\u2022 sacroiliac joints</li><li>\u2022 spondyloarthritis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Psoriatic arthritis is typically seronegative , unlike rheumatoid arthritis, which is usually seropositive . PsA is characterized by involvement of the DIP joints, familial aggregation, and potential involvement of the spine and sacroiliac joints.</li><li>\u27a4 seronegative</li><li>\u27a4 seropositive</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "574d0f03",
      "audio": ""
    },
    {
      "text": "A 40-year-old male with a history of joint pain presents for evaluation. A radionuclide bone scan is done and shown. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Psoriatic arthritis",
          "correct": false
        },
        {
          "label": "B",
          "text": "IBD-associated arthritis",
          "correct": false
        },
        {
          "label": "C",
          "text": "SAPHO syndrome",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ankylosing spondylitis",
          "correct": false
        }
      ],
      "correct_answer": "C. SAPHO syndrome",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20162213.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) SAPHO syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The \"bull\u2019s head\" sign on a radionuclide bone scan is characteristic of SAPHO syndrome , which stands for Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis . This syndrome is a rare disorder that involves the skin and joints, often affecting the sternoclavicular joints and clavicles. The radionuclide bone scan is particularly useful in identifying the involvement of the clavicles and sternoclavicular joints, which is key to the diagnosis.</li><li>\u2022 SAPHO syndrome</li><li>\u2022 Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Psoriatic arthritis: Psoriatic arthritis can involve the joints, including the fingers, toes, and spine, but it does not typically present with the \"bull\u2019s head\" sign. Psoriatic arthritis is associated with other radiographic findings, such as pencil-in-cup deformities in the fingers, but not the characteristic pattern seen in SAPHO syndrome.</li><li>\u2022 Option A. Psoriatic arthritis:</li><li>\u2022 Option B. IBD-associated arthritis: Inflammatory bowel disease (IBD)-associated arthritis can affect peripheral joints and the spine but is not typically associated with the \"bull\u2019s head\" sign. IBD-associated arthritis is more commonly seen with enteropathic arthritis, which involves the sacroiliac joints and peripheral joints, not the sternoclavicular joints.</li><li>\u2022 Option B. IBD-associated arthritis:</li><li>\u2022 Option D. Ankylosing spondylitis: Ankylosing spondylitis typically affects the sacroiliac joints and spine, with characteristic findings such as the \"bamboo spine\" on radiographs. It is not associated with the \"bull\u2019s head\" sign, which is specific to SAPHO syndrome.</li><li>\u2022 Option D. Ankylosing spondylitis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The \"bull\u2019s head\" sign on a radionuclide bone scan is a classic finding in SAPHO syndrome , which is characterized by skin involvement (such as acne and pustulosis) and joint symptoms, particularly affecting the sternoclavicular joints and clavicles.</li><li>\u27a4 SAPHO syndrome</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ec8a37c9",
      "audio": ""
    },
    {
      "text": "A 25-year-old female with a history of systemic lupus erythematosus (SLE) presents with worsening proteinuria, hematuria, and swelling in her legs. A kidney biopsy is performed and the findings are consistent with lupus nephritis. What is the most accurate description of the most common type of lupus nephritis?",
      "options": [
        {
          "label": "A",
          "text": "Mesangial Proliferative Lupus Nephritis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Focal Lupus Nephritis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Diffuse Lupus Nephritis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Membranous Lupus Nephritis",
          "correct": false
        }
      ],
      "correct_answer": "C. Diffuse Lupus Nephritis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Diffuse Lupus Nephritis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The most common type of lupus nephritis is class IV lupus nephritis and is characterized by diffuse lupus nephritis , which involves widespread inflammation affecting both kidneys. This is the most severe form of lupus nephritis and typically presents with significant proteinuria, hematuria, and nephrotic syndrome. It can lead to renal failure if not properly treated. On biopsy, the findings show diffuse glomerular involvement with inflammation, often requiring aggressive treatment to prevent progression to end-stage renal disease.</li><li>\u2022 The most common type of lupus nephritis is class IV lupus nephritis</li><li>\u2022 diffuse lupus nephritis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Mesangial Proliferative Lupus Nephritis: Class II lupus nephritis is classified as mesangial proliferative and is the mildest form of lupus nephritis. It primarily involves the mesangium, with minimal glomerular damage and usually does not cause significant clinical symptoms.</li><li>\u2022 Option A. Mesangial Proliferative Lupus Nephritis:</li><li>\u2022 mesangial proliferative</li><li>\u2022 Option B. Focal Lupus Nephritis: Class III lupus nephritis is focal lupus nephritis , where fewer than 50% of the glomeruli are affected by inflammation. It can present with some symptoms but is typically less severe than class IV.</li><li>\u2022 Option B. Focal Lupus Nephritis:</li><li>\u2022 focal lupus nephritis</li><li>\u2022 Option D. Membranous Lupus Nephritis: Class V lupus nephritis is membranous lupus nephritis , characterized by thickening of the glomerular basement membrane. It is more commonly associated with nephrotic syndrome but does not present with the diffuse, widespread inflammation seen in class IV.</li><li>\u2022 Option D. Membranous Lupus Nephritis:</li><li>\u2022 membranous lupus nephritis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Class IV lupus nephritis is characterized by diffuse lupus nephritis , the most common and the most severe form of lupus nephritis, involving widespread inflammation and often requiring aggressive treatment to prevent kidney failure.</li><li>\u27a4 Class IV lupus nephritis</li><li>\u27a4 diffuse lupus nephritis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8c2e8819",
      "audio": ""
    },
    {
      "text": "A 32-year-old female with a history of recurrent miscarriages presents to the clinic for evaluation of possible antiphospholipid syndrome. Which of the following autoantibodies is detected by the dilute Russell viper venom test (DRVVT)?",
      "options": [
        {
          "label": "A",
          "text": "Antibodies against cardiolipin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Antibodies against \u03b22 GPI",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lupus anticoagulant",
          "correct": true
        },
        {
          "label": "D",
          "text": "Antiphosphatidylserine",
          "correct": false
        }
      ],
      "correct_answer": "C. Lupus anticoagulant",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Lupus anticoagulant</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The dilute Russell viper venom test (DRVVT) is used to detect lupus anticoagulant (LA) , which is an antibody associated with antiphospholipid syndrome (APS). The DRVVT is a clotting test that measures the effect of lupus anticoagulant on the clotting cascade. LA is an antibody that interferes with normal phospholipid-dependent clotting reactions, leading to prolonged clotting times, as seen in the DRVVT.</li><li>\u2022 dilute Russell viper venom test (DRVVT)</li><li>\u2022 lupus anticoagulant (LA)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Antibodies against cardiolipin: Antibodies against cardiolipin (aCL) are detected using an enzyme-linked immunosorbent assay (ELISA), not by DRVVT. These antibodies are one of the markers for antiphospholipid syndrome but are different from lupus anticoagulant.</li><li>\u2022 Option A. Antibodies against cardiolipin:</li><li>\u2022 Option B. Antibodies against \u03b22 GPI: Antibodies against \u03b22 glycoprotein I (\u03b22 GPI) are typically detected using an ELISA, similar to the test for cardiolipin antibodies. These antibodies are associated with antiphospholipid syndrome but are not detected by DRVVT.</li><li>\u2022 Option B. Antibodies against \u03b22 GPI:</li><li>\u2022 \u03b22 glycoprotein I (\u03b22 GPI)</li><li>\u2022 Option D. Antiphosphatidylserine: Antibodies against phosphatidylserine are not typically measured in routine antiphospholipid syndrome testing. Phosphatidylserine is involved in clotting processes, but this antibody is not a standard test for APS and is not detected by DRVVT.</li><li>\u2022 Option D. Antiphosphatidylserine:</li><li>\u2022 phosphatidylserine</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The dilute Russell viper venom test (DRVVT) is specifically used to detect lupus anticoagulant (LA) , an antibody often present in antiphospholipid syndrome, and is crucial for evaluating patients with a prolonged aPTT and recurrent thrombotic events.</li><li>\u27a4 dilute Russell viper venom test (DRVVT)</li><li>\u27a4 lupus anticoagulant (LA)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0cb15760",
      "audio": ""
    },
    {
      "text": "A 19-year-old male presents with purpuric lesions on his lower extremities and abdominal pain. Biopsy of the skin lesion demonstrated immune complexes around small vessels. What is the most likely cause of the vasculitis in this patient, given the laboratory findings and clinical presentation?",
      "options": [
        {
          "label": "A",
          "text": "Granulomatosis with polyangiitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Henoch-Sch\u00f6nlein purpura",
          "correct": true
        },
        {
          "label": "C",
          "text": "Microscopic polyangiitis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Eosinophilic granulomatosis with polyangiitis",
          "correct": false
        }
      ],
      "correct_answer": "B. Henoch-Sch\u00f6nlein purpura",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B)\u00a0Henoch-Sch\u00f6nlein purpura</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Henoch-Sch\u00f6nlein purpura (also called as IgA vasculitis) is characterized by the deposition of IgA immune complexes in small vessels, leading to vasculitis, especially in the skin, joints, and gastrointestinal system. It typically presents with purpuric lesions , especially on the lower extremities, abdominal pain, and arthritis. The production of immune complexes, rather than antineutrophilic cytoplasmic antibodies (ANCA) , is the primary mechanism of vessel damage in IgA vasculitis .</li><li>\u2022 Henoch-Sch\u00f6nlein purpura (also called as IgA vasculitis)</li><li>\u2022 IgA immune complexes</li><li>\u2022 purpuric lesions</li><li>\u2022 antineutrophilic cytoplasmic antibodies (ANCA)</li><li>\u2022 IgA vasculitis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Granulomatosis with polyangiitis: Granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) is an ANCA-associated vasculitis. It involves the production of antineutrophilic cytoplasmic antibodies (ANCA) , which play a key role in the pathogenesis of the disease, causing inflammation of small to medium-sized vessels. It is not related to immune complex deposition like in IgA vasculitis .</li><li>\u2022 Option A. Granulomatosis with polyangiitis:</li><li>\u2022 antineutrophilic cytoplasmic antibodies (ANCA)</li><li>\u2022 IgA vasculitis</li><li>\u2022 Option C. Microscopic polyangiitis: Microscopic polyangiitis is another ANCA-associated vasculitis. It is characterized by the presence of ANCA , which causes damage to small vessels and is not associated with immune complex deposition. This distinguishes it from IgA vasculitis .</li><li>\u2022 Option C. Microscopic polyangiitis: Microscopic polyangiitis</li><li>\u2022 ANCA</li><li>\u2022 IgA vasculitis</li><li>\u2022 Option D. Eosinophilic granulomatosis with polyangiitis: Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) is also an ANCA-associated vasculitis, characterized by asthma, eosinophilia, and vasculitis involving small to medium vessels. Like the other ANCA-associated vasculitides, it does not involve immune complex deposition as the primary mechanism of vessel damage.</li><li>\u2022 Option D. Eosinophilic granulomatosis with polyangiitis:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 IgA vasculitis (Henoch-Sch\u00f6nlein) is caused by immune complex deposition , specifically IgA, and is characterized by purpuric lesions , abdominal pain, and joint swelling. It is distinct from the ANCA-associated vasculitides, which include granulomatosis with polyangiitis , microscopic polyangiitis , and eosinophilic granulomatosis with polyangiitis .</li><li>\u27a4 IgA vasculitis (Henoch-Sch\u00f6nlein)</li><li>\u27a4 immune complex deposition</li><li>\u27a4 purpuric lesions</li><li>\u27a4 granulomatosis with polyangiitis</li><li>\u27a4 microscopic polyangiitis</li><li>\u27a4 eosinophilic granulomatosis with polyangiitis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "782f73e2",
      "audio": ""
    },
    {
      "text": "A 45-year-old male presents with symptoms of hypertension, abdominal pain, and muscle weakness. Laboratory investigations show elevated creatinine levels and hematuria without RBC casts. A biopsy reveals necrotizing vasculitis of small- and medium-sized muscular arteries. Based on these findings, which of the following is not a feature of this condition?",
      "options": [
        {
          "label": "A",
          "text": "Pulmonary involvement",
          "correct": true
        },
        {
          "label": "B",
          "text": "Negative ANCA",
          "correct": false
        },
        {
          "label": "C",
          "text": "Absence of granulomas",
          "correct": false
        },
        {
          "label": "D",
          "text": "HBV association",
          "correct": false
        }
      ],
      "correct_answer": "A. Pulmonary involvement",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Pulmonary involvement</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The presentation is consistent with polyarteritis nodosa (PAN) , a systemic necrotizing vasculitis involving small- and medium-sized arteries. Typical features include renal involvement (elevated creatinine, hematuria without RBC casts), hypertension, abdominal pain, and muscle weakness. PAN spares the pulmonary vessels, and pulmonary involvement is not a feature of this condition.</li><li>\u2022 polyarteritis nodosa (PAN)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B . Negative ANCA: PAN is typically ANCA-negative, distinguishing it from other vasculitides like microscopic polyangiitis (MPA).</li><li>\u2022 Option</li><li>\u2022 B</li><li>\u2022 Negative ANCA:</li><li>\u2022 Option C . Absence of granulomas: PAN does not involve granuloma formation, differentiating it from granulomatosis with polyangiitis (GPA).</li><li>\u2022 Option C</li><li>\u2022 Absence of granulomas:</li><li>\u2022 Option D . HBV association: PAN is strongly associated with hepatitis B virus (HBV) infection in approximately 10\u201330% of cases.</li><li>\u2022 Option</li><li>\u2022 D</li><li>\u2022 HBV association:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis of small- and medium-sized arteries, characterized by ANCA negativity , absence of granulomas , and HBV association . Pulmonary involvement is not a feature of PAN, which helps differentiate it from other vasculitides.</li><li>\u27a4 Polyarteritis nodosa (PAN)</li><li>\u27a4 ANCA negativity</li><li>\u27a4 absence of granulomas</li><li>\u27a4 HBV association</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1ca0144f",
      "audio": ""
    },
    {
      "text": "A 70-year-old female presents with a 2-month history of bilateral shoulder and hip pain, along with morning stiffness lasting for over an hour. Laboratory tests reveal an elevated ESR. Which of the following is not typical of this disorder?",
      "options": [
        {
          "label": "A",
          "text": "Anti-cyclic citrullinated peptide (CCP) is negative",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prompt therapeutic response to low-dose prednisone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Rheumatoid factor is positive",
          "correct": true
        },
        {
          "label": "D",
          "text": "Presence of arthritis",
          "correct": false
        }
      ],
      "correct_answer": "C. Rheumatoid factor is positive",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Rheumatoid factor is positive</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation suggests polymyalgia rheumatica (PMR) , an inflammatory disorder typically seen in older adults. PMR is characterized by pain and stiffness in the shoulders and hips, elevated ESR or CRP, and a dramatic response to low-dose corticosteroids. Rheumatoid factor positivity is not associated with PMR, making it an atypical finding and indicative of an alternative diagnosis such as rheumatoid arthritis (RA).</li><li>\u2022 polymyalgia rheumatica (PMR)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A . Anti-cyclic citrullinated peptide (CCP) is negative : CCP is not a feature of PMR and is more specific to RA. A negative CCP test is typical in PMR.</li><li>\u2022 Option A</li><li>\u2022 Anti-cyclic citrullinated peptide (CCP) is negative</li><li>\u2022 Option B . Prompt therapeutic response to low-dose prednisone : A hallmark feature of PMR is its dramatic response to corticosteroids, which often leads to symptom resolution within days.</li><li>\u2022 Option B</li><li>\u2022 Prompt therapeutic response to low-dose prednisone</li><li>\u2022 Option D . Presence of arthritis : While PMR is primarily periarticular, mild arthritis may be present and is not uncommon in the clinical presentation.</li><li>\u2022 Option D</li><li>\u2022 Presence of arthritis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Polymyalgia rheumatica (PMR) is an inflammatory condition affecting the elderly, characterized by proximal muscle stiffness, elevated inflammatory markers, and rapid response to low-dose corticosteroids. Autoimmune markers like RF and CCP are absent, distinguishing PMR from other autoimmune diseases like RA.</li><li>\u27a4 Polymyalgia rheumatica (PMR)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d9a19860",
      "audio": ""
    },
    {
      "text": "A 55-year-old male presents with progressive muscle weakness and difficulty climbing stairs. He has no skin changes but reports noticeable muscle wasting and weakness, particularly in the quadriceps and forearms. Laboratory tests show elevated muscle enzymes (CPK and aldolase). Given the patient's age and presentation, what is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Dermatomyositis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Inclusion body myositis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Polymyositis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Immune-mediated necrotizing myopathy",
          "correct": false
        }
      ],
      "correct_answer": "B. Inclusion body myositis",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Inclusion body myositis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Inclusion body myositis (IBM) is the most common cause of myositis in individuals over 50 years . It is a progressive, idiopathic inflammatory muscle disease that typically presents with muscle weakness and atrophy , most commonly affecting the quadriceps and forearms . The disease is more common in men and presents with characteristic features such as muscle wasting and elevated muscle enzymes . Muscle biopsy typically shows inclusion bodies and rimmed vacuoles, which are pathognomonic for IBM.</li><li>\u2022 Inclusion body myositis (IBM)</li><li>\u2022 myositis in individuals over 50 years</li><li>\u2022 muscle weakness and atrophy</li><li>\u2022 quadriceps</li><li>\u2022 forearms</li><li>\u2022 men</li><li>\u2022 muscle wasting</li><li>\u2022 elevated muscle enzymes</li><li>\u2022 inclusion bodies</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Dermatomyositis: Dermatomyositis (DM) is a type of inflammatory myopathy that typically affects younger individuals and is associated with skin involvement , such as a heliotrope rash and Gottron's papules . While DM can occur in adults, it is less common in those over 50 years of age and is more likely to occur in women .</li><li>\u2022 Option A. Dermatomyositis: Dermatomyositis (DM)</li><li>\u2022 younger individuals</li><li>\u2022 skin involvement</li><li>\u2022 heliotrope rash</li><li>\u2022 Gottron's papules</li><li>\u2022 women</li><li>\u2022 Option C. Polymyositis: Polymyositis (PM) is another form of inflammatory myopathy that often presents with muscle weakness in the proximal muscles (e.g., hips and shoulders). However, it is less common than IBM in older adults, and the disease tends to present in younger individuals , typically 30-60 years old. It also usually affects women more than men.</li><li>\u2022 Option C. Polymyositis: Polymyositis (PM)</li><li>\u2022 muscle weakness</li><li>\u2022 younger individuals</li><li>\u2022 30-60 years</li><li>\u2022 women</li><li>\u2022 Option D. Immune-mediated necrotizing myopathy: Immune-mediated necrotizing myopathy (IMNM) is a rare form of myopathy that can result from autoimmune diseases or as a consequence of statin use . It tends to cause severe muscle weakness, but it is less common than inclusion body myositis in older individuals.</li><li>\u2022 Option D. Immune-mediated necrotizing myopathy: Immune-mediated necrotizing myopathy (IMNM)</li><li>\u2022 autoimmune diseases</li><li>\u2022 statin use</li><li>\u2022 inclusion body myositis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Inclusion body myositis (IBM) is the most common form of myositis in individuals over 50, typically presenting with progressive muscle weakness, particularly affecting the quadriceps and forearms , and is characterized by muscle wasting and elevated muscle enzymes</li><li>\u27a4 Inclusion body myositis (IBM)</li><li>\u27a4 quadriceps</li><li>\u27a4 forearms</li><li>\u27a4 muscle wasting</li><li>\u27a4 elevated muscle enzymes</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f98c7c2f",
      "audio": ""
    },
    {
      "text": "A 25-year-old female presents with fatigue. Her iron studies reveal the following: Hb: Normal MCV: Normal RBC protoporphyrin (\u00b5g/dL): 150 (normal: 30-50) Saturation (%): 15 (normal: 30-50) Marrow iron stores: 0 Serum ferritin (\u00b5g/L): 10 (normal: 50-200) Based on the findings, what is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Normal iron balance",
          "correct": false
        },
        {
          "label": "B",
          "text": "Negative iron balance",
          "correct": false
        },
        {
          "label": "C",
          "text": "Iron deficient erythropoiesis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Iron deficiency anemia",
          "correct": false
        }
      ],
      "correct_answer": "C. Iron deficient erythropoiesis",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20162246.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Iron deficient erythropoiesis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The findings indicate that the patient is in the stage of iron deficient erythropoiesis , where there is depletion of iron stores (marrow iron stores: 0, ferritin: 10 \u00b5g/L) and a low transferrin saturation (15%). Although hemoglobin and MCV are still normal, the elevated RBC protoporphyrin level reflects iron-deficient heme synthesis. This stage precedes the development of full-blown iron deficiency anemia, where hemoglobin levels become low.</li><li>\u2022 iron deficient erythropoiesis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A . Normal iron balance: The absence of marrow iron stores and low ferritin indicate an abnormal iron balance.</li><li>\u2022 Option A</li><li>\u2022 Normal iron balance:</li><li>\u2022 Option B . Negative iron balance: This is an earlier stage where iron stores begin to deplete, but RBC protoporphyrin and transferrin saturation remain normal.</li><li>\u2022 Option B</li><li>\u2022 Negative iron balance:</li><li>\u2022 Option D . Iron deficiency anemia: This is a later stage where hemoglobin levels are low, and microcytosis develops, neither of which is present in this patient.</li><li>\u2022 Option D</li><li>\u2022 Iron deficiency anemia:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Iron deficiency progresses in stages, beginning with negative iron balance (depleting stores), followed by iron deficient erythropoiesis (impaired iron incorporation into RBCs), and culminating in iron deficiency anemia (low Hb and microcytosis). Elevated RBC protoporphyrin and low marrow iron stores signal iron deficient erythropoiesis before anemia develops.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "21d9129c",
      "audio": ""
    },
    {
      "text": "A 32-year-old male with sickle cell anemia presents with frequent episodes of pain and difficulty managing his disease. His physician recommends a monthly intravenous therapy to reduce acute painful episodes by blocking P-selectin , a molecule involved in endothelial cell adhesion. Which of the following medications is being used for this purpose?",
      "options": [
        {
          "label": "A",
          "text": "Teplizumab",
          "correct": false
        },
        {
          "label": "B",
          "text": "Voxelotor",
          "correct": false
        },
        {
          "label": "C",
          "text": "Crizanlizumab",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ofatumumab",
          "correct": false
        }
      ],
      "correct_answer": "C. Crizanlizumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Crizanlizumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Crizanlizumab is a P-selectin-blocking monoclonal antibody that is used in sickle cell anemia to prevent the adhesive interactions between endothelial cells, platelets, leukocytes, and erythrocytes, which contribute to vaso-occlusion. By blocking P-selectin, Crizanlizumab reduces the frequency of acute painful episodes by approximately 45% , providing relief for patients. This mechanism of action helps reduce the complications of sickle cell disease, such as vaso-occlusive crises, without affecting hemolysis directly.</li><li>\u2022 Crizanlizumab</li><li>\u2022 P-selectin-blocking monoclonal antibody</li><li>\u2022 Crizanlizumab</li><li>\u2022 acute painful episodes</li><li>\u2022 45%</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Teplizumab: Teplizumab is a monoclonal antibody used in the treatment of type 1 diabetes . It does not have a role in the treatment of sickle cell anemia or in blocking P-selectin.</li><li>\u2022 Option A. Teplizumab: Teplizumab</li><li>\u2022 type 1 diabetes</li><li>\u2022 Option B. Voxelotor: Voxelotor works by increasing the oxygen affinity of hemoglobin and stabilizing hemoglobin in its oxygenated form, thereby reducing sickling. It is not a P-selectin blocker, so it does not target the adhesion process between cells.</li><li>\u2022 Option B. Voxelotor: Voxelotor</li><li>\u2022 Option D. Ofatumumab: Ofatumumab is a monoclonal antibody used for the treatment of chronic lymphocytic leukemia (CLL) and multiple sclerosis . It is not used in sickle cell anemia and does not block P-selectin.</li><li>\u2022 Option D. Ofatumumab: Ofatumumab</li><li>\u2022 chronic lymphocytic leukemia</li><li>\u2022 multiple sclerosis</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Crizanlizumab is a P-selectin-blocking monoclonal antibody used in sickle cell anemia to reduce acute painful episodes by preventing sickle cell\u2013endothelial adhesion, improving the patient's quality of life and reducing complications</li><li>\u27a4 Crizanlizumab</li><li>\u27a4 P-selectin-blocking monoclonal antibody</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1ee81d8a",
      "audio": ""
    },
    {
      "text": "A newborn presents with severe anemia, and the clinician suspects alpha-thalassemia. Laboratory tests reveal a deletion of all four alpha globin genes. What is the structural composition of the hemoglobin in this newborn?",
      "options": [
        {
          "label": "A",
          "text": "\u03b13 \u03b31",
          "correct": false
        },
        {
          "label": "B",
          "text": "\u03b1 \u03b33",
          "correct": false
        },
        {
          "label": "C",
          "text": "\ud835\udefd4",
          "correct": false
        },
        {
          "label": "D",
          "text": "\u03b34",
          "correct": true
        }
      ],
      "correct_answer": "D. \u03b34",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) \u03b34</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Deletion of all four alpha globin genes results in Hb Bart's hydrops fetalis , a condition in which no alpha chains are produced. In the absence of alpha chains, gamma chains (produced in the fetal stage) form tetramers (\u03b34), called Hb Bart's. Hb Bart's has a very high oxygen affinity and cannot effectively deliver oxygen to tissues, leading to severe hypoxia, hydrops fetalis, and typically, in utero death.</li><li>\u2022 Hb Bart's hydrops fetalis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A . \u03b13 \u03b31 : This combination is not physiologically possible, as alpha and gamma chains form heterotetramers, not uneven combinations like \u03b13\u03b31.</li><li>\u2022 Option A</li><li>\u2022 \u03b13 \u03b31</li><li>\u2022 Option B . \u03b1 \u03b33 : While gamma chains are present in the fetal stage, they form tetramers (\u03b34) in the absence of alpha chains, not this combination.</li><li>\u2022 Option B</li><li>\u2022 \u03b1 \u03b33</li><li>\u2022 Option C . \ud835\udefd4 : Beta tetramers (Hb H) form in alpha-thalassemia with a milder deletion (three alpha genes lost), typically manifesting as Hb H disease, not Hb Bart's hydrops fetalis.</li><li>\u2022 Option C</li><li>\u2022 \ud835\udefd4</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In alpha-thalassemia with deletion of all four alpha genes, gamma chains form tetramers (\u03b34), known as Hb Bart's, which is pathognomonic for Hb Bart's hydrops fetalis and results in severe anemia and hypoxia.</li><li>\u27a4 Hb Bart's hydrops fetalis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6adf2365",
      "audio": ""
    },
    {
      "text": "A 4-year-old male presents with failure to thrive. He is diagnosed with Imerslund's syndrome. What is the defining characteristic of this condition?",
      "options": [
        {
          "label": "A",
          "text": "Selective malabsorption of folate with proteinuria",
          "correct": false
        },
        {
          "label": "B",
          "text": "Selective malabsorption of cobalamin with folate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Selective malabsorption of cobalamin with proteinuria",
          "correct": true
        },
        {
          "label": "D",
          "text": "Selective malabsorption of cobalamin with lymphopenia",
          "correct": false
        }
      ],
      "correct_answer": "C. Selective malabsorption of cobalamin with proteinuria",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Selective malabsorption of cobalamin with proteinuria</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Imerslund's syndrome (also known as Imerslund-Gr\u00e4sbeck syndrome ) is a rare, autosomal recessive disorder characterized by selective malabsorption of cobalamin (vitamin B12) and the presence of proteinuria . This condition typically leads to megaloblastic anemia due to vitamin B12 deficiency and is the most common cause of cobalamin malabsorption in infancy in Western countries. The syndrome is associated with defects in the cobalamin absorption process and renal complications (proteinuria).</li><li>\u2022 Imerslund's syndrome</li><li>\u2022 Imerslund-Gr\u00e4sbeck syndrome</li><li>\u2022 selective malabsorption of cobalamin (vitamin B12)</li><li>\u2022 proteinuria</li><li>\u2022 megaloblastic anemia</li><li>\u2022 cobalamin malabsorption</li><li>\u2022 cobalamin absorption process</li><li>\u2022 renal complications</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Selective malabsorption of folate with proteinuria: This is not a feature of Imerslund's syndrome . While folate malabsorption can occur in certain disorders, Imerslund's syndrome specifically involves cobalamin malabsorption , not folate.</li><li>\u2022 Option A. Selective malabsorption of folate with proteinuria:</li><li>\u2022 Imerslund's syndrome</li><li>\u2022 Imerslund's syndrome</li><li>\u2022 cobalamin malabsorption</li><li>\u2022 Option B. Selective malabsorption of cobalamin with folate: While Imerslund's syndrome does involve cobalamin malabsorption , it does not involve folate malabsorption as described in this option.</li><li>\u2022 Option B. Selective malabsorption of cobalamin with folate:</li><li>\u2022 Imerslund's syndrome</li><li>\u2022 cobalamin malabsorption</li><li>\u2022 Option D. Selective malabsorption of cobalamin with lymphopenia: Cobalamin malabsorption is the hallmark of Imerslund's syndrome and is associated with proteinuria .</li><li>\u2022 Option D. Selective malabsorption of cobalamin with lymphopenia: Cobalamin malabsorption</li><li>\u2022 Imerslund's syndrome</li><li>\u2022 proteinuria</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Imerslund's syndrome is characterized by selective malabsorption of cobalamin and proteinuria . It causes megaloblastic anemia and is typically diagnosed in infancy.</li><li>\u27a4 Imerslund's syndrome</li><li>\u27a4 selective malabsorption of cobalamin</li><li>\u27a4 proteinuria</li><li>\u27a4 megaloblastic anemia</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "093d2952",
      "audio": ""
    },
    {
      "text": "A 6-year-old child presents with hemoglobinuria after a recent viral infection. Laboratory testing reveals the presence of Donath-Landsteiner antibodies. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Paroxysmal nocturnal hemoglobinuria",
          "correct": false
        },
        {
          "label": "B",
          "text": "March hemoglobinuria",
          "correct": false
        },
        {
          "label": "C",
          "text": "Paroxysmal cold hemoglobinuria",
          "correct": true
        },
        {
          "label": "D",
          "text": "Warm autoimmune hemolytic anemia (WAIHA)",
          "correct": false
        }
      ],
      "correct_answer": "C. Paroxysmal cold hemoglobinuria",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Paroxysmal cold hemoglobinuria</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Paroxysmal cold hemoglobinuria (PCH) is a rare form of autoimmune hemolytic anemia (AIHA) , typically seen in children , and often triggered by a viral infection . It is characterized by the presence of Donath-Landsteiner antibodies , which are cold-reactive antibodies that cause hemolysis upon exposure to cold temperatures. In this condition, hemoglobinuria occurs after cold exposure, and the hemolysis typically resolves when the body temperature returns to normal. The presence of Donath-Landsteiner antibodies is diagnostic of this condition.</li><li>\u2022 Paroxysmal cold hemoglobinuria (PCH)</li><li>\u2022 autoimmune hemolytic anemia (AIHA)</li><li>\u2022 children</li><li>\u2022 viral infection</li><li>\u2022 Donath-Landsteiner antibodies</li><li>\u2022 cold-reactive antibodies</li><li>\u2022 hemolysis</li><li>\u2022 hemoglobinuria</li><li>\u2022 Donath-Landsteiner antibodies</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Paroxysmal nocturnal hemoglobinuria (PNH): PNH is characterized by complement-mediated red blood cell lysis due to a defect in glycosylphosphatidylinositol (GPI)-anchored proteins . It is not associated with Donath-Landsteiner antibodies and has a different pathophysiology than paroxysmal cold hemoglobinuria .</li><li>\u2022 Option A. Paroxysmal nocturnal hemoglobinuria (PNH): PNH</li><li>\u2022 complement-mediated red blood cell lysis</li><li>\u2022 glycosylphosphatidylinositol (GPI)-anchored proteins</li><li>\u2022 Donath-Landsteiner antibodies</li><li>\u2022 paroxysmal cold hemoglobinuria</li><li>\u2022 Option B. March hemoglobinuria: March hemoglobinuria occurs after strenuous exercise , especially when there is trauma to the red blood cells (e.g., from running or marching). It is not an autoimmune condition and is unrelated to Donath-Landsteiner antibodies . It results in hemoglobinuria due to physical damage to red blood cells.</li><li>\u2022 Option B. March hemoglobinuria: March hemoglobinuria</li><li>\u2022 strenuous exercise</li><li>\u2022 Donath-Landsteiner antibodies</li><li>\u2022 hemoglobinuria</li><li>\u2022 Option D. Warm autoimmune hemolytic anemia (WAIHA): WAIHA involves warm-reacting antibodies , typically IgG antibodies , which cause hemolysis at normal body temperatures. It is not related to Donath-Landsteiner antibodies , which are cold-reacting antibodies found in PCH .</li><li>\u2022 Option D. Warm autoimmune hemolytic anemia (WAIHA): WAIHA</li><li>\u2022 warm-reacting antibodies</li><li>\u2022 IgG antibodies</li><li>\u2022 hemolysis</li><li>\u2022 Donath-Landsteiner antibodies</li><li>\u2022 PCH</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Donath-Landsteiner antibodies are characteristic of paroxysmal cold hemoglobinuria (PCH) , a condition often triggered by viral infections, leading to hemolysis upon cold exposure. It is an autoimmune hemolytic anemia, predominantly seen in children</li><li>\u27a4 Donath-Landsteiner antibodies</li><li>\u27a4 paroxysmal cold hemoglobinuria (PCH)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dba1c927",
      "audio": ""
    },
    {
      "text": "A 55-year-old female, who has been on heparin therapy for 5 days after surgery, presents with thrombocytopenia and new-onset skin lesions at the injection site. Laboratory testing reveals a platelet count drop of 50% from baseline. Which of the following antibodies is implicated in the pathogenesis of the disorder?",
      "options": [
        {
          "label": "A",
          "text": "Platelet factor 1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Platelet factor 2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Platelet factor 3",
          "correct": false
        },
        {
          "label": "D",
          "text": "Platelet factor 4",
          "correct": true
        }
      ],
      "correct_answer": "D. Platelet factor 4",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Platelet factor 4</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation is consistent with heparin-induced thrombocytopenia (HIT) , a prothrombotic disorder caused by antibodies directed against complexes of heparin and platelet factor 4 (PF4) . These antibodies activate platelets, leading to thrombocytopenia and an increased risk of thrombosis. The hallmark features of HIT include a >50% drop in platelet count, usually 5\u201310 days after starting heparin, and thrombosis or other complications such as skin necrosis.</li><li>\u2022 heparin-induced thrombocytopenia (HIT)</li><li>\u2022 heparin and platelet factor 4 (PF4)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A . Platelet factor 1 : This is not involved in the pathogenesis of HIT.</li><li>\u2022 Option A</li><li>\u2022 Platelet factor 1</li><li>\u2022 Option B . Platelet factor 2 : This is incorrect; the implicated factor is platelet factor 4.</li><li>\u2022 Option B</li><li>\u2022 Platelet factor 2</li><li>\u2022 Option C . Platelet factor 3 : This refers to a phospholipid complex involved in the coagulation cascade but is unrelated to HIT.</li><li>\u2022 Option C</li><li>\u2022 Platelet factor 3</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In heparin-induced thrombocytopenia , antibodies target the heparin-platelet factor 4 complex, leading to platelet activation, thrombocytopenia, and a high risk of thrombosis. Early recognition and discontinuation of heparin are essential to prevent complications.</li><li>\u27a4 heparin-induced thrombocytopenia</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a899abd5",
      "audio": ""
    },
    {
      "text": "A 45-year-old female presents with 2 days of fever and altered mental status. Peripheral smear reveals microangiopathic hemolytic anemia and thrombocytopenia with high serum creatinine. The physician orders a test to evaluate ADAMTS13 activity. What level of activity is diagnostic for the disorder?",
      "options": [
        {
          "label": "A",
          "text": "<5%",
          "correct": false
        },
        {
          "label": "B",
          "text": "<15%",
          "correct": false
        },
        {
          "label": "C",
          "text": "<10%",
          "correct": true
        },
        {
          "label": "D",
          "text": "<20%",
          "correct": false
        }
      ],
      "correct_answer": "C. <10%",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) <10%</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation is consistent with thrombotic thrombocytopenic purpura (TTP) , a condition caused by severe deficiency of ADAMTS13 activity. ADAMTS13 is a protease that cleaves large von Willebrand factor (vWF) multimers. When its activity is reduced to <10% , unregulated vWF activity leads to platelet aggregation, thrombocytopenia, microangiopathic hemolytic anemia, and end-organ damage. Testing ADAMTS13 activity confirms the diagnosis of TTP.</li><li>\u2022 thrombotic thrombocytopenic purpura (TTP)</li><li>\u2022 <10%</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. <5%: While TTP involves severe ADAMTS13 deficiency, a diagnostic threshold of <10% is standard.</li><li>\u2022 Option A. <5%:</li><li>\u2022 Option B. <15%: This threshold is too high and would lead to overdiagnosis.</li><li>\u2022 Option B. <15%:</li><li>\u2022 Option D. <20%: This level is also not diagnostic for TTP. It's closer to the normal range, but it falls outside the diagnostic criteria for TTP based on ADAMTS13 activity. A patient with this level would likely have other causes for their symptoms investigated.</li><li>\u2022 Option</li><li>\u2022 D. <20%:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Thrombotic thrombocytopenic purpura (TTP) is characterized by ADAMTS13 activity levels of <10% , leading to microangiopathic hemolytic anemia and thrombocytopenia. Prompt recognition and initiation of plasma exchange are critical for management.</li><li>\u27a4 Thrombotic thrombocytopenic purpura (TTP)</li><li>\u27a4 <10%</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e39a89f9",
      "audio": ""
    },
    {
      "text": "A 10-year-old boy presents with purpura on his legs, abdominal pain, and hematuria. His parents report that he had an upper respiratory infection a few days prior. Which of the following statements is not true about the disorder?",
      "options": [
        {
          "label": "A",
          "text": "Associated with starry sky appearance in renal biopsy",
          "correct": true
        },
        {
          "label": "B",
          "text": "Arthritis is common",
          "correct": false
        },
        {
          "label": "C",
          "text": "PT, aPTT is likely to be normal",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glucocorticoids can provide symptomatic relief",
          "correct": false
        }
      ],
      "correct_answer": "A. Associated with starry sky appearance in renal biopsy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Associated with starry sky appearance in renal biopsy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The clinical presentation is consistent with IgA vasculitis (Henoch-Sch\u00f6nlein purpura, HSP) , a small-vessel vasculitis commonly seen in children. It is characterized by palpable purpura, abdominal pain, arthralgia/arthritis, and renal involvement (hematuria or proteinuria). Renal biopsy in IgA vasculitis typically shows mesangial IgA deposition , not a \"starry sky\" appearance, which is more characteristic of post-streptococcal glomerulonephritis (PSGN).</li><li>\u2022 IgA vasculitis (Henoch-Sch\u00f6nlein purpura, HSP)</li><li>\u2022 mesangial IgA deposition</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B . Arthritis is common: Arthritis or arthralgia, particularly affecting the knees and ankles, is a frequent symptom of IgA vasculitis.</li><li>\u2022 Option B</li><li>\u2022 Arthritis is common:</li><li>\u2022 Option C . PT, aPTT is likely to be normal: Coagulation studies are usually normal in IgA vasculitis, as the condition involves immune-mediated vasculitis rather than a coagulopathy.</li><li>\u2022 Option C</li><li>\u2022 PT, aPTT is likely to be normal:</li><li>\u2022 Option D . Glucocorticoids can provide symptomatic relief: While not curative, glucocorticoids can help alleviate severe abdominal pain or renal involvement in IgA vasculitis.</li><li>\u2022 Option D</li><li>\u2022 Glucocorticoids can provide symptomatic relief:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 IgA vasculitis (HSP) is characterized by immune complex deposition in small vessels, with renal biopsy showing mesangial IgA deposition . A \"starry sky\" appearance is not a feature of this disorder, distinguishing it from PSGN.</li><li>\u27a4 IgA vasculitis (HSP)</li><li>\u27a4 mesangial IgA deposition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "27f53446",
      "audio": ""
    },
    {
      "text": "A 5-year-old male presents with a history of severe mucosal bleeding, joint bleeding, and excessive bleeding after surgery. Laboratory tests show virtually no von Willebrand factor (VWF) protein and factor VIII (FVIII) levels <10%. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Type 1 VWD",
          "correct": false
        },
        {
          "label": "B",
          "text": "Type 2 VWD",
          "correct": false
        },
        {
          "label": "C",
          "text": "Type 3 VWD",
          "correct": true
        },
        {
          "label": "D",
          "text": "Type 4 VWD",
          "correct": false
        }
      ],
      "correct_answer": "C. Type 3 VWD",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Type 3 VWD</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Type 3 von Willebrand disease (VWD) is the most severe form of VWD . It is characterized by virtually no VWF protein and FVIII levels <10% , which leads to a significant bleeding tendency. This type of VWD is typically autosomal recessive and manifests with severe mucosal bleeding , joint bleeding , and excessive bleeding during surgery. The lack of VWF impairs platelet adhesion to the vascular wall, and the low levels of FVIII contribute to reduced clot formation.</li><li>\u2022 Type 3 von Willebrand disease (VWD)</li><li>\u2022 VWD</li><li>\u2022 virtually no VWF protein</li><li>\u2022 FVIII levels <10%</li><li>\u2022 autosomal recessive</li><li>\u2022 mucosal bleeding</li><li>\u2022 joint bleeding</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Type 1 VWD: Type 1 VWD is a mild form of the disease where VWF levels are reduced but still detectable. FVIII levels are usually normal or slightly decreased, and the bleeding tendency is less severe when compared to Type 3.</li><li>\u2022 Option A. Type 1 VWD: Type 1 VWD</li><li>\u2022 VWF levels are reduced</li><li>\u2022 Option B. Type 2 VWD: Type 2 VWD is characterized by a qualitative defect in VWF rather than a quantitative deficiency. VWF is present, but it is dysfunctional. FVIII levels are usually mildly decreased , and patients may have bleeding, but it is not as severe as in Type 3 VWD .</li><li>\u2022 Option B. Type 2 VWD: Type 2 VWD</li><li>\u2022 qualitative defect</li><li>\u2022 mildly decreased</li><li>\u2022 Type 3 VWD</li><li>\u2022 Option D. Type 4 VWD: Type 4 VWD is not a recognized subtype of von Willebrand disease . The classification of VWD includes Types 1, 2, and 3 , with Type 3 being the most severe form.</li><li>\u2022 Option D. Type 4 VWD: Type 4 VWD</li><li>\u2022 von Willebrand disease</li><li>\u2022 Types 1, 2, and 3</li><li>\u2022 Type 3</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Type 3 VWD is characterized by virtually no VWF protein and FVIII levels <10% , leading to severe bleeding symptoms including mucosal and joint bleeding. It is the most severe form of von Willebrand disease .</li><li>\u27a4 Type 3 VWD</li><li>\u27a4 virtually no VWF protein</li><li>\u27a4 FVIII levels <10%</li><li>\u27a4 severe bleeding symptoms</li><li>\u27a4 von Willebrand disease</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "66cb5514",
      "audio": ""
    },
    {
      "text": "A 45-year-old male with chronic myelogenous leukemia (CML) shows suboptimal response with imatinib. Genetic testing reveals a T315I mutation. Which of the following is the treatment of choice?",
      "options": [
        {
          "label": "A",
          "text": "Dasatinib",
          "correct": false
        },
        {
          "label": "B",
          "text": "Nilotinib",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ponatinib",
          "correct": true
        },
        {
          "label": "D",
          "text": "Bosutinib",
          "correct": false
        }
      ],
      "correct_answer": "C. Ponatinib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Ponatinib</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Ponatinib is the only tyrosine kinase inhibitor (TKI) that remains active in the setting of the T315I mutation in chronic myelogenous leukemia (CML) . The T315I mutation causes resistance to several earlier TKIs, including imatinib , dasatinib , nilotinib , and bosutinib , but ponatinib has been shown to have activity against this mutation. It is an effective option for patients with the T315I mutation and has demonstrated high response rates, including complete cytogenetic response in 50-70% of patients who had failed two or more TKIs.</li><li>\u2022 Ponatinib</li><li>\u2022 tyrosine kinase inhibitor (TKI)</li><li>\u2022 active</li><li>\u2022 T315I mutation</li><li>\u2022 chronic myelogenous leukemia (CML)</li><li>\u2022 T315I mutation</li><li>\u2022 imatinib</li><li>\u2022 dasatinib</li><li>\u2022 nilotinib</li><li>\u2022 bosutinib</li><li>\u2022 ponatinib</li><li>\u2022 T315I mutation</li><li>\u2022 complete cytogenetic response</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Dasatinib: Dasatinib is not effective in the presence of the T315I mutation . This mutation confers resistance to dasatinib , along with other first- and second-generation TKIs.</li><li>\u2022 Option A. Dasatinib: Dasatinib</li><li>\u2022 T315I mutation</li><li>\u2022 dasatinib</li><li>\u2022 Option B. Nilotinib: Nilotinib , like dasatinib , is ineffective against the T315I mutation and therefore not a good treatment option for patients harboring this mutation.</li><li>\u2022 Option B. Nilotinib: Nilotinib</li><li>\u2022 dasatinib</li><li>\u2022 ineffective</li><li>\u2022 T315I mutation</li><li>\u2022 Option D. Bosutinib: Bosutinib also does not have activity against the T315I mutation and is ineffective in treating CML with this specific mutation.</li><li>\u2022 Option D. Bosutinib: Bosutinib</li><li>\u2022 T315I mutation</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ponatinib is the only TKI that remains active against the T315I mutation in chronic myelogenous leukemia (CML) , providing an important treatment option for patients who have developed resistance to other TKIs.</li><li>\u27a4 Ponatinib</li><li>\u27a4 TKI</li><li>\u27a4 active</li><li>\u27a4 T315I mutation</li><li>\u27a4 chronic myelogenous leukemia (CML)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1217da25",
      "audio": ""
    },
    {
      "text": "A 10-year-old child presents with rapidly enlarging lymph nodes and abdominal mass. A biopsy of the node reveals the following. What is the typical doubling time of this aggressive malignancy?",
      "options": [
        {
          "label": "A",
          "text": "<24 h",
          "correct": true
        },
        {
          "label": "B",
          "text": "48 h",
          "correct": false
        },
        {
          "label": "C",
          "text": "72 h",
          "correct": false
        },
        {
          "label": "D",
          "text": "96 h",
          "correct": false
        }
      ],
      "correct_answer": "A. <24 h",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20162337.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) <24 h</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The biopsy shows starry sky appearance which is characteristic of Burkitt\u2019s lymphoma. Burkitt\u2019s lymphoma is one of the fastest-growing non-Hodgkin lymphomas (NHL) , particularly in children. It has a doubling time of less than 24 hours , which means it can rapidly progress and requires aggressive treatment . This rapid growth is a hallmark of the disease, and the tumor often presents with massive lymphadenopathy , abdominal masses , or bowel involvement .</li><li>\u2022 The biopsy shows starry sky appearance which is characteristic of Burkitt\u2019s lymphoma. Burkitt\u2019s lymphoma</li><li>\u2022 non-Hodgkin lymphomas (NHL)</li><li>\u2022 doubling time of less than 24 hours</li><li>\u2022 aggressive treatment</li><li>\u2022 massive lymphadenopathy</li><li>\u2022 abdominal masses</li><li>\u2022 bowel involvement</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. 48 h: While Burkitt\u2019s lymphoma is a rapidly growing malignancy, its doubling time is usually <24 hours , not 48 hours. A doubling time of 48 hours would indicate a slower-growing tumor.</li><li>\u2022 Option B. 48 h:</li><li>\u2022 doubling time</li><li>\u2022 <24 hours</li><li>\u2022 Option C. 72 h: A 72-hour doubling time would be considered slower than the rapid progression seen in Burkitt\u2019s lymphoma . The tumor grows significantly faster than this in most cases.</li><li>\u2022 Option C. 72 h:</li><li>\u2022 72-hour doubling time</li><li>\u2022 Burkitt\u2019s lymphoma</li><li>\u2022 Option D. 96 h: A 96-hour doubling time would be considered even slower, which is not characteristic of Burkitt\u2019s lymphoma , which is known for its aggressive behavior and extremely rapid growth rate.</li><li>\u2022 Option D. 96 h:</li><li>\u2022 96-hour doubling time</li><li>\u2022 Burkitt\u2019s lymphoma</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Burkitt\u2019s lymphoma is one of the most aggressive types of non-Hodgkin lymphoma , with a doubling time of <24 hours . Early diagnosis and prompt treatment are crucial for patient outcomes.</li><li>\u27a4 Burkitt\u2019s lymphoma</li><li>\u27a4 non-Hodgkin lymphoma</li><li>\u27a4 doubling time of <24 hours</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c7989640",
      "audio": ""
    },
    {
      "text": "A 60-year-old male presents with splenomegaly and pancytopenia. Peripheral blood smear is shown and bone marrow biopsy reveals monomorphic infiltrate of small B-cells. Which of the following markers is not expressed by these cells?",
      "options": [
        {
          "label": "A",
          "text": "CD30",
          "correct": true
        },
        {
          "label": "B",
          "text": "CD103",
          "correct": false
        },
        {
          "label": "C",
          "text": "CD25",
          "correct": false
        },
        {
          "label": "D",
          "text": "CD123",
          "correct": false
        }
      ],
      "correct_answer": "A. CD30",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20163326.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) CD30</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Hairy Cell Leukemia (HCL) is a B-cell neoplasm characterized by small lymphocytes with cytoplasmic projections (\"hairy\" cells) on peripheral smear. Patients are usually elderly males and present with massive splenomegaly &/or cytopenias. HCL cells express CD103 , CD25 , and CD123 , among others, but they do not express CD30 . CD30 is typically associated with Hodgkin lymphoma and some T-cell lymphomas, not HCL.</li><li>\u2022 CD103</li><li>\u2022 CD25</li><li>\u2022 CD123</li><li>\u2022 CD30</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B . CD103: This is a hallmark marker for HCL and is highly specific for the diagnosis.</li><li>\u2022 Option B</li><li>\u2022 CD103:</li><li>\u2022 Option C. CD25: This marker is commonly expressed in HCL and contributes to the immunophenotypic profile.</li><li>\u2022 Option C.</li><li>\u2022 CD25:</li><li>\u2022 Option D . CD123: This marker is also expressed in HCL, although less specific than CD103.</li><li>\u2022 Option D</li><li>\u2022 CD123:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hairy Cell Leukemia can be identified by its characteristic morphology and immunophenotypic markers such as CD103, CD25, and CD123 . It does not express markers like CD30 , which are associated with other hematologic malignancies.</li><li>\u27a4 CD103, CD25, and CD123</li><li>\u27a4 CD30</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5acc8903",
      "audio": ""
    },
    {
      "text": "A 70-year-old male with a history of multiple myeloma presents with worsening symptoms of fatigue, bone pain, and renal dysfunction. What is the single most powerful predictor of survival in multiple myeloma?",
      "options": [
        {
          "label": "A",
          "text": "Elevated LDH",
          "correct": false
        },
        {
          "label": "B",
          "text": "High-risk gene expression profile",
          "correct": false
        },
        {
          "label": "C",
          "text": "\u03b22-microglobulin",
          "correct": true
        },
        {
          "label": "D",
          "text": "De novo plasma cell leukemia",
          "correct": false
        }
      ],
      "correct_answer": "C. \u03b22-microglobulin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) \u03b22-microglobulin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 In multiple myeloma , \u03b22-microglobulin is considered the single most powerful predictor of survival . Elevated levels of \u03b22-microglobulin correlate with disease burden and tumor cell proliferation . It is used both in prognostic scoring and as a biomarker to assess the severity of the disease. \u03b22-microglobulin is part of the major histocompatibility complex (MHC-I) and is expressed on the surface of all cells, with levels elevated in multiple myeloma due to the increased production of light chains by plasma cells.</li><li>\u2022 multiple myeloma</li><li>\u2022 \u03b22-microglobulin</li><li>\u2022 single most powerful predictor of survival</li><li>\u2022 \u03b22-microglobulin</li><li>\u2022 disease burden</li><li>\u2022 tumor cell proliferation</li><li>\u2022 prognostic scoring</li><li>\u2022 biomarker</li><li>\u2022 \u03b22-microglobulin</li><li>\u2022 major histocompatibility complex (MHC-I)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Elevated LDH: Lactate dehydrogenase (LDH) can be elevated in multiple myeloma and is associated with disease activity, but it is not as strong a predictor of survival as \u03b22-microglobulin . It may indicate tissue damage but is not as specific as \u03b22-microglobulin .</li><li>\u2022 Option A. Elevated LDH: Lactate dehydrogenase (LDH)</li><li>\u2022 not as strong a predictor</li><li>\u2022 \u03b22-microglobulin</li><li>\u2022 \u03b22-microglobulin</li><li>\u2022 Option B. High-risk gene expression profile: A high-risk gene expression profile can predict poor prognosis in multiple myeloma, but it is generally not as commonly used in routine clinical practice as \u03b22-microglobulin . While important in research, it is not the single most powerful predictor .</li><li>\u2022 Option B. High-risk gene expression profile:</li><li>\u2022 high-risk gene expression profile</li><li>\u2022 \u03b22-microglobulin</li><li>\u2022 single most powerful predictor</li><li>\u2022 Option D. De novo plasma cell leukemia: De novo plasma cell leukemia is a high-risk variant of multiple myeloma and is associated with poor prognosis. However, it is not a predictor of survival on its own in the general population of patients with multiple myeloma.</li><li>\u2022 Option D. De novo plasma cell leukemia: De novo plasma cell leukemia</li><li>\u2022 high-risk variant</li><li>\u2022 not a predictor of survival</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 \u03b22-microglobulin is the most powerful and commonly used predictor of survival in multiple myeloma , providing valuable prognostic information and helping guide treatment decisions.</li><li>\u27a4 \u03b22-microglobulin</li><li>\u27a4 most powerful</li><li>\u27a4 predictor of survival</li><li>\u27a4 multiple myeloma</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "595520d1",
      "audio": ""
    },
    {
      "text": "A 50-year-old male with a history of chronic alcohol consumption presents with jaundice and abdominal pain. Laboratory tests show prolonged prothrombin time and serum bilirubin elevation. Which of the following is the correct formula for calculating Maddrey\u2019s discriminant function in alcoholic hepatitis?",
      "options": [
        {
          "label": "A",
          "text": "2.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]",
          "correct": false
        },
        {
          "label": "B",
          "text": "3.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]",
          "correct": false
        },
        {
          "label": "C",
          "text": "4.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]",
          "correct": true
        },
        {
          "label": "D",
          "text": "5.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]",
          "correct": false
        }
      ],
      "correct_answer": "C. 4.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 4.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The Maddrey Discriminant Function (MDF) is used to assess the short-term mortality risk in patients with alcoholic hepatitis . The formula for calculating MDF is:</li><li>\u2022 Maddrey Discriminant Function (MDF)</li><li>\u2022 short-term mortality risk</li><li>\u2022 alcoholic hepatitis</li><li>\u2022 MDF</li><li>\u2022 MDF = 4.6 \u00d7 (prolongation of prothrombin time above control in seconds) + serum bilirubin in mg/dL</li><li>\u2022 MDF = 4.6 \u00d7 (prolongation of prothrombin time above control in seconds) + serum bilirubin in mg/dL</li><li>\u2022 A MDF score >32 suggests a higher risk of short-term mortality, and patients with a score above this threshold may benefit from more aggressive treatment.</li><li>\u2022 MDF score >32</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. 2.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]: This is not the correct formula. The correct factor to be used is 4.6 , not 2.6.</li><li>\u2022 Option A. 2.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]:</li><li>\u2022 correct factor</li><li>\u2022 4.6</li><li>\u2022 Option B. 3.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]: This is also incorrect, as the correct factor is 4.6 , not 3.6.</li><li>\u2022 Option B. 3.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]:</li><li>\u2022 correct factor</li><li>\u2022 4.6</li><li>\u2022 Option D. 5.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]: This is incorrect because the correct factor is 4.6 , not 5.6.</li><li>\u2022 Option D. 5.6 \u00d7 [The prolongation of the prothrombin time above control {seconds}] + serum bilirubin [mg/dL]:</li><li>\u2022 correct factor</li><li>\u2022 4.6</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The Maddrey Discriminant Function (MDF) , calculated as 4.6 \u00d7 (prolongation of prothrombin time above control in seconds) + serum bilirubin , is used to predict short-term mortality in patients with alcoholic hepatitis .</li><li>\u27a4 Maddrey Discriminant Function (MDF)</li><li>\u27a4 4.6 \u00d7 (prolongation of prothrombin time above control in seconds) + serum bilirubin</li><li>\u27a4 short-term mortality</li><li>\u27a4 alcoholic hepatitis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2a95c74c",
      "audio": ""
    },
    {
      "text": "In which of the following scenarios is Hy\u2019s Law most commonly used?",
      "options": [
        {
          "label": "A",
          "text": "Alcoholic hepatitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Chronic Hepatitis B",
          "correct": false
        },
        {
          "label": "C",
          "text": "Drug-induced liver injury",
          "correct": true
        },
        {
          "label": "D",
          "text": "Liver carcinoma",
          "correct": false
        }
      ],
      "correct_answer": "C. Drug-induced liver injury",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Drug-induced liver injury</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Hy\u2019s Law is used to predict the risk of severe hepatotoxicity in cases of drug-induced liver injury . It was established by Dr. Hyman Zimmerman in the 1970s, and it describes the increased risk of acute liver failure when jaundice develops in patients taking a new drug . Hy's Law specifically predicts that if jaundice occurs during a clinical trial of a drug, the likelihood of severe hepatotoxicity and liver failure increases, with a 10:1 ratio between jaundice and liver failure . This finding is particularly important in the drug development process, as it often leads to the discontinuation of drug approval if severe liver injury is observed.</li><li>\u2022 Hy\u2019s Law</li><li>\u2022 risk of severe hepatotoxicity</li><li>\u2022 drug-induced liver injury</li><li>\u2022 Dr. Hyman Zimmerman</li><li>\u2022 acute liver failure</li><li>\u2022 jaundice</li><li>\u2022 new drug</li><li>\u2022 jaundice occurs</li><li>\u2022 severe hepatotoxicity</li><li>\u2022 liver failure</li><li>\u2022 10:1 ratio</li><li>\u2022 jaundice and liver failure</li><li>\u2022 severe liver injury</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Alcoholic hepatitis: While alcoholic hepatitis involves liver injury, Hy\u2019s Law is specifically used to predict drug-induced liver injury and is not applicable to alcoholic hepatitis.</li><li>\u2022 Option A. Alcoholic hepatitis:</li><li>\u2022 alcoholic hepatitis</li><li>\u2022 Hy\u2019s Law</li><li>\u2022 drug-induced liver injury</li><li>\u2022 Option B. Chronic Hepatitis B: Hy\u2019s Law is not relevant to the management or progression of chronic Hepatitis B . It is specific to drug-induced liver injury and the risks associated with jaundice during clinical trials.</li><li>\u2022 Option B. Chronic Hepatitis B: Hy\u2019s Law</li><li>\u2022 chronic Hepatitis B</li><li>\u2022 drug-induced liver injury</li><li>\u2022 Option D. Liver carcinoma: Hy\u2019s Law is not used to assess liver carcinoma , which is a cancer and not a condition directly related to drug-induced liver injury. It is a concept used primarily in the context of drug hepatotoxicity .</li><li>\u2022 Option D. Liver carcinoma: Hy\u2019s Law</li><li>\u2022 liver carcinoma</li><li>\u2022 drug hepatotoxicity</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hy\u2019s Law is used in the context of drug-induced liver injury and predicts the risk of acute liver failure if jaundice occurs during clinical drug trials. It is a crucial concept in the drug development process, particularly for evaluating the liver toxicity of new medications.</li><li>\u27a4 Hy\u2019s Law</li><li>\u27a4 drug-induced liver injury</li><li>\u27a4 acute liver failure</li><li>\u27a4 jaundice</li><li>\u27a4 liver toxicity</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "eb61d2d9",
      "audio": ""
    },
    {
      "text": "A 35-year-old male with a history of mild conjugated hyperbilirubinemia presents with dark pigmentation of the liver seen on imaging. Which of the following genes is defective in this condition?",
      "options": [
        {
          "label": "A",
          "text": "ABCCA",
          "correct": true
        },
        {
          "label": "B",
          "text": "SLCO1B1",
          "correct": false
        },
        {
          "label": "C",
          "text": "ATP8B1",
          "correct": false
        },
        {
          "label": "D",
          "text": "ABCB11",
          "correct": false
        }
      ],
      "correct_answer": "A. ABCCA",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) ABCCA</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Dubin-Johnson syndrome (DJS) is a rare inherited disorder characterized by mild conjugated hyperbilirubinemia , normal liver function, and dark pigmentation in the liver. The defective gene in Dubin-Johnson syndrome is ABCCA , which encodes MRP2 (Multidrug Resistance Protein 2) . This gene defect impairs the excretion of conjugated bilirubin into the bile, leading to the characteristic features of DJS, including dark liver pigmentation and a characteristic urinary coproporphyrin pattern .</li><li>\u2022 Dubin-Johnson syndrome (DJS)</li><li>\u2022 mild conjugated hyperbilirubinemia</li><li>\u2022 dark pigmentation</li><li>\u2022 Dubin-Johnson syndrome</li><li>\u2022 ABCCA</li><li>\u2022 MRP2 (Multidrug Resistance Protein 2)</li><li>\u2022 dark liver pigmentation</li><li>\u2022 a characteristic urinary coproporphyrin pattern</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option B. SLCO1B1: SLCO1B1 encodes the OATP1B1 transporter and is associated with other disorders of bile acid transport , such as Rotor syndrome , not Dubin-Johnson syndrome .</li><li>\u2022 Option B. SLCO1B1: SLCO1B1</li><li>\u2022 OATP1B1 transporter</li><li>\u2022 bile acid transport</li><li>\u2022 Rotor syndrome</li><li>\u2022 Dubin-Johnson syndrome</li><li>\u2022 Option C. ATP8B1: ATP8B1 is associated with familial intrahepatic cholestasis type 1 (PFIC1) , a condition that causes severe cholestasis and liver dysfunction beginning in childhood. It is not related to Dubin-Johnson syndrome .</li><li>\u2022 Option C. ATP8B1: ATP8B1</li><li>\u2022 familial intrahepatic cholestasis type 1 (PFIC1)</li><li>\u2022 severe cholestasis</li><li>\u2022 liver dysfunction</li><li>\u2022 Dubin-Johnson syndrome</li><li>\u2022 Option D. ABCB11: ABCB11 encodes the BSEP (Bile Salt Export Pump) and is associated with familial intrahepatic cholestasis type 2 (PFIC2) , which also causes severe cholestasis . This gene is not related to Dubin-Johnson syndrome .</li><li>\u2022 Option D. ABCB11: ABCB11</li><li>\u2022 BSEP (Bile Salt Export Pump)</li><li>\u2022 familial intrahepatic cholestasis type 2 (PFIC2)</li><li>\u2022 severe cholestasis</li><li>\u2022 Dubin-Johnson syndrome</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Dubin-Johnson syndrome is caused by a defect in the ABCCA gene encoding MRP2 , leading to impaired bilirubin excretion and dark liver pigmentation on imaging.</li><li>\u27a4 Dubin-Johnson syndrome</li><li>\u27a4 ABCCA</li><li>\u27a4 MRP2</li><li>\u27a4 impaired bilirubin excretion</li><li>\u27a4 dark liver pigmentation</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "185608d8",
      "audio": ""
    },
    {
      "text": "A 55-year-old male with cirrhosis presents for evaluation of portal hypertension. Measurement of the hepatic venous pressure gradient (HVPG) is done. What is the threshold for clinically significant portal hypertension with HVPG?",
      "options": [
        {
          "label": "A",
          "text": "< 5 mmHg",
          "correct": false
        },
        {
          "label": "B",
          "text": "5-10 mmHg",
          "correct": false
        },
        {
          "label": "C",
          "text": "> 10 mmHg",
          "correct": true
        },
        {
          "label": "D",
          "text": "< 10 mmHg",
          "correct": false
        }
      ],
      "correct_answer": "C. > 10 mmHg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) > 10 mmHg</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Portal hypertension is clinically significant when the hepatic venous pressure gradient (HVPG) is \u226510 mmHg . This threshold marks the transition from compensated cirrhosis (with HVPG between 5-10 mmHg) to a more advanced stage with a higher risk of complications, including variceal bleeding , ascites , and hepatic encephalopathy . When HVPG exceeds 10 mmHg, it indicates a greater risk of decompensation in patients with cirrhosis.</li><li>\u2022 Portal hypertension</li><li>\u2022 hepatic venous pressure gradient (HVPG)</li><li>\u2022 \u226510 mmHg</li><li>\u2022 compensated cirrhosis</li><li>\u2022 variceal bleeding</li><li>\u2022 ascites</li><li>\u2022 hepatic encephalopathy</li><li>\u2022 decompensation</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. < 5 mmHg: An HVPG <5 mmHg is typically considered normal and would not suggest clinically significant portal hypertension. In the absence of other complications, patients with HVPG below this value are usually asymptomatic.</li><li>\u2022 Option A. < 5 mmHg:</li><li>\u2022 <5 mmHg</li><li>\u2022 Option B. 5-10 mmHg: An HVPG in the range of 5-10 mmHg may represent compensated cirrhosis , where the patient may remain asymptomatic for a prolonged period, but this range does not denote clinically significant portal hypertension , which is defined as \u226510 mmHg .</li><li>\u2022 Option B. 5-10 mmHg:</li><li>\u2022 5-10 mmHg</li><li>\u2022 compensated cirrhosis</li><li>\u2022 clinically significant portal hypertension</li><li>\u2022 \u226510 mmHg</li><li>\u2022 Option D. < 10 mmHg: An HVPG <10 mmHg is not considered clinically significant for portal hypertension. \u226510 mmHg is the key threshold for identifying patients at higher risk for liver-related complications.</li><li>\u2022 Option D. < 10 mmHg:</li><li>\u2022 <10 mmHg</li><li>\u2022 \u226510 mmHg</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Clinically significant portal hypertension is defined as an HVPG of \u226510 mmHg , signaling a higher risk of complications in cirrhosis, including variceal bleeding , ascites , and hepatic encephalopathy .</li><li>\u27a4 Clinically significant portal hypertension</li><li>\u27a4 HVPG of \u226510 mmHg</li><li>\u27a4 variceal bleeding</li><li>\u27a4 ascites</li><li>\u27a4 hepatic encephalopathy</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cbd49d5e",
      "audio": ""
    },
    {
      "text": "A 25-year-old male presents with dysphagia and chronic reflux symptoms. An endoscopy is done and is shown. Which of the following is the most likely diagnosis based on these findings?",
      "options": [
        {
          "label": "A",
          "text": "Reflux esophagitis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Herpes simplex virus esophagitis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Eosinophilic esophagitis",
          "correct": true
        },
        {
          "label": "D",
          "text": "Candida esophagitis",
          "correct": false
        }
      ],
      "correct_answer": "C. Eosinophilic esophagitis",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20163355.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Eosinophilic esophagitis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The endoscopic image showing multiple circular rings and a narrowed esophagogastric junction is characteristic of eosinophilic esophagitis (EoE) . The \"corrugated\" appearance of the esophagus, along with impacted grape-like structures at the esophagogastric junction, is typical for this condition. EoE is a chronic, immune-mediated disorder that requires a biopsy showing >15-20 eosinophils per high-power field (HPF) for diagnosis.</li><li>\u2022 endoscopic image</li><li>\u2022 multiple circular rings</li><li>\u2022 narrowed esophagogastric junction</li><li>\u2022 eosinophilic esophagitis (EoE)</li><li>\u2022 \"corrugated\" appearance</li><li>\u2022 impacted grape-like structures</li><li>\u2022 EoE</li><li>\u2022 >15-20 eosinophils per high-power field (HPF)</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Reflux esophagitis: Reflux esophagitis (or gastroesophageal reflux disease, GERD) often presents with erosions or ulcerations in the esophagus, but it does not typically cause the circular rings and narrowed esophagogastric junction seen in EoE . GERD typically presents with esophageal inflammation due to acid reflux, not eosinophilic infiltration .</li><li>\u2022 Option A. Reflux esophagitis: Reflux esophagitis</li><li>\u2022 erosions</li><li>\u2022 ulcerations</li><li>\u2022 circular rings</li><li>\u2022 narrowed esophagogastric junction</li><li>\u2022 EoE</li><li>\u2022 esophageal inflammation</li><li>\u2022 eosinophilic infiltration</li><li>\u2022 Option B. Herpes simplex virus esophagitis: Herpes simplex virus (HSV) esophagitis typically presents with ulcerations and vesicular lesions on endoscopy, not the circular rings seen in EoE . HSV esophagitis is often associated with painful swallowing (odynophagia) and fever .</li><li>\u2022 Option B. Herpes simplex virus esophagitis: Herpes simplex virus (HSV) esophagitis</li><li>\u2022 ulcerations</li><li>\u2022 vesicular lesions</li><li>\u2022 circular rings</li><li>\u2022 EoE</li><li>\u2022 painful swallowing</li><li>\u2022 fever</li><li>\u2022 Option D. Candida esophagitis: Candida esophagitis presents with white plaques on endoscopy, typically adherent to the esophageal mucosa. This appearance is quite different from the circular rings and narrowed junction seen in EoE . Candida is more common in immunocompromised patients.</li><li>\u2022 Option D. Candida esophagitis: Candida esophagitis</li><li>\u2022 white plaques</li><li>\u2022 adherent</li><li>\u2022 circular rings</li><li>\u2022 narrowed junction</li><li>\u2022 EoE</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Eosinophilic esophagitis is characterized by multiple circular rings and a narrowed esophagogastric junction , which is a classic endoscopic finding. Diagnosis requires histology showing >15-20 eosinophils per HPF .</li><li>\u27a4 Eosinophilic esophagitis</li><li>\u27a4 multiple circular rings</li><li>\u27a4 narrowed esophagogastric junction</li><li>\u27a4 >15-20 eosinophils per HPF</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0c2d9af8",
      "audio": ""
    },
    {
      "text": "A 45-year-old male presents with intermittent chest pain and dysphagia. High resolution manometry is done and shown. What is the most likely diagnosis based on these findings?",
      "options": [
        {
          "label": "A",
          "text": "Jackhammer esophagus",
          "correct": false
        },
        {
          "label": "B",
          "text": "Achalasia cardia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Diffuse esophageal spasm",
          "correct": true
        },
        {
          "label": "D",
          "text": "Esophageal carcinoma",
          "correct": false
        }
      ],
      "correct_answer": "C. Diffuse esophageal spasm",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20163418.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/Screenshot%202025-01-31%20164640.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Diffuse esophageal spasm</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 The esophageal pressure topography (or manometry) showing disorganized contractions and spasms in the esophagus, with normal lower esophageal sphincter (LES) pressure , is indicative of diffuse esophageal spasm (DES) . This condition is characterized by uncoordinated, irregular contractions of the esophagus, which can lead to intermittent chest pain and dysphagia . The absence of abnormal LES pressure helps distinguish DES from conditions like achalasia .</li><li>\u2022 esophageal pressure topography</li><li>\u2022 disorganized contractions</li><li>\u2022 spasms</li><li>\u2022 normal lower esophageal sphincter (LES) pressure</li><li>\u2022 diffuse esophageal spasm (DES)</li><li>\u2022 uncoordinated, irregular contractions</li><li>\u2022 intermittent chest pain</li><li>\u2022 dysphagia</li><li>\u2022 abnormal LES pressure</li><li>\u2022 achalasia</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Jackhammer esophagus: Jackhammer esophagus is characterized by hypercontractility and excessively high-pressure contractions of the esophagus, typically seen on manometry. This is different from diffuse esophageal spasm , which involves disorganized spasms rather than excessively strong contractions .</li><li>\u2022 Option A. Jackhammer esophagus: Jackhammer esophagus</li><li>\u2022 hypercontractility</li><li>\u2022 excessively high-pressure contractions</li><li>\u2022 diffuse esophageal spasm</li><li>\u2022 disorganized spasms</li><li>\u2022 excessively strong contractions</li><li>\u2022 Option B. Achalasia cardia: Achalasia is characterized by impaired relaxation of the LES and absence of peristalsis in the esophagus. On manometry, this shows a high LES pressure and absent or incomplete peristalsis , which is not seen in diffuse esophageal spasm .</li><li>\u2022 Option B. Achalasia cardia: Achalasia</li><li>\u2022 impaired relaxation of the LES</li><li>\u2022 absence of peristalsis</li><li>\u2022 high LES pressure</li><li>\u2022 absent or incomplete peristalsis</li><li>\u2022 diffuse esophageal spasm</li><li>\u2022 Option D. Esophageal carcinoma: Esophageal carcinoma typically presents with progressive dysphagia and weight loss . Manometry does not typically show disorganized contractions or spasms . Imaging and biopsy are the primary diagnostic tools for esophageal cancer , not manometry.</li><li>\u2022 Option D. Esophageal carcinoma: Esophageal carcinoma</li><li>\u2022 progressive dysphagia</li><li>\u2022 weight loss</li><li>\u2022 disorganized contractions</li><li>\u2022 spasms</li><li>\u2022 esophageal cancer</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Diffuse esophageal spasm is characterized by disorganized esophageal contractions with normal LES pressure , leading to symptoms like chest pain and dysphagia , which are typically observed on esophageal pressure topography .</li><li>\u27a4 Diffuse esophageal spasm</li><li>\u27a4 disorganized esophageal contractions</li><li>\u27a4 normal LES pressure</li><li>\u27a4 chest pain</li><li>\u27a4 dysphagia</li><li>\u27a4 esophageal pressure topography</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8e45961e",
      "audio": ""
    },
    {
      "text": "A 30-year-old male with a history of oculocutaneous albinism, granulomatous colitis, platelet dysfunction, and pulmonary fibrosis is diagnosed with a rare genetic disorder. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Wiskott-Aldrich syndrome (WAS)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hermansky-Pudlak syndrome",
          "correct": true
        },
        {
          "label": "C",
          "text": "Immune dysregulation polyendocrinopathy, enteropathy X-linked (IPEX)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glycogen storage disease type B1",
          "correct": false
        }
      ],
      "correct_answer": "B. Hermansky-Pudlak syndrome",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Hermansky-Pudlak syndrome</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Hermansky-Pudlak syndrome (HPS) is a rare genetic disorder that is characterized by granulomatous colitis , oculocutaneous albinism , platelet dysfunction , and pulmonary fibrosis . It is caused by mutations in one of several genes involved in lysosomal function and organelle trafficking. The syndrome affects multiple organ systems, leading to immunodeficiency , bleeding tendencies due to platelet dysfunction, and progressive pulmonary fibrosis .</li><li>\u2022 Hermansky-Pudlak syndrome (HPS)</li><li>\u2022 granulomatous colitis</li><li>\u2022 oculocutaneous albinism</li><li>\u2022 platelet dysfunction</li><li>\u2022 pulmonary fibrosis</li><li>\u2022 immunodeficiency</li><li>\u2022 bleeding tendencies</li><li>\u2022 progressive pulmonary fibrosis</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Wiskott-Aldrich syndrome (WAS): Wiskott-Aldrich syndrome is an immunodeficiency disorder associated with eczema , thrombocytopenia , recurrent infections , and autoimmune manifestations , but it does not typically present with granulomatous colitis or pulmonary fibrosis . It is more commonly associated with severe platelet dysfunction and immunodeficiency .</li><li>\u2022 Option A. Wiskott-Aldrich syndrome (WAS): Wiskott-Aldrich syndrome</li><li>\u2022 eczema</li><li>\u2022 thrombocytopenia</li><li>\u2022 recurrent infections</li><li>\u2022 autoimmune manifestations</li><li>\u2022 granulomatous colitis</li><li>\u2022 pulmonary fibrosis</li><li>\u2022 severe platelet dysfunction</li><li>\u2022 immunodeficiency</li><li>\u2022 Option C. Immune dysregulation polyendocrinopathy, enteropathy X-linked (IPEX): IPEX syndrome is characterized by autoimmune enteropathy (similar to ulcerative colitis ), endocrinopathy (such as type 1 diabetes ), and dermatitis . However, it does not involve the characteristic findings of oculocutaneous albinism or pulmonary fibrosis , which are seen in Hermansky-Pudlak syndrome .</li><li>\u2022 Option C. Immune dysregulation polyendocrinopathy, enteropathy X-linked (IPEX): IPEX syndrome</li><li>\u2022 autoimmune enteropathy</li><li>\u2022 ulcerative colitis</li><li>\u2022 endocrinopathy</li><li>\u2022 type 1 diabetes</li><li>\u2022 dermatitis</li><li>\u2022 oculocutaneous albinism</li><li>\u2022 pulmonary fibrosis</li><li>\u2022 Hermansky-Pudlak syndrome</li><li>\u2022 Option D. Glycogen storage disease type B1: Glycogen storage disease type B1 (GSD-Ib) is primarily characterized by hypoglycemia , growth retardation , and liver enlargement due to defects in glucose metabolism . It does not present with the combination of granulomatous colitis , pulmonary fibrosis , or oculocutaneous albinism seen in Hermansky-Pudlak syndrome .</li><li>\u2022 Option D. Glycogen storage disease type B1: Glycogen storage disease type B1 (GSD-Ib)</li><li>\u2022 hypoglycemia</li><li>\u2022 growth retardation</li><li>\u2022 liver enlargement</li><li>\u2022 defects in glucose metabolism</li><li>\u2022 granulomatous colitis</li><li>\u2022 pulmonary fibrosis</li><li>\u2022 oculocutaneous albinism</li><li>\u2022 Hermansky-Pudlak syndrome</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hermansky-Pudlak syndrome is a genetic disorder with characteristic features such as granulomatous colitis , oculocutaneous albinism , platelet dysfunction , and pulmonary fibrosis , which helps distinguish it from other syndromes.</li><li>\u27a4 Hermansky-Pudlak syndrome</li><li>\u27a4 granulomatous colitis</li><li>\u27a4 oculocutaneous albinism</li><li>\u27a4 platelet dysfunction</li><li>\u27a4 pulmonary fibrosis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2aa3ef3a",
      "audio": ""
    },
    {
      "text": "A 50-year-old male presents with yellowing of the eyes (scleral icterus) and is concerned about his liver function. His serum bilirubin level is measured. At what serum bilirubin level is scleral icterus typically first noticeable?",
      "options": [
        {
          "label": "A",
          "text": "2 mg/dL",
          "correct": false
        },
        {
          "label": "B",
          "text": "3 mg/dL",
          "correct": true
        },
        {
          "label": "C",
          "text": "4 mg/dL",
          "correct": false
        },
        {
          "label": "D",
          "text": "5 mg/dL",
          "correct": false
        }
      ],
      "correct_answer": "B. 3 mg/dL",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 3 mg/dL</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Scleral icterus occurs when the serum bilirubin level reaches approximately 3 mg/dL (51 \u03bcmol/L). The sclerae of the eyes have a particular affinity for bilirubin due to their high elastin content , and jaundice or icterus of the sclera is typically the first noticeable sign when serum bilirubin levels exceed 3 mg/dL .</li><li>\u2022 Scleral icterus</li><li>\u2022 3 mg/dL</li><li>\u2022 sclerae</li><li>\u2022 bilirubin</li><li>\u2022 elastin content</li><li>\u2022 jaundice</li><li>\u2022 icterus</li><li>\u2022 serum bilirubin levels exceed 3 mg/dL</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. 2 mg/dL: At a serum bilirubin level of 2 mg/dL , jaundice may not yet be evident in the sclera, as scleral icterus typically appears at levels closer to 3 mg/dL .</li><li>\u2022 Option A. 2 mg/dL:</li><li>\u2022 serum bilirubin level of 2 mg/dL</li><li>\u2022 3 mg/dL</li><li>\u2022 Option C. 4 mg/dL: While scleral icterus may be more noticeable at 4 mg/dL , it is typically detectable at 3 mg/dL , making this option less accurate than the correct answer.</li><li>\u2022 Option C. 4 mg/dL:</li><li>\u2022 scleral icterus</li><li>\u2022 4 mg/dL</li><li>\u2022 3 mg/dL</li><li>\u2022 Option D. 5 mg/dL: 5 mg/dL is a higher bilirubin level and scleral icterus would definitely be present at this level, but the earliest detectable level for scleral icterus is typically around 3 mg/dL , not 5.</li><li>\u2022 Option D. 5 mg/dL: 5 mg/dL</li><li>\u2022 scleral icterus</li><li>\u2022 earliest detectable level</li><li>\u2022 scleral icterus</li><li>\u2022 3 mg/dL</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Scleral icterus (yellowing of the eyes) typically occurs when the serum bilirubin level reaches at least 3 mg/dL .</li><li>\u27a4 Scleral icterus</li><li>\u27a4 serum bilirubin level reaches at least 3 mg/dL</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9bedad29",
      "audio": ""
    },
    {
      "text": "A 40-year-old male with moderate to severe ulcerative colitis is being considered for biologic therapy. The physician is planning to start the patient on Vedolizumab. What is the mechanism of action?",
      "options": [
        {
          "label": "A",
          "text": "Sphingosine-1-phosphate (S1P1) receptor modulator",
          "correct": false
        },
        {
          "label": "B",
          "text": "Recombinant humanized IgG4 antibody against \u03b14-integrin",
          "correct": false
        },
        {
          "label": "C",
          "text": "IgG1 monoclonal antibody, blocks the biologic activity of IL-12 and IL-23",
          "correct": false
        },
        {
          "label": "D",
          "text": "Monoclonal antibody directed against \u03b14\u03b27-integrin",
          "correct": true
        }
      ],
      "correct_answer": "D. Monoclonal antibody directed against \u03b14\u03b27-integrin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Monoclonal antibody directed against \u03b14\u03b27-integrin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Vedolizumab is a monoclonal antibody that targets \u03b14\u03b27-integrin . It selectively inhibits the migration of lymphocytes into the gut by blocking the interaction of \u03b14\u03b27-integrin with the MAdCAM-1 receptor on the vascular endothelium of the gut. This gut-selective immunosuppression helps treat inflammatory bowel diseases like ulcerative colitis and Crohn's disease , with reduced systemic immunosuppressive effects compared to other biologics.</li><li>\u2022 Vedolizumab</li><li>\u2022 monoclonal antibody</li><li>\u2022 \u03b14\u03b27-integrin</li><li>\u2022 migration of lymphocytes</li><li>\u2022 gut</li><li>\u2022 \u03b14\u03b27-integrin</li><li>\u2022 MAdCAM-1</li><li>\u2022 gut-selective immunosuppression</li><li>\u2022 inflammatory bowel diseases</li><li>\u2022 ulcerative colitis</li><li>\u2022 Crohn's disease</li><li>\u2022 Other Options:</li><li>\u2022 Other Options:</li><li>\u2022 Option A. Sphingosine-1-phosphate (S1P1) receptor modulator: This mechanism is associated with Fingolimod , a drug used in multiple sclerosis and ulcerative colitis , which modulates lymphocyte trafficking by acting on the S1P1 receptor .</li><li>\u2022 Option A. Sphingosine-1-phosphate (S1P1) receptor modulator:</li><li>\u2022 Fingolimod</li><li>\u2022 multiple sclerosis</li><li>\u2022 ulcerative colitis</li><li>\u2022 modulates lymphocyte trafficking</li><li>\u2022 S1P1 receptor</li><li>\u2022 Option B. Recombinant humanized IgG4 antibody against \u03b14-integrin: This mechanism is related to Natalizumab , a humanized IgG4 monoclonal antibody that targets \u03b14-integrin and is used in multiple sclerosis and Crohn's disease . Unlike Vedolizumab , Natalizumab is not gut-selective and has more systemic effects.</li><li>\u2022 Option B. Recombinant humanized IgG4 antibody against \u03b14-integrin:</li><li>\u2022 Natalizumab</li><li>\u2022 humanized IgG4 monoclonal antibody</li><li>\u2022 \u03b14-integrin</li><li>\u2022 multiple sclerosis</li><li>\u2022 Crohn's disease</li><li>\u2022 Vedolizumab</li><li>\u2022 Natalizumab</li><li>\u2022 Option C. IgG1 monoclonal antibody, blocks the biologic activity of IL-12 and IL-23: This mechanism is associated with Ustekinumab , an antibody targeting IL-12 and IL-23 , which is used in the treatment of psoriasis , Crohn's disease , and ulcerative colitis . It does not specifically target \u03b14\u03b27-integrin .</li><li>\u2022 Option C. IgG1 monoclonal antibody, blocks the biologic activity of IL-12 and IL-23:</li><li>\u2022 Ustekinumab</li><li>\u2022 IL-12</li><li>\u2022 IL-23</li><li>\u2022 psoriasis</li><li>\u2022 Crohn's disease</li><li>\u2022 ulcerative colitis</li><li>\u2022 \u03b14\u03b27-integrin</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Vedolizumab is a gut-selective biologic that works by inhibiting the \u03b14\u03b27-integrin interaction, reducing lymphocyte migration into the gut and effectively treating ulcerative colitis and Crohn's disease .</li><li>\u27a4 Vedolizumab</li><li>\u27a4 gut-selective</li><li>\u27a4 \u03b14\u03b27-integrin</li><li>\u27a4 ulcerative colitis</li><li>\u27a4 Crohn's disease</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bd4805dd",
      "audio": ""
    }
  ]
}